<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">100197</article-id><article-id pub-id-type="doi">10.7554/eLife.100197</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.100197.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cozzolino</surname><given-names>Kira A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sanford</surname><given-names>Lynn</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hunter</surname><given-names>Samuel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Molison</surname><given-names>Kayla</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Erickson</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Courvan</surname><given-names>Meaghan CS</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Taylor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ajit</surname><given-names>Deepa</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Galbraith</surname><given-names>Matthew D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0485-3927</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Espinosa</surname><given-names>Joaquín M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9048-1941</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author"><name><surname>Bentley</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Allen</surname><given-names>Mary Ann</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Dowell</surname><given-names>Robin D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7665-9985</contrib-id><email>robin.dowell@colorado.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Taatjes</surname><given-names>Dylan J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4444-5688</contrib-id><email>taatjes@colorado.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02ttsq026</institution-id><institution>Department of Biochemistry, University of Colorado</institution></institution-wrap><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02ttsq026</institution-id><institution>Department of Molecular, Cellular, and Developmental Biology, University of Colorado</institution></institution-wrap><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02ttsq026</institution-id><institution>BioFrontiers Institute, University of Colorado</institution></institution-wrap><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006jjmw19</institution-id><institution>Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>UC-Denver RNA Bioscience Initiative</institution><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Crnic Institute Boulder Branch</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wmf1y16</institution-id><institution>Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus</institution></institution-wrap><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/033qhvk72</institution-id><institution>Metabolon Inc, Durham</institution></institution-wrap><addr-line><named-content content-type="city">Morrisville</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wmf1y16</institution-id><institution>Department of Pharmacology, University of Colorado Anschutz Medical Campus</institution></institution-wrap><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hinnebusch</surname><given-names>Alan G</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04byxyr05</institution-id><institution>Eunice Kennedy Shriver National Institute of Child Health and Human Development</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dalal</surname><given-names>Yamini</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040gcmg81</institution-id><institution>National Cancer Institute</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>10</day><month>02</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP100197</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-06-13"><day>13</day><month>06</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-05-28"><day>28</day><month>05</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.07.05.547813"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-08-14"><day>14</day><month>08</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100197.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-01-17"><day>17</day><month>01</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100197.2"/></event></pub-history><permissions><copyright-statement>© 2024, Cozzolino et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Cozzolino et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-100197-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-100197-figures-v1.pdf"/><abstract><p>Hyperactive interferon (IFN) signaling is a hallmark of Down syndrome (DS), a condition caused by Trisomy 21 (T21); strategies that normalize IFN signaling could benefit this population. Mediator-associated kinases CDK8 and CDK19 drive inflammatory responses through incompletely understood mechanisms. Using sibling-matched cell lines with/without T21, we investigated Mediator kinase function in the context of hyperactive IFN in DS over a 75 min to 24 hr timeframe. Activation of IFN-response genes was suppressed in cells treated with the CDK8/CDK19 inhibitor cortistatin A (CA), via rapid suppression of IFN-responsive transcription factor (TF) activity. We also discovered that CDK8/CDK19 affect splicing, a novel means by which Mediator kinases control gene expression. To further probe Mediator kinase function, we completed cytokine screens and metabolomics experiments. Cytokines are master regulators of inflammatory responses; by screening 105 different cytokine proteins, we show that Mediator kinases help drive IFN-dependent cytokine responses at least in part through transcriptional regulation of cytokine genes and receptors. Metabolomics revealed that Mediator kinase inhibition altered core metabolic pathways in cell type-specific ways, and broad upregulation of anti-inflammatory lipid mediators occurred specifically in kinase-inhibited cells during hyperactive IFNγ signaling. A subset of these lipids (e.g. oleamide, desmosterol) serve as ligands for nuclear receptors PPAR and LXR, and activation of these receptors occurred specifically during hyperactive IFN signaling in CA-treated cells, revealing mechanistic links between Mediator kinases, lipid metabolism, and nuclear receptor function. Collectively, our results establish CDK8/CDK19 as context-specific metabolic regulators, and reveal that these kinases control gene expression not only via TFs, but also through metabolic changes and splicing. Moreover, we establish that Mediator kinase inhibition antagonizes IFN signaling through transcriptional, metabolic, and cytokine responses, with implications for DS and other chronic inflammatory conditions.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>mitochondria</kwd><kwd>cytokine</kwd><kwd>interferons</kwd><kwd>Down syndrome</kwd><kwd>gene expression</kwd><kwd>metabolism</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R35GM139550</award-id><principal-award-recipient><name><surname>Taatjes</surname><given-names>Dylan J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01AI156739</award-id><principal-award-recipient><name><surname>Taatjes</surname><given-names>Dylan J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>MCB-1818147</award-id><principal-award-recipient><name><surname>Taatjes</surname><given-names>Dylan J</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009633</institution-id><institution>Eunice Kennedy Shriver National Institute of Child Health and Human Development</institution></institution-wrap></funding-source><award-id>R01HD100935</award-id><principal-award-recipient><name><surname>Bentley</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01AI50305</award-id><principal-award-recipient><name><surname>Espinosa</surname><given-names>Joaquín M</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>T32GM065103</award-id><principal-award-recipient><name><surname>Cozzolino</surname><given-names>Kira A</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000997</institution-id><institution>Arnold and Mabel Beckman Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Molison</surname><given-names>Kayla</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008086</institution-id><institution>Global Down Syndrome Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Espinosa</surname><given-names>Joaquín M</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000179</institution-id><institution>Office of the Director</institution></institution-wrap></funding-source><award-id>S10OD021601</award-id><principal-award-recipient><name><surname>Taatjes</surname><given-names>Dylan J</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000179</institution-id><institution>Office of the Director</institution></institution-wrap></funding-source><award-id>S10OD025267</award-id><principal-award-recipient><name><surname>Taatjes</surname><given-names>Dylan J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The Mediator-associated kinases CDK8 and CDK19 help drive inflammatory responses to interferon, and it is discovered that kinase-dependent transcriptional responses manifest in part through splicing changes and lipid metabolites.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Down syndrome (DS) is relatively common in the human population (ca. 1 in 700 live births) (<xref ref-type="bibr" rid="bib21">de Graaf et al., 2017</xref>) and results from trisomy of chromosome 21 (T21). T21 manifests in myriad ways, including an increased propensity for autoimmune and neurological disorders, as well as elevated incidence of leukemia (<xref ref-type="bibr" rid="bib32">Hasle et al., 2000</xref>; <xref ref-type="bibr" rid="bib5">Antonarakis, 2017</xref>; <xref ref-type="bibr" rid="bib6">Antonarakis et al., 2020</xref>). Notably, T21 also results in chronic immune dysregulation associated with hyperactivation of interferon (IFN) signaling (<xref ref-type="bibr" rid="bib77">Sullivan et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">Araya et al., 2019</xref>; <xref ref-type="bibr" rid="bib83">Waugh et al., 2019</xref>).</p><p>The chronic, hyperactive IFN response in DS can be attributed, at least in part, to the fact that four IFN receptors are encoded on chromosome 21: IFNAR1 and IFNAR2 for Type I IFNs (e.g. IFNβ, IFNγ), IFNGR2 for IFNγ, and the Type III subunit IL10RB for IFNλ, which also serves as a subunit of the IL10 receptor. Numerous pathologies associated with DS, including autoimmune-related disorders, are considered direct consequences of chronic IFN pathway activation (<xref ref-type="bibr" rid="bib52">Madan et al., 2006</xref>; <xref ref-type="bibr" rid="bib54">Mårild et al., 2013</xref>; <xref ref-type="bibr" rid="bib7">Araya et al., 2019</xref>; <xref ref-type="bibr" rid="bib83">Waugh et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Bush et al., 2021</xref>). For these reasons, hyperactive IFN signaling lies at the heart of DS pathophysiology (<xref ref-type="bibr" rid="bib84">Waugh et al., 2023</xref>), and therapeutic strategies to dampen IFN responses are being tested in clinical trials (NCT04246372, NCT05662228).</p><p>We recently demonstrated that the Mediator kinases (CDK8 and its paralog CDK19) are drivers of inflammatory responses to the universal cytokine IFNγ (<xref ref-type="bibr" rid="bib75">Steinparzer et al., 2019</xref>). This discovery has implications for DS, because hyperactive IFN signaling underlies many DS symptoms and because Mediator kinases are promising targets for molecular therapeutics, in part due to low toxicity of a selective inhibitor in mouse models (<xref ref-type="bibr" rid="bib56">Pelish et al., 2015</xref>). Many studies have linked Mediator kinase activity to immune system function and inflammatory responses (<xref ref-type="bibr" rid="bib13">Bancerek et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Johannessen et al., 2017</xref>; <xref ref-type="bibr" rid="bib85">Yamamoto et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Guo et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Steinparzer et al., 2019</xref>; <xref ref-type="bibr" rid="bib33">Hofmann et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Freitas et al., 2022</xref>), and CDK8/CDK19 inhibition can suppress autoimmune disease in animal models (<xref ref-type="bibr" rid="bib1">Akamatsu et al., 2019</xref>). Mediator kinases target the STAT transcription factor (TF) family (<xref ref-type="bibr" rid="bib13">Bancerek et al., 2013</xref>; <xref ref-type="bibr" rid="bib57">Poss et al., 2016</xref>) and activation of JAK/STAT pathway TFs (e.g. STAT1, IRF1) is blocked upon Mediator kinase inhibition in IFNγ-stimulated human or mouse cells (<xref ref-type="bibr" rid="bib75">Steinparzer et al., 2019</xref>). Collectively, these results suggest that Mediator kinase inhibition could mitigate chronic, hyperactive IFN signaling in T21.</p><p>Mediator is a 26-subunit complex that regulates RNA polymerase II (RNAPII) transcription genome-wide (<xref ref-type="bibr" rid="bib60">Richter et al., 2022</xref>). Mediator is recruited to specific genomic loci through interactions with sequence-specific, DNA-binding TFs, and Mediator interacts with the RNAPII enzyme at transcription start sites. Through these distinct interactions, Mediator enables TF-dependent control of RNAPII function. CDK8 or CDK19 can reversibly associate with Mediator as part of a 4-subunit ‘Mediator kinase module’ that contains additional subunits MED12, MED13, and CCNC (<xref ref-type="bibr" rid="bib50">Luyties and Taatjes, 2022</xref>).</p><p>Mediator kinases have not been studied in the context of DS, and a goal of this project was to define their roles in the context of IFNγ signaling, using donor-derived cell lines. We also sought to address fundamental questions regarding Mediator kinase function that remained largely unexplored. For instance, it is not known whether Mediator kinases impact pre-mRNA splicing that is coupled to RNAPII transcription, despite evidence that CDK8 and/or CDK19 phosphorylate splicing regulatory proteins (<xref ref-type="bibr" rid="bib57">Poss et al., 2016</xref>). Furthermore, metabolic changes are at least as important as transcriptional changes in driving biological responses (<xref ref-type="bibr" rid="bib62">Rinschen et al., 2019</xref>; <xref ref-type="bibr" rid="bib89">Zhu and Thompson, 2019</xref>), but how Mediator kinases impact metabolism in human cells remains incompletely understood (<xref ref-type="bibr" rid="bib88">Zhao et al., 2012</xref>; <xref ref-type="bibr" rid="bib28">Galbraith et al., 2017</xref>). Finally, cytokines serve as key drivers of IFNγ responses, and despite links between CDK8/CDK19 function and inflammation (<xref ref-type="bibr" rid="bib16">Chen et al., 2017</xref>; <xref ref-type="bibr" rid="bib75">Steinparzer et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Freitas et al., 2022</xref>), it is largely unknown whether Mediator kinases impact cytokine levels.</p><p>Using a combination of approaches, we have identified novel and diverse mechanisms by which Mediator kinases control IFNγ responses under both basal and IFNγ-stimulated conditions. Beyond effects on the RNAPII transcriptome, our results indicate that Mediator kinases act by governing TF activation and suggest that they selectively control gene expression through pre-mRNA splicing; furthermore, regulation of cytokine and metabolite levels contributes to CDK8/CDK19-dependent control of inflammatory signaling, including downstream activation of nuclear receptors through context-specific, kinase-dependent changes in lipid metabolites. Taken together, our findings identify Mediator kinases as therapeutic targets that could mitigate immune system dysregulation in individuals with DS.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Experimental overview: transcriptomics, metabolomics, and cytokine screens</title><p>The goals of this project were to compare and contrast transcriptional and metabolic changes in the following experimental contexts: (1) T21 vs. D21, (2) ±IFNγ stimulation, (3) ±Mediator kinase inhibition, and (4) IFNγ stimulation + Mediator kinase inhibition. For T21 vs. D21 comparisons, we selected lymphoblastoid cells from the Nexus Biobank that were derived from siblings matched in age (3- or 5-year old) and sex (male). We used the natural product cortistatin A (CA) to inhibit CDK8 and CDK19 (<xref ref-type="bibr" rid="bib56">Pelish et al., 2015</xref>). CA is the most potent and selective Mediator kinase inhibitor available (<xref ref-type="bibr" rid="bib19">Clopper and Taatjes, 2022</xref>); for example, kinome-wide screens showed no off-target kinase inhibition even at 1 µM, a concentration 5000 times greater than its measured <italic>K</italic><sub>D</sub> of 0.2 nM (<xref ref-type="bibr" rid="bib56">Pelish et al., 2015</xref>). Throughout this project, we used CA at a concentration of 100 nM, to minimize potential off-target effects. Immunoblots confirmed CA-dependent inhibition of STAT1 S727 phosphorylation, a known CDK8 substrate (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>).</p><p>Prior to completion of RNA-seq experiments, we probed the timing of the IFNγ response at IFN target genes GBP1 and IRF1 by RT-qPCR (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Based upon these results, we chose the 4-hr time point for RNA-seq (see Methods). We also completed experiments in T21 cells after 24 hr ±CA. An overview of the RNA-seq experiments is shown in <xref ref-type="fig" rid="fig1">Figure 1A</xref>, with data for all genes across all conditions in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Experimental overview; elevated cytokines in T21 cells.</title><p>(<bold>A</bold>) Schematic of cell treatment and data collection workflow for metabolomics, cytokine screen (green shading) and RNA-seq (purple shading). (<bold>B</bold>) Simplified diagram of human metabolic pathways, with an emphasis on those relevant to this study. Figure adapted from <xref ref-type="bibr" rid="bib49">Lunt and Vander Heiden, 2011</xref>. (<bold>C</bold>) Heatmap of all cytokines measured (<italic>n</italic> = 105), comparing relative levels in vehicle-treated T21 cells vs. vehicle-treated D21 cells (left column) and relative levels in IFNγ-treated T21 cells vs. IFNγ-treated D21 cells (right column). Asterisk denotes padj ≤ 0.1.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>RNA-seq data summary.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Metabolomics data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig1-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Cytokine screen data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig1-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><caption><title>Gene set enrichment analysis (GSEA) results.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig1-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata5"><label>Figure 1—source data 5.</label><caption><title>Ingenuity Pathway Analysis (IPA) results.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig1-data5-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata6"><label>Figure 1—source data 6.</label><caption><title>GO pathway analysis involving comparisons with Human Trisome Project large cohort study.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig1-data6-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Comparisons between T21 and D21 cells.</title><p>(<bold>A</bold>) Western blots of STAT1 S727 phosphorylation following 45-min treatment with IFNγ with or without 30-min pretreatment with cortistatin A (100 nM) or CCT251545 (250 nM), two structurally distinct inhibitors of CDK8/19. At right, data represented as mean ± SD from two biological replicate experiments. (<bold>B</bold>) Time course of relative gene expression levels measured by real-time quantitative PCR (RT-qPCR) of GBP1 and IRF1, two interferon stimulated genes, following treatment with 10 ng/ml IFNγ compared to untreated cells. Data normalized to expression of GAPDH and represented as mean ± SD from two independent experiments. Inset panel represents relative basal expression of each gene in untreated T21 cells compared to untreated D21 cells. (<bold>C</bold>) Representative data from cytokine protein arrays. Arrays were incubated with cell lysates (250 µg total protein) treated as shown. Multiple exposures were taken to ensure that every spot was measured in the linear range; duplicate spots were averaged. Averaged intensity values from two biological replicates/condition were analyzed using ANOVA. (<bold>D</bold>) Volcano plot of differentially expressed genes in T21 cells compared to D21; selected genes are color-coded based on pro-inflammatory (red), anti-inflammatory (green), or other (black) roles in IFN signaling. Genes represented by red dots have an adjusted p-value of &lt;0.01. (<bold>E</bold>) Gene set enrichment analysis (GSEA) moustache plot of Hallmark pathways comparing T21 cells with D21. (<bold>F</bold>) Ingenuity Pathway Analysis of upstream regulators predicted to be responsible for differential transcription in T21 cells compared to D21 cells. Analysis used genes &gt;1.25× up- or downregulated, with an adjusted p-value &lt;0.1. List of regulators was filtered to exclude drugs or other exogenous compounds. (<bold>G</bold>) Selected results of pathway analysis based on metabolite levels in untreated T21 compared with D21 cells, using the ‘Diseases &amp; Functions’ list from Ingenuity Pathway Analysis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Metabolic differences in T21 vs. D21; data comparison with whole blood cohort clinical studies.</title><p>(<bold>A</bold>) Relative levels of metabolites from core metabolic pathways in untreated T21 cells compared with untreated D21 cells. (<bold>B</bold>) Differential metabolites summary (ANOVA p-value &lt;0.1) in untreated T21 cells relative to untreated D21 cells, broken down by category; excludes unknown and xenobiotic metabolites. (<bold>C</bold>) Gene set enrichment analysis (GSEA) moustache plot of Hallmark pathway activation in whole blood samples from a cohort study of T21 individuals compared to euploid controls (<xref ref-type="bibr" rid="bib84">Waugh et al., 2023</xref>). (<bold>D</bold>) Venn diagram of up- or downregulated genes (adjusted p-value &lt;0.01) in Trisomy 21 from this study and in whole blood samples from the cohort study (NCT02864108). Genes either up- or downregulated in both studies were analyzed using Gene Ontology Enrichment Analysis with the GO aspect ‘Biological Processes’. (<bold>E</bold>) The IFN score (<xref ref-type="bibr" rid="bib29">Galbraith et al., 2023</xref>) is elevated in T21 cell line compared with D21, suggesting IFN hyperactivity in T21.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig1-figsupp2-v1.tif"/></fig></fig-group><p>Large-scale, untargeted metabolomic analyses were completed 24 hr post-IFNγ stimulation in D21 and T21 cells. This time point was chosen to approximate a ‘steady state’ following IFNγ treatment and to allow time for metabolic adaptations to occur; this time point was also consistent with prior metabolite analyses in IFN-treated cells (<xref ref-type="bibr" rid="bib81">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Lee et al., 2021b</xref>). An overview of the metabolomics experiments is shown in <xref ref-type="fig" rid="fig1">Figure 1A</xref>, with raw data for all identified metabolites across conditions in <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>.</p><p>DS has been described as a ‘cytokinopathy’ based upon evaluation of blood plasma from individuals with or without T21. Arrays screening 29 different cytokines showed elevated levels in DS individuals (<xref ref-type="bibr" rid="bib53">Malle et al., 2023</xref>). Based upon these and other results, we sought to directly measure cytokine levels to assess IFNγ- and CA-dependent effects. We completed a series of cytokine screens (<italic>n</italic> = 105 different cytokines) in T21 and D21 cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>), using the same experimental design as the metabolomics experiments (basal conditions, +CA, +IFNγ, or +CA+IFNγ). Biological replicate cytokine screens were completed for each condition after 24 hr treatment; measurements for all cytokines in both replicates can be found in <xref ref-type="supplementary-material" rid="fig1sdata3">Figure 1—source data 3</xref>.</p></sec><sec id="s2-2"><title>The T21 transcriptome, metabolome, and cytokine levels are consistent with hyperactive IFN signaling</title><p>For RNA-seq, biological triplicate experiments were completed, and a normalization (<xref ref-type="bibr" rid="bib34">Hunter et al., 2023</xref>) was performed to account for the potential 1.5-fold expression differences from chromosome 21 in T21 cells (<xref ref-type="bibr" rid="bib36">Hwang et al., 2021</xref>). Comparison of gene expression in T21 vs. D21 cells revealed massive differences, as expected (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>; <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Gene set enrichment analysis (GSEA)(<xref ref-type="bibr" rid="bib76">Subramanian et al., 2005</xref>) revealed significant upregulation of inflammatory pathways (e.g. IFNγ, IFNα, Complement, TNFα) in T21 vs. D21 cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>; <xref ref-type="supplementary-material" rid="fig1sdata4">Figure 1—source data 4</xref>), consistent with prior reports (<xref ref-type="bibr" rid="bib77">Sullivan et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Sullivan et al., 2017</xref>; <xref ref-type="bibr" rid="bib53">Malle et al., 2023</xref>). Furthermore, the ‘upstream regulators’ identified from Ingenuity Pathway Analysis (IPA) (<xref ref-type="bibr" rid="bib42">Krämer et al., 2014</xref>) predicted activation of numerous inflammatory markers in T21 cells (e.g. IFNγ, IFNα, TNF, TGFβ1, NFκB), based upon the RNA-seq results (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>; <xref ref-type="supplementary-material" rid="fig1sdata5">Figure 1—source data 5</xref>). Negatively enriched pathways in T21 cells (GSEA Hallmarks, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>, <xref ref-type="supplementary-material" rid="fig1sdata4">Figure 1—source data 4</xref>) reflected proliferative gene expression programs (e.g. MYC targets, G2M checkpoint); in agreement, we observed slower growth rates for T21 cells compared with their D21 counterparts.</p><p>Untargeted metabolomics experiments identified and quantified over 600 biochemicals representing every major metabolic pathway (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). We observed evidence that inflammatory pathways were activated in T21 cells under basal conditions (IPA results, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>; <xref ref-type="supplementary-material" rid="fig1sdata5">Figure 1—source data 5</xref>), and 196 biochemicals increased and 214 decreased in T21 vs. D21 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B</xref>; <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). Pathways related to fatty acid transport, growth, and energy metabolism were reduced in T21 cells (vs. D21; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>). Supporting these general trends, the metabolomics data revealed T21-specific changes in glycolysis, nucleotide and lipid biosynthesis, and other fundamental cellular processes (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>; <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). Metabolic distinctions between T21 and D21 cells will be described in more detail later, in the context of IFNγ treatment and/or Mediator kinase inhibition. An overview of metabolic pathways that are relevant for this study is shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</p><p>As with the RNA-seq and metabolomics data, the cytokine screen results implicated chronic activation of the IFN response in T21 cells under basal conditions; for example, levels of many cytokines were elevated in T21 vs. D21 cells (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, left column). Furthermore, treatment with IFNγ appeared to ‘normalize’ cytokine levels in T21 vs. D21 cells (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, right column), such that many cytokines were detected at roughly equal levels in IFNγ-stimulated T21 and D21 cells.</p></sec><sec id="s2-3"><title>T21-specific transcriptional, metabolic, and cytokine changes are reflected in population-level data</title><p>For practical reasons, the transcriptomics, metabolomics, and cytokine screening experiments completed here precluded parallel examination of additional genetically distinct donor-derived T21 and D21 cell lines (but see below). A basic observation from past studies was that the transcriptomes of T21 individuals are not only tissue- and cell type-specific, but also reflect individual-to-individual differences within the same cell types (<xref ref-type="bibr" rid="bib77">Sullivan et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Hwang et al., 2021</xref>). However, we hypothesized that the general trends in our sibling-matched T21 vs. D21 lines would show some commonality with large-scale cohort studies.</p><p>We analyzed RNA-seq data from whole blood samples from individuals with DS (<italic>n</italic> = 304) or euploid (i.e. D21; <italic>n</italic> = 96) controls (<xref ref-type="bibr" rid="bib84">Waugh et al., 2023</xref>), generated by the Human Trisome Project (<ext-link ext-link-type="uri" xlink:href="https://www.trisome.org/">https://www.trisome.org/</ext-link>, NCT02864108). The data revealed upregulation of the IFNγ response, Complement, cytokine production, and other inflammatory pathways in T21 individuals (vs. D21; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>; <xref ref-type="supplementary-material" rid="fig1sdata4">Figure 1—source data 4</xref>). Approximately 10% of differentially expressed genes were shared between the Human Trisome Project cohort study (T21 vs. D21; whole blood transcriptomes from individuals varying in age and sex) and our RNA-seq results from sibling-matched T21 and D21 lymphoblastoid cell lines (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>), consistent with individual-to-individual variation within the human population (<xref ref-type="bibr" rid="bib77">Sullivan et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Hwang et al., 2021</xref>). However, the shared ‘core sets’ of genes reflected prominent trends in our T21/D21 RNA-seq comparisons. For example, upregulated genes represented cytokine production and other inflammatory pathways, whereas downregulated genes involved nucleotide and fatty acid metabolism, splicing, G-protein-coupled receptor (GPCR) signaling, and proliferation. These pathway trends are well-represented in our RNA-seq and metabolomics data (e.g. <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E–G</xref>; <xref ref-type="supplementary-material" rid="fig1sdata6">Figure 1—source data 6</xref>) and additional data supporting these T21-specific changes (vs. D21) will be described in more detail later.</p><p>We also used the IFN score metric (<xref ref-type="bibr" rid="bib29">Galbraith et al., 2023</xref>) to evaluate our sibling-matched T21 and D21 lines. The IFN score considers expression of 18 genes from a set of 382 genes comprising the IFNγ, IFNα, and inflammatory response GSEA Hallmarks gene sets. It has been used to evaluate differences between whole blood transcriptomes in a cohort of 502 participants (<italic>n</italic> = 356 T21, <italic>n</italic> = 146 D21). As shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>, the sibling-matched T21 line had an elevated IFN score, consistent with comparative trends from a large cohort of whole blood transcriptomes of T21 or D21 individuals (<xref ref-type="bibr" rid="bib29">Galbraith et al., 2023</xref>).</p><p>A recent analysis of blood plasma cytokine levels, measuring 29 cytokines from DS individuals (<italic>n</italic> = 21) or age-matched euploid controls (<italic>n</italic> = 10) identified elevated levels of approximately 10 to as many as 22 of these 29 cytokines (<xref ref-type="bibr" rid="bib53">Malle et al., 2023</xref>). In agreement, at least 13 of the 22 cytokines (59%) were elevated in our T21 vs. D21 comparison (red font in <xref ref-type="fig" rid="fig1">Figure 1C</xref>). Collectively, the RNA-seq and cytokine data from a large cohort of DS individuals indicate that the two model cell lines evaluated here, derived from age- and sibling-matched D21 and T21 individuals, broadly reflect population-wide trends.</p></sec><sec id="s2-4"><title>Mediator kinase inhibition tempers T21 inflammatory pathways under basal conditions</title><p>We next asked whether Mediator kinases influenced hyperactive IFNγ signaling in T21 vs. D21 cells. We first describe how Mediator kinase inhibition impacted T21 or D21 cells under basal conditions.</p><sec id="s2-4-1"><title>Transcriptome</title><p>As shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–D</xref>, and <xref ref-type="supplementary-material" rid="fig1sdata4">Figure 1—source data 4</xref>, CA caused similar changes to gene expression programs in T21 and D21 cells, although some T21-specific differences were evident (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C, D</xref>). CA treatment upregulated 445 genes in D21 (331 in T21; 210 shared) and downregulated 233 genes (191 in T21, 112 shared; padj 0.01). GSEA showed downregulation of MYC targets, consistent with prior studies in CDK8-depleted cells (<xref ref-type="bibr" rid="bib71">Sooraj et al., 2022</xref>). Downregulation of the inflammatory ‘TNFα signaling via NFκB’ pathway was also observed in CA-treated D21 and T21 cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C, D</xref>); decreased expression of the NFKB1 and NFKB2 transcripts themselves likely contributed to this effect (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Regulation of NFκB transcriptional programs has been previously linked to Mediator kinases (<xref ref-type="bibr" rid="bib16">Chen et al., 2017</xref>) although direct control of NFκB transcription levels has not been reported. Activation of GSEA Hallmarks related to mTOR signaling, cholesterol and fatty acid metabolism were observed in CA-treated D21 and T21 cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C, D</xref>), in agreement with prior studies in other cell types (<xref ref-type="bibr" rid="bib57">Poss et al., 2016</xref>; <xref ref-type="bibr" rid="bib9">Audetat et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Andrysik et al., 2021</xref>). The genes significantly upregulated in these pathways are highlighted in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>. Importantly, the gene expression changes matched the metabolome changes in CA-treated cells (see below).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Mediator kinase inhibition tempers inflammatory pathways under basal conditions, with T21-specific effects.</title><p>(<bold>A</bold>) Heatmap of genes with differential expression in D21 or T21 cells treated with cortistatin A (CA) (100 nM) compared to DMSO controls. Genes with adjusted p-value &lt;0.01 in one or both cell lines are shown. (<bold>B</bold>) Table of activation <italic>Z</italic>-scores for selected upstream regulators predicted for gene expression changes in CA-treated T21 cells relative to DMSO controls. (<bold>C</bold>) Box plots showing relative levels of selected lipid metabolites in CA-treated D21 and T21 cells compared to DMSO controls. (<bold>D</bold>) Simplified diagram of pathways through which selected lipid metabolites regulate inflammation. (<bold>E</bold>) Heatmap of average relative cytokine levels in CA-treated cells compared to DMSO controls. Only cytokines with relative levels of ≥1.5 (log2FC; red shading) or ≤0.75 (blue shading) in one or both cell lines are shown; cytokines meeting this threshold are outlined in black. Asterisk (*) denotes adjusted p-value &lt;0.1 using ANOVA. (<bold>F</bold>) Venn diagrams of cytokines and cytokine receptor genes (in <italic>italics</italic>) that were downregulated (FC &lt;0.8, left diagram) or upregulated (FC &gt;1.2, right diagram) in CA-treated D21 and T21 cells, compared to DMSO controls. Cytokines with matching trends from RNA-seq (4 hr) are listed in bold, whereas cytokines with inverse trends in at least one cell type are marked with an asterisk.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Metabolomics data sibling-matched T21 vs. D21.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Metabolomics data sibling-matched T21 and D21 ±CA.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig2-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Cortistatin A (CA) suppresses T21 inflammatory pathways under basal conditions.</title><p>Volcano plots showing differentially expressed genes following CA treatment in D21 (<bold>A</bold>) or T21 (<bold>B</bold>) cells, with selected genes color-coded based on pro-inflammatory (red), anti-inflammatory (green) roles. Genes represented by red dots have an adjusted p-value of &lt;0.01. (<bold>C, D</bold>) Gene set enrichment analysis (GSEA) moustache plots of Hallmark pathway activation in CA-treated D21 (<bold>C</bold>) and T21 (<bold>D</bold>) cells compared to DMSO controls. (<bold>E</bold>) Tables of genes involved in fatty acid metabolism (left) or cholesterol metabolism (right) that are differentially expressed (adjusted p-value ≤0.1) in CA-treated T21 cells relative to vehicle controls, showing consistent upregulation in both pathways. (<bold>F</bold>) Ingenuity Pathway Analysis of upstream regulators predicted for differential gene expression (RNA-seq) in CA-treated D21 and T21 cells compared to DMSO controls. Predicted regulators specific for T21 cells are labeled in orange font. Analysis used genes with an adjusted p-value &lt;0.1. Inset: <italic>Z</italic>-score of genes related to PPAR and LXR activation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Persistent activation of lipid metabolism and associated transcription factors (TFs) in cortistatin A (CA)-treated T21 cells; reduced expression of RNA processing factors.</title><p>(<bold>A</bold>) Volcano plot showing differentially expressed genes following 24 hr CA treatment (vs. DMSO controls), with selected genes color-coded based on pro-inflammatory (red), anti-inflammatory (green) roles. Genes represented by red dots have an adjusted p-value of &lt;0.01. (<bold>B</bold>) Gene set enrichment analysis (GSEA) moustache plot of Hallmark pathway activation in CA-treated T21 cells compared to DMSO controls (<italic>t</italic> = 24 hr). (<bold>C</bold>) Dot plots representing average NES for pathways with specific lipid- or inflammatory-related terms; terms are on the left. Pathways were analyzed using GSEA GO Biological Processes (GOBP) of relative gene expression in T21 cells treated with CA for 4.5 or 24 hr relative to DMSO. Dot color indicates direction of average NES, with positive = red and negative = blue. Dot size corresponds to the NES magnitude. All pathways with ‘negative regulation of…’ were excluded to avoid confounding the analysis. (<bold>D</bold>) Ingenuity Pathway Analysis upstream regulators results from differential gene expression in T21 cells ±CA treatment for 24 hr. Selected TFs and other factors associated with inflammatory responses are labeled. Analysis used only genes with padj &lt; 0.1. Inset: <italic>Z</italic>-scores of genes related to PPAR and LXR activation. (<bold>E</bold>) Heatmap of GSEA pathways that significantly change (padj ≤ 0.1) in CA-treated T21 cells vs. DMSO controls.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Cortistatin A (CA) treatment suppresses oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in T21 cells.</title><p>Normalized OCR in D21 (<bold>A</bold>) or T21 cells (<bold>B</bold>) treated with 100 nM CA or DMSO for 24 hr. Line plots were generated from biological replicates (<italic>n</italic> = 3) with error bars representing standard error of the mean. Injection times for compounds affecting OCR are depicted with vertical dashed lines. Bar plots below represent quantitation of mitochondrial stress test parameters. (<bold>C</bold>) Heatmap showing genes in the gene set enrichment analysis (GSEA) Hallmarks ‘Oxidative phosphorylation’ pathway set with differential expression (RNA-seq ±CA 24 hr, padj ≤ 0.1) in sibling T21 cells. CA treatment (100 nM, 24 hr) reduces ECAR in D21 (<bold>D</bold>) and T21 cells (<bold>E</bold>). Line plots were generated from biological replicates (<italic>n</italic> = 3) with error bars representing standard error of the mean.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Elevated oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in T21 vs. D21; cortistatin A (CA) treatment normalizes mitochondrial function and ECAR toward D21 levels.</title><p>(<bold>A</bold>) Bar plots showing quantitation of mitochondrial stress test parameters in vehicle-treated D21 or sibling-matched T21 cells. Lines represent standard error of the mean (<italic>n</italic> = 3). (<bold>B, C</bold>) Comparison of OCR and ECAR in vehicle-treated D21 vs. T21 cells. Line plots were generated from biological replicates (<italic>n</italic> = 3) with error bars representing standard error of the mean. Injection times for compounds affecting OCR or ECAR are depicted with vertical dashed lines. (<bold>D</bold>) Bar plots showing quantitation of mitochondrial stress test parameters in vehicle-treated D21 or sibling-matched T21 cells +CA (100 nM, <italic>t</italic> = 24 hr). Lines represent standard error of the mean (<italic>n</italic> = 3). (<bold>E, F</bold>) Comparison of OCR and ECAR in vehicle-treated D21 vs. CA-treated T21 cells. Line plots were generated from biological replicates (<italic>n</italic> = 3) with error bars representing standard error of the mean. Injection times for compounds affecting OCR or ECAR are identical to panels B, C.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig2-figsupp4-v1.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>Cortistatin A (CA) treatment increases expression of lipid biosynthesis genes and suppresses inflammation and IFN-related genes in a different T21 donor line.</title><p>(<bold>A</bold>) Volcano plot showing differentially expressed genes following 4.5 hr CA treatment (vs. DMSO controls), with selected genes color-coded based on pro-inflammatory (red), anti-inflammatory (green) roles. Genes represented by red dots have an adjusted p-value of &lt;0.01. (<bold>B</bold>) Gene set enrichment analysis (GSEA) moustache plot of Hallmark pathway activation in CA-treated ‘non-sibling’ T21 cells compared to DMSO controls (<italic>t</italic> = 4.5 hr). (<bold>C</bold>) GO analysis of shared CA-responsive genes among each T21 cell line (sibling and non-sibling), based upon RNA-seq data ±CA, <italic>t</italic> = 4.5 hr. Top = upregulated genes; bottom = downregulated genes (padj ≤ 0.1 in one or both lines). Pathways related to lipid biosynthesis highlighted in red and those related to inflammatory response highlighted in blue. All displayed pathways meet an FDR ≤0.05 cutoff. (<bold>D</bold>) Dot plots representing average NES for pathways with specific lipid- or inflammation-related terms; terms are on the left. Pathways were analyzed using GSEA GO Biological Processes (GOBP) of relative gene expression in T21 cells treated with CA for 4.5 hr relative to DMSO. Dot color indicates direction of average NES, with positive = red and negative = blue. Dot size corresponds to the NES magnitude. All pathways with ‘negative regulation of…’ were excluded to avoid confounding the analysis. (<bold>E</bold>) Ingenuity Pathway Analysis of upstream regulators predicted for differential gene expression (RNA-seq) in CA-treated ‘non-sibling’ vs. ‘sibling’ T21 cells compared to DMSO controls. Predicted regulators with absolute <italic>Z</italic>-score ≥2.0 in both lines labeled in red, whereas regulators with absolute <italic>Z</italic>-score ≥2.0 in only one line labeled in orange font. Analysis used genes with an adjusted p-value &lt;0.1. Inset: <italic>Z</italic>-score of genes related to PPAR and LXR activation. (<bold>F</bold>) Heatmap of GSEA pathways that significantly change (padj ≤ 0.1) in CA-treated T21 cells vs. DMSO controls.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig2-figsupp5-v1.tif"/></fig></fig-group><p>We next completed an ‘upstream regulators’ analysis (IPA; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>, <xref ref-type="supplementary-material" rid="fig1sdata5">Figure 1—source data 5</xref>) based upon the RNA-seq data. In agreement with the GSEA results, factors regulating cholesterol homeostasis (e.g. SCAP, SREBF1/2, INSIG1; up), fatty acid metabolism (e.g. ACSS2, FASN; up), and inflammation (e.g. NFKB1, MYD88, IL1B; down) were significantly altered by CA treatment in T21 cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>), with similar results in D21 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). The IPA results also implicated CA-dependent repression of pro-inflammatory TFs specifically in T21 cells, including RELA (NFκB complex), FOXO3, and ILF3 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>; <xref ref-type="supplementary-material" rid="fig1sdata5">Figure 1—source data 5</xref>), consistent with repression of chronic basal IFN signaling upon Mediator kinase inhibition.</p></sec><sec id="s2-4-2"><title>Metabolome</title><p>CA-dependent changes in the metabolomes of D21 and T21 cells were strikingly distinct. This is likely due to (1) the longer timeframe used for metabolomics analyses (24 vs. 4.5 hr for RNA-seq), and (2) the massive ‘pre-existing’ basal metabolome differences in T21 vs. D21 cells (<xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). Here, we will focus on the T21 vs. D21 metabolic differences that relate to pathways that were impacted by Mediator kinase inhibition.</p><p>In <xref ref-type="fig" rid="fig2">Figure 2C</xref>, we highlight examples of CA-dependent increases in anti-inflammatory lipid metabolites. In T21 cells selectively, CA treatment broadly increased levels of long chain mono- and poly-unsaturated FA (PUFA; <xref ref-type="fig" rid="fig2">Figure 2C</xref>), including oleic acid, eicosapentaenoate (EPA), docosapentaenoate (DPA), docosahexaenoate (DHA), and various other ω3 and ω6 PUFAs (<xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>). These metabolites act as signaling molecules by binding to extracellular GPCRs to trigger anti-inflammatory signaling cascades (<xref ref-type="bibr" rid="bib14">Basil and Levy, 2016</xref>; <xref ref-type="bibr" rid="bib35">Husted et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Kimura et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Jordan and Werz, 2022</xref>), as shown in the simplified schematic in <xref ref-type="fig" rid="fig2">Figure 2D</xref>. Similar to LCFAs, endocannabinoids were broadly elevated in CA-treated T21 cells (vs. D21; <xref ref-type="fig" rid="fig2">Figure 2C</xref>). Endocannabinoids mediate anti-inflammatory effects in part through PPAR TFs (<xref ref-type="bibr" rid="bib2">Alhouayek and Muccioli, 2014</xref>) for example, oleoylethanolamide (OEA) and oleamide are PPARα ligands (<xref ref-type="bibr" rid="bib27">Fu et al., 2003</xref>; <xref ref-type="bibr" rid="bib63">Roy et al., 2016</xref>) and OEA can suppress pro-inflammatory NFκB signaling (<xref ref-type="bibr" rid="bib87">Yang et al., 2016</xref>).</p><p>Consistent with lipid-dependent activation of LXR and PPAR nuclear receptors, the RNA-seq results showed evidence of CA-dependent LXR and PPAR activation specifically in T21 cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>), which correlated with the elevated levels of LCFAs, desmosterol, oleamide, and endocannabinoids in CA-treated T21 cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Although metabolites were measured 24 hr after CA treatment, these data suggest that altered lipid metabolites influence LXR and PPAR function within 4.5 hr; moreover, evidence for PPAR activation in CA-treated T21 cells was also observed from RNA-seq data 24 hr after CA treatment (see below). Collectively, these results implicate lipid metabolites as key ‘downstream’ regulators of the transcriptional response to Mediator kinase inhibition. Importantly, this link between lipid metabolites and LXR or PPAR activation was observed in T21 but not D21 cells, suggesting that this CA-dependent effect selectively occurs in the context of hyperactive IFN signaling.</p></sec><sec id="s2-4-3"><title>Cytokine</title><p>CA treatment was also shown to be anti-inflammatory based upon the cytokine screen results. Under basal conditions, the levels of about two dozen cytokines changed in response to CA treatment (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). In D21 cells, the anti-inflammatory cytokine IL10 increased upon Mediator kinase inhibition, in agreement with prior reports in other cell types (<xref ref-type="bibr" rid="bib37">Johannessen et al., 2017</xref>), whereas the pro-inflammatory cytokines GMCSF, IL3, and MIP1α/β (a.k.a. CCL3/4) decreased; an exception was TNFα. Similar results were obtained in T21 cells; however, CA treatment reduced the levels of pro-inflammatory cytokines in T21 cells that were not reduced in D21 (e.g. IL32, IL33, IL34), although CXCL10 and GMCSF were exceptions. The selective CA-dependent decrease in IFNγ in T21 cells under basal conditions (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) further supports the chronic high baseline IFN signaling in these cells (<xref ref-type="bibr" rid="bib77">Sullivan et al., 2016</xref>). Note that some cytokines cannot be clearly defined as either pro- or anti-inflammatory and their roles may be cell type-specific (<xref ref-type="bibr" rid="bib23">Dinarello, 2007</xref>).</p><p>Because cytokine protein levels were measured 24 hr after CA treatment, we hypothesized that their altered levels would partially correspond to gene expression changes that were measured earlier, at 4.5 hr post-treatment. Indeed, this was observed for many cytokines impacted by Mediator kinase inhibition, as shown in <xref ref-type="fig" rid="fig2">Figure 2F</xref>. (Note that expression changes for cytokine receptors are also shown.)</p></sec></sec><sec id="s2-5"><title>T21 transcriptome shows elevation of lipid biosynthesis genes and reduced levels of splicing regulators with 24 hr CA treatment</title><p>We next assessed longer-term effects of Mediator kinase inhibition on the transcriptome in T21 cells. We completed biological triplicate RNA-seq experiments in T21 cells 24 hr after CA treatment (or DMSO controls; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). As shown in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>, GSEA Hallmarks showed little evidence for suppression of anti-inflammatory pathways, in contrast to the results in T21 cells after 4.5 hr CA treatment. This was further supported by GSEA with the GO Biological Processes (GOBP) pathway set (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>), which includes more gene sets (<italic>n</italic> = 7641 for GOBP vs. <italic>n</italic> = 50 for Hallmarks; see Methods) and more with relevance to IFN signaling and inflammation.</p><p>Gene sets related to cholesterol and lipid metabolism remained activated in CA-treated cells after 24 hr, consistent with the RNA-seq data at the shorter 4.5 hr timeframe. Moreover, the <italic>t</italic> = 24 hr RNA-seq results showed evidence for sustained activation of SREBP as well as PPAR and LXR in CA-treated cells, a result that was inferred from the metablomics data (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). For instance, IPA upstream regulators showed activation of ‘PPARA:RXRA coactivator’ and NR1H3/LXRA (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>). This coincided with elevated levels of PPAR and LXR ligands (e.g. OEA, oleamide, desmosterol), as measured by metabolomics 24 hr after CA treatment (<xref ref-type="fig" rid="fig2">Figure 2C, D</xref>; <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>). We also generated GOBP heatmaps comparing the 4.5 vs. 24 hr ±CA RNA-seq data (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E</xref>). The results are distinct from the dot plots shown in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref> because the heatmaps are not narrowly focused on selected GOBP terms and because a cutoff (padj ≤ 0.1) was applied. The gene sets change over time, underscoring the importance of timing in evaluation of kinase inhibitors. Also noteworthy were the many pathways related to RNA processing and splicing in the CA-treated cells at 24 hr. Splicing defects in CA-treated cells are described in a later section, but the results summarized in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E</xref> suggest that CA-dependent splicing changes are caused by reduced expression of splicing regulators, at least at longer timeframes.</p></sec><sec id="s2-6"><title>Mediator kinases influence T21 mitochondrial function</title><p>GSEA results from RNA-seq data in T21 cells after 24 hr CA treatment (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>) showed downregulation of oxidative phosphorylation, a result consistent with a prior proteomics study completed in HCT116 cells ±CA (<xref ref-type="bibr" rid="bib57">Poss et al., 2016</xref>). To probe further, we measured the oxygen consumption rate (OCR) in D21 or T21 cells ±CA (<italic>t</italic> = 24 hr). As shown in <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A, B</xref>, OCR was reduced in CA-treated D21 or T21 cells, and reached statistical confidence in T21 cells. The reduced OCR in CA-treated T21 cells tracked with reduced mRNA levels for oxidative phosphorylation genes, measured by RNA-seq (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3C</xref>). We also measured extracellular acidification rate (ECAR) in D21 or T21 cells ±CA (<italic>t</italic> = 24 hr). Extracellular acidification is elevated by lactate, an end-product of glycolysis. As shown in <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3D, E</xref>, CA treatment reduced ECAR in both D21 and T21 cells, a result consistent with our metabolomics data (lactate reduced in CA-treated cells; <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>) and prior CDK8-dependent links to expression of glycolysis enzymes (<xref ref-type="bibr" rid="bib28">Galbraith et al., 2017</xref>).</p><p>A comparison of mitochondrial function in sibling-matched D21 and T21 cells is shown in <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A, B</xref> and ECAR is shown in <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4C</xref>. The data show significant differences in T21 cells; these results are consistent with a T21 mouse model study, although we note that T21/D21 OCR differences may be tissue-specific (<xref ref-type="bibr" rid="bib66">Sarver et al., 2023</xref>). Because CA treatment lowered OCR and ECAR, and reduced mitochondrial respiration in T21 cells (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref>), we next compared D21 cells with CA-treated T21 cells. The results suggest that Mediator kinase inhibition shifts T21 mitochondrial function and ECAR toward D21 levels (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4D–F</xref>); however, we emphasize that this represents only one pair of cell lines and more work is needed to rigorously assess this topic.</p></sec><sec id="s2-7"><title>Similar CA-dependent transcriptome changes in different donor T21 cell line</title><p>Although completing parallel metabolomic, cytokine, and transcriptomics analyses across many cell lines was impractical, we did complete RNA-seq experiments in a different T21 donor cell line. Biological triplicate RNA-seq experiments were performed in a non-sibling T21 line ±CA (<italic>t</italic> = 4.5 hr). Similar to the ‘sibling-matched’ T21 line, CA-treated cells showed elevated expression of genes in the cholesterol homeostasis, fatty acid metabolism, and peroxisome pathways (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5A, B</xref>). Moreover, GSEA completed with the GOBP set showed suppression of pathways related to IFN signaling and inflammation (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5C, D</xref>). In fact, the CA-dependent suppression was amplified in this ‘non-sibling’ T21 line, which may reflect higher basal IFN signaling compared with the sibling-matched T21 line. IPA upstream regulators results (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5E</xref>) also showed evidence for CA-dependent suppression of IFN signaling, with negative <italic>Z</italic>-scores for pro-inflammatory TFs (e.g. STAT2, IRF1, NFKB1) and cytokines (e.g. IFNG, IFNA2, IFNL1). Conversely, SREBP TFs were activated, as were LXR and PPAR, similar to the sibling-matched T21 line (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5E</xref>). A heatmap summarizing transcriptome changes upon CA treatment in the two different T21 donor cell lines is shown in <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5F</xref>. Taken together, the transcriptomics data from this ‘non-sibling’ T21 cell line showed robust CA-dependent suppression of inflammatory pathways, with evidence for CA-dependent activation of SREBP, PPAR, and LXR TFs, consistent with the results from the different sibling-matched T21 line.</p></sec><sec id="s2-8"><title>Mediator kinase inhibition blocks IFNγ-induced transcriptional, metabolic, and cytokine responses</title><p>We next evaluated the transcriptomic, metabolomic, and cytokine data from IFNγ-treated cells. As shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, the transcriptional response to IFNγ was broadly similar in the sibling-matched T21 and D21 cells; however, T21 cells showed higher basal expression of inflammatory genes. This can be seen upon comparison of gene expression in T21 vs. D21 cells under basal (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>) or IFNγ-stimulated conditions (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C–E</xref>). Only 10 genes showed greater induction in T21 cells in response to IFNγ, whereas 68 genes had reduced induction in T21 compared with D21 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>; <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Pathway analysis (GOBP) of these 68 genes showed predominant roles in IFN signaling and inflammatory responses (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>; <xref ref-type="supplementary-material" rid="fig1sdata6">Figure 1—source data 6</xref>). This result is consistent with hyperactive IFN signaling in T21 cells (<xref ref-type="bibr" rid="bib77">Sullivan et al., 2016</xref>), such that induction upon exogenous IFNγ stimulation was reduced compared with D21 cells. Next, we focus on how Mediator kinase inhibition influenced transcriptional, metabolic, and cytokine responses in IFNγ-treated D21 and T21 cells.</p><sec id="s2-8-1"><title>Transcriptome</title><p>The regulatory roles of the Mediator kinases CDK8 and CDK19 are context- and cell type-specific, and their functions appear to be especially important for initiating changes in gene expression programs, such as during an acute stimulus (<xref ref-type="bibr" rid="bib50">Luyties and Taatjes, 2022</xref>). As shown in <xref ref-type="fig" rid="fig3">Figure 3A</xref>, many of the mRNAs responsive to IFNγ (activated or repressed) were impacted in the opposite way in CA + IFNγ-treated D21 or T21 cells (see also <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A, B</xref>). This CA-dependent antagonism of IFNγ-response genes is best illustrated with difference heatmaps that compared levels of IFN-dependent transcriptional changes with IFN + CA conditions (i.e. IFN vs. Ctrl – IFN + CA vs. Ctrl; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C, D</xref>). An example at the CXCL9 gene locus is shown in <xref ref-type="fig" rid="fig3">Figure 3B</xref>; CXCL9 is a pro-inflammatory cytokine. GSEA also reflected CA-dependent suppression of the transcriptional response to IFNγ. In both D21 and T21 cell lines, IFNγ response and other inflammatory pathways were downregulated with CA treatment compared with IFNγ alone (<xref ref-type="fig" rid="fig3">Figure 3C, D</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2E</xref>; <xref ref-type="supplementary-material" rid="fig1sdata4">Figure 1—source data 4</xref>). Similar results were obtained with an assessment of inflammatory pathways using IPA (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2F</xref>; <xref ref-type="supplementary-material" rid="fig1sdata5">Figure 1—source data 5</xref>). Thus, Mediator kinase inhibition blocked normal transcriptional responses to IFNγ, consistent with prior studies in Murine Embryonic Fibroblasts (MEFs) and human cancer cells (<xref ref-type="bibr" rid="bib13">Bancerek et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Steinparzer et al., 2019</xref>). The upregulated Hallmark pathways included cholesterol homeostasis and fatty acid metabolism (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>; <xref ref-type="supplementary-material" rid="fig1sdata4">Figure 1—source data 4</xref>). A set of factors from the IPA upstream regulators analysis underscores this result, identifying TFs and enzymes involved in cholesterol and lipid metabolism as activated in CA-treated T21 cells (<xref ref-type="fig" rid="fig3">Figure 3E–G</xref>), with similar results in D21 (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2G, H</xref>; <xref ref-type="supplementary-material" rid="fig1sdata5">Figure 1—source data 5</xref>). Furthermore, an array of pro-inflammatory TFs were induced in IFNγ-treated T21 and D21 cells, as expected; however, activation of these same TFs was blocked in CA-treated cells (D21 and T21; <xref ref-type="fig" rid="fig3">Figure 3F, G</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2G, H</xref>). These results suggest that inhibition of CDK8/CDK19 suppresses IFNγ responses, in part, through inhibition of pro-inflammatory TF activity, in agreement with prior experiments (<xref ref-type="bibr" rid="bib75">Steinparzer et al., 2019</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Mediator kinase inhibition antagonizes IFNγ transcriptional responses in T21 and D21.</title><p>(<bold>A</bold>) Heatmap comparing gene expression patterns (RNA-seq) in IFNγ-treated D21 or T21 cells ±CA. This comparison shows cortistatin A (CA)-specific effects during IFNγ stimulation, which broadly counter changes caused by IFNγ alone. Genes with statistically significant (padj &lt; 0.01) levels in one or both cell lines in IFNγ vs. control comparisons are shown. (<bold>B</bold>) Representative genome browser tracks for CXCL9 locus in D21 and T21 cells treated with vehicle, IFNγ, or IFNγ + CA. Gene set enrichment analysis (GSEA) moustache plots of Hallmark pathways in D21 (<bold>C</bold>) and T21 (<bold>D</bold>) cells treated with IFNγ + CA compared to IFNγ alone. This shows CA-specific effects during IFNγ stimulation. (<bold>E</bold>) Table of activation <italic>Z</italic>-scores for selected upstream regulators in CA-treated T21 cells treated with IFNγ + CA relative to IFNγ alone. This curated set emphasizes lipid metabolite changes. Ingenuity Pathway Analysis upstream regulators results from comparison of differential gene expression in T21 cells during IFNγ treatment (<bold>F</bold>) or in cells treated with IFNγ + CA compared to IFNγ alone (<bold>G</bold>). Selected transcription factors (TFs) and other factors associated with inflammatory responses are labeled. Analysis used only genes with padj &lt; 0.1.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>The response to exogenous IFNγ is suppressed in T21 vs. D21 cells.</title><p>(<bold>A</bold>) Heatmap of genes with differential expression in D21 or T21 cells treated with IFNγ compared to controls. Genes with adjusted p-value &lt;0.01 in one or both cell lines are shown. (<bold>B</bold>) Average values across biological replicates for reads per kilobase of transcript, per million mapped reads (RPKM) in vehicle-treated D21 cells (<italic>x</italic>-axis) and vehicle-treated T21 cells (<italic>y</italic>-axis). Gray dots represent all genes with an RPKM value &gt;0, and red dots represent genes from the gene set enrichment analysis (GSEA) Hallmarks IFNγ and IFNα signaling pathways. Linear regression trendlines for each set are depicted as follows; black: all genes; red: IFN-response genes. The greater slope for IFN-responsive genes indicates higher basal expression of these genes in T21 cells. (<bold>C</bold>) Similar to panel B, except in IFNγ-treated D21 (<italic>x</italic>-axis) and IFNγ-treated T21 cells (<italic>y</italic>-axis). Note the linear regression trendlines are more similar under IFNγ stimulation conditions, compared with basal conditions (panel B), which provides evidence for dampened IFNγ transcriptional response in T21 cells, likely from higher basal level expression, such that gene expression ends up being similar in T21 and D21 cells treated with exogenous IFNγ. Representative genome browser tracks (RNA-seq data) for SOCS3 (<bold>D</bold>) or STAT1 (<bold>E</bold>) in D21 and T21 cells ±IFNγ treatment. (<bold>F</bold>) Genes with lower (green) or higher (red) relative expression in IFNγ-treated T21 cells (vs. IFNγ-treated D21; adjusted p-value &lt;0.1). Only genes with a log2FC ≥ |0.5| are shown. (<bold>G</bold>) Gene Ontology Enrichment Analysis with the GO aspect ‘Biological Processes’ for genes with reduced responsiveness to IFNγ stimulation in T21 cells. Many genes with reduced expression in T21 cells represent inflammatory pathways, consistent with a suppressed response to exogenous IFNγ in T21 cells, vs. D21.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Mediator kinase inhibition antagonizes IFNγ transcriptional responses.</title><p>Volcano plots of differentially expressed genes in IFNγ-treated cells ±CA in D21 (<bold>A</bold>) or T21 (<bold>B</bold>) cells. Names of selected genes are color-coded based on pro-inflammatory (red) or anti-inflammatory (green) roles. Genes represented by red dots have an adjusted p-value of &lt;0.01. Heatmaps and ‘difference’ heatmaps based upon RNA-seq data under various conditions in D21 (<bold>C</bold>) or T21 (<bold>D</bold>) cells. At left (panel <bold>C, D</bold>), heatmaps represent all genes with an adjusted p-value &lt;0.01 in IFNγ vs. Control comparisons for each cell line. Log2FC values were used to sort genes by expression trends in D21 and T21 cells. Data for IFNγ + CA vs. Ctrl are shown alongside IFNγ vs. Ctrl to better visualize cortistatin A (CA)-dependent effects. For difference heatmaps (at right in panel<bold> C, D</bold>), Log2FC values for each gene in the IFNγ vs. Control comparison were subtracted from Log2FC values for CA + IFNγ vs. Control comparisons to generate ‘difference’ Log2FC values, which are shown in the difference heatmap on the right. (<bold>E</bold>) Dot plots representing average NES for pathways with specific lipid- or inflammation-related terms; terms are on the left. Pathways were analyzed using gene set enrichment analysis (GSEA) GO Biological Processes (GOBP) of relative gene expression in D21 or T21 cells treated with CA for 4.5 hr relative to DMSO. Dot color indicates direction of average NES, with positive = red and negative = blue. Dot size corresponds to the NES magnitude. All pathways with ‘negative regulation of…’ were excluded to avoid confounding the analysis. (<bold>F</bold>) Heatmaps showing inflammatory pathways in the Ingenuity Pathway Analysis ‘Diseases &amp; Functions’ list, generated from RNA-seq data. Heatmaps show pathway activation in IFNγ vs. Control compared to IFNγ + CA vs. IFNγ in both D21 and T21 cells, to focus on CA-dependent effects during IFNγ response. Volcano plots from Ingenuity Pathway Analysis (IPA) upstream regulators results, derived from differential gene expression (RNA-seq) in D21 cells during IFNγ treatment (<bold>G</bold>) or in cells treated with IFNγ + CA compared to IFNγ alone (<bold>H</bold>). Selected transcription factors (TFs) and other factors associated with inflammatory responses are labeled. Note prominent activation of pro-inflammatory TFs in +IFNγ cells (<bold>G</bold>), whereas these same TFs are predicted to be repressed in CA-treated cells (<bold>H</bold>). Analysis used only genes with an adjusted p-value &lt;0.1. Inset: genes related to PPAR or LXR activation. (<bold>I</bold>) Venn diagram showing overlap of leading edge genes in the GSEA ‘Interferon Gamma Response’ pathway based upon RNA-seq data from a T21 vs. D21 whole blood cohort study (<xref ref-type="bibr" rid="bib84">Waugh et al., 2023</xref>) and RNA-seq data from the sibling-matched T21 vs. D21 cells in this study. A substantial number of genes with the IFN ‘leading edge’ designation in this study (i.e. increased expression in T21 vs. D21; 69 out of 80) were shared among the whole blood clinical cohort study; these 69 genes were downregulated by CA treatment in T21 cells. A partial list of these genes is shown, with Log2FC and adjusted p-values. (<bold>J</bold>) The IFN score (<xref ref-type="bibr" rid="bib29">Galbraith et al., 2023</xref>) increases upon IFN stimulation and decreases with CA treatment.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig3-figsupp2-v1.tif"/></fig></fig-group><p>To probe further, we compared the GSEA ‘leading edge’ IFN-response gene set from a whole blood transcriptome dataset generated by the Human Trisome Project (<xref ref-type="bibr" rid="bib84">Waugh et al., 2023</xref>) with the CA-responsive genes in our T21 cell line. As shown in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2I</xref>, 86% of these genes (69 out of 80) overlapped with those identified as elevated in the Human Trisome Project dataset, reflecting a common transcriptional response to IFNγ. Among these IFN-responsive genes were many whose expression decreased upon CA treatment, including STAT1, IRF1, GBP4, MX2, XCL1, and CXCL9. Moreover, CA treatment decreased the IFN score (<xref ref-type="bibr" rid="bib29">Galbraith et al., 2023</xref>) in IFN-stimulated T21 cells (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2J</xref>). These results reveal that Mediator kinase inhibition suppresses transcriptional responses that are typically hyperactivated in DS individuals.</p></sec><sec id="s2-8-2"><title>Metabolome</title><p>Consistent with the RNA-seq results, metabolic changes in D21 and T21 cells reflected a CA-dependent suppression of IFNγ-induced inflammation. CA treatment reversed metabolic changes induced by IFNγ alone (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>). For example, LCFAs, endocannabinoids, oleamide, desmosterol, and bile acids were reduced in D21 cells under IFNγ stimulation conditions, consistent with the anti-inflammatory roles of these metabolites (<xref ref-type="bibr" rid="bib2">Alhouayek and Muccioli, 2014</xref>; <xref ref-type="bibr" rid="bib14">Basil and Levy, 2016</xref>; <xref ref-type="bibr" rid="bib35">Husted et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Kimura et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Jordan and Werz, 2022</xref>). In contrast, their levels were elevated in CA-treated D21 cells. The metabolic effects of Mediator kinase inhibition were blunted in IFNγ-treated T21 cells, which may reflect the already elevated basal IFN signaling in T21 cells (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>; <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). In <xref ref-type="fig" rid="fig4">Figure 4C</xref>, we highlight the CA-dependent elevation of desmosterol and oleamide (LXR and PPAR ligands, respectively), and the CA-dependent decline in quinolinic acid, a tryptophan derivative that is typically elevated in DS (<xref ref-type="bibr" rid="bib58">Powers et al., 2019</xref>). Collectively, the data summarized in <xref ref-type="fig" rid="fig4">Figure 4A–C</xref> are consistent with CA-dependent anti-inflammatory effects.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Mediator kinase inhibition reverses pro-inflammatory metabolic and cytokine changes triggered by IFNγ.</title><p>Effect of IFNγ treatment on select classes of lipid metabolites is shown (IFNγ vs. Ctrl) alongside the effect of cortistatin A (CA) treatment in IFNγ-treated cells, in D21 (<bold>A</bold>) and T21 (<bold>B</bold>) cells. The LCFAs represented here include saturated, mono- and poly-unsaturated FA, shown in rows 3–28 in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>. Each point represents a different metabolite, with line and whiskers representing the mean and SD. Note CA treatment reverses IFNγ effects generally (arrows). (<bold>C</bold>) Box plots showing levels of anti-inflammatory metabolites desmosterol or oleamide, and pro-inflammatory metabolite quinolinate, in D21 or T21 cells treated with DMSO (Ctrl), IFNγ, or IFNγ + CA. Heatmaps showing changes in cytokine levels in D21 (<bold>D</bold>) and T21 (<bold>E</bold>) cells, after the indicated treatments. Only cytokines with relative levels of ≥2.0 (log2FC; red shading) or ≤0.5 (blue shading) in one or both cell lines are shown; cytokines meeting this threshold are outlined in black. Asterisk (*) denotes adjusted padj &lt; 0.1 using ANOVA. Alongside each heatmap set (D21 or T21) is a ‘difference’ heatmap (IFN + CA vs. Ctrl – IFN vs. Ctrl levels) that highlights how Mediator kinase inhibition suppresses cytokine responses to IFNγ.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Metabolomics data sibling-matched T21 and D21 ±CA ±IFNγ.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Mediator kinases transcriptionally enable cytokine responses to IFNγ.</title><p>(<bold>A</bold>) Heatmap of average relative cytokine levels in cells treated with IFNγ + CA compared to IFNγ alone. Only cytokines with relative levels of ≥1.5 (log2FC; red shading) or ≤0.75 (blue shading) in one or both cell lines are shown; cytokines meeting this threshold are outlined in black. Cytokines with an asterisk (*) had an adjusted p-value &lt;0.1 using ANOVA. (<bold>B</bold>) Venn diagrams (RNA-seq data) of cytokines and cytokine receptor genes (in <italic>italics</italic>) that were downregulated (FC &lt;0.8, left diagram) or upregulated (FC &gt;1.2, right diagram) in IFNγ + CA-treated cells compared to IFNγ alone (D21 and T21). Cytokines with matching trends from RNA-seq (4 hr) and cytokine protein measurements (24 hr) are listed in bold, whereas cytokines with inverse trends in at least one cell type are marked with an asterisk.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-8-3"><title>Cytokines</title><p>Compared with basal conditions, many more cytokines showed CA-responsiveness in the context of IFNγ stimulation, and a majority of the changes countered IFNγ-induced inflammatory responses (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). This CA-dependent antagonism of IFNγ cytokine responses is illustrated in the difference heatmaps shown in <xref ref-type="fig" rid="fig4">Figure 4D, E</xref>. Levels of many pro-inflammatory cytokines were reduced in IFNγ + CA-treated D21 and T21 cells, including CXCL9, C5, IL33, IL1α, and others (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>).</p><p>Because cytokine levels were measured 24 hr after treatment, we hypothesized that their altered levels would at least partially correspond to gene expression changes measured earlier, at 4.5 hr post-treatment. This was observed for many IFNγ-induced cytokines impacted by Mediator kinase inhibition, as shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>. (Note that expression changes for cytokine receptors are also shown.) Collectively, the cytokine screen demonstrated that inhibition of Mediator kinase function generally downregulated pro-inflammatory cytokines while upregulating anti-inflammatory cytokines (e.g. IL10, LIF, IL19). In the context of DS, this could potentially mitigate pathological immune system hyperactivation.</p></sec></sec><sec id="s2-9"><title>Mediator kinases regulate splicing in pathway- and cell type-specific ways</title><p>As Mediator-associated kinases, CDK8 and CDK19 are established regulators of RNAPII transcription (<xref ref-type="bibr" rid="bib50">Luyties and Taatjes, 2022</xref>) however, their potential impact on splicing has not been examined. Over 95% of human mRNAs are alternatively spliced and defects in this process contribute to errors in gene expression in human diseases (<xref ref-type="bibr" rid="bib69">Scotti and Swanson, 2016</xref>). We compared alternative splicing events using rMATS (<xref ref-type="bibr" rid="bib70">Shen et al., 2014</xref>), separately evaluating all RNA-seq replicates (biological triplicates; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). The data revealed 741 differential exon skipping events in T21 cells (vs. sibling-matched D21) under basal conditions (<xref ref-type="fig" rid="fig5">Figure 5A, B</xref>; <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>), with approximately equal numbers of increased exon inclusion (<italic>n</italic> = 382) and increased exon skipping events (<italic>n</italic> = 359). A smaller number of other alternative splicing events (e.g. intron retention) were detected (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). We observed similar trends in IFNγ-treated T21 and D21 cells, in which a greater number of exon skipping events (<italic>n</italic> = 418 vs. <italic>n</italic> = 296) occurred in IFNγ-stimulated T21 vs. D21 cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B, C</xref>; <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Mediator kinases regulate splicing in pathway-specific ways.</title><p>(<bold>A</bold>) Table of alternative exon usage from untreated T21 cells compared to D21. Inclusion criteria were assessed at FDR &lt;0.05, |InclusionLevelDifference| &gt;0.2, and ≥2 reads/replicate. (<bold>B</bold>) Sashimi plots for the IFI44L gene, with normalized read numbers for D21 control (black) and T21 control (red) samples on the <italic>y</italic>-axis, and splice junction read numbers (representing each of three replicate experiments). (<bold>C</bold>) Table of alternative exon usage from cortistatin A (CA)-treated D21 or T21 cells compared to controls. Inclusion criteria were same as for panel A. (<bold>D</bold>) Table of alternative exon usage from D21 or T21 cells treated with IFNγ and CA compared to IFNγ alone. Inclusion criteria were same as for panel A. (<bold>E</bold>) Ingenuity Pathway Analysis enrichment results of genes with alternative exon skipping events in T21 vs. D21 cells; different treatment conditions indicated at bottom. Pathways relevant to IFNγ signaling are highlighted in red. Genes affected by alternative splicing in T21 vs. D21 cells could be grouped into different signaling pathways (e.g. RAC, mTOR, integrin) that are important for robust immune responses (<xref ref-type="bibr" rid="bib38">Jones and Pearce, 2017</xref>; <xref ref-type="bibr" rid="bib44">Lee et al., 2021a</xref>), suggesting how alternative splicing may influence inflammatory signaling in T21 cells. Ingenuity Pathway Analysis enrichment results of genes with alternative exon skipping events in D21 (<bold>F</bold>) or T21 (<bold>G</bold>) cells treated with CA (±IFNγ).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Splicing data (rMATS); sibling-matched T21 and D21.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Splicing data (rMATS); non-sibling T21 and sibling T21 <italic>t</italic> = 24 hr.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig5-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Ingenuity Pathway Analysis (IPA) results from splicing data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig5-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Additional information about splicing changes.</title><p>(<bold>A</bold>) Table of alternative splicing events (RNA-seq data) from untreated T21 cells compared to D21. Inclusion criteria were an FDR &lt;0.05, |InclusionLevelDifference| &gt;0.2, and ≥2 reads/replicate. (<bold>B</bold>) Table of alternative splicing events from D21 or T21 cells treated with IFNγ compared to control cells. Inclusion criteria were as indicated in A. (<bold>C</bold>) Sashimi plots of the CBWD3 gene, with normalized read numbers for T21 control (black) and T21 IFNγ (red) samples on the <italic>y</italic>-axis and splice junction read numbers (representing each of three replicate experiments). (<bold>D</bold>) Table of alternative splicing events from D21 or T21 cells treated with cortistatin A (CA) compared to controls. Inclusion criteria were as indicated in A. (<bold>E</bold>) Sashimi plots for the CDK19 gene, with normalized read numbers for T21 Ctrl (black) and T21 +CA (red) samples on the <italic>y</italic>-axis, and splice junction read numbers (representing each of three replicate experiments). Arrow denotes greater inclusion of alternative exon T21 +CA. (<bold>F</bold>) Sashimi plots for the DNHD1 gene, with normalized read numbers for D21 +IFNγ (black) and D21 +IFNγ +CA (red) samples on the <italic>y</italic>-axis, and splice junction read numbers (representing each of three replicate experiments). Arrow denotes greater inclusion of alternative exon D21 +IFNγ +CA. (<bold>G</bold>) Table of alternative splicing events from D21 or T21 cells treated with IFNγ and CA compared to IFNγ alone. Inclusion criteria were as indicated in A. Ingenuity Pathway Analysis enrichment results of genes with alternative exon skipping events in D21 (<bold>H</bold>) or T21 (<bold>I</bold>) cells treated with IFNγ (±CA).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Summary of splicing changes ±CA in non-sibling T21 (<italic>t</italic> = 4.5 hr) and sibling-matched T21 at 24 hr.</title><p>(<bold>A</bold>) Table of alternative exon usage from non-sibling T21 cells ±CA at <italic>t</italic> = 4.5 hr. Inclusion criteria were assessed at FDR &lt;0.05, |InclusionLevelDifference| &gt;0.2, and ≥2 reads/replicate. (<bold>B</bold>) Table of alternative exon usage from sibling T21 cells ±CA at <italic>t</italic> = 24 hr. Inclusion criteria were as described in panel A. (<bold>C</bold>) Ingenuity Pathway Analysis enrichment results of genes with alternative exon skipping events in non-sibling T21 cells ±CA at <italic>t</italic> = 4.5 hr. Pathways relevant to IFN and inflammation are highlighted in red. (<bold>D</bold>) Ingenuity Pathway Analysis enrichment results of genes with alternative exon skipping events in sibling T21 cells ±CA at <italic>t</italic> = 24 hr. Pathways relevant to IFN and inflammation are highlighted in red; RNA splicing/processing in blue.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig5-figsupp2-v1.tif"/></fig></fig-group><p>To determine whether Mediator kinase activity might influence splicing, we next evaluated CA-treated D21 and T21 cells. We found that CA treatment had a substantial impact on splicing, in both D21 and T21 cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). We identified 432 or 444 sites with altered exon skipping events (D21 or T21, respectively) in CA-treated cells compared with controls (ΔPSI [percent spliced in] ≥0.2, padj &lt; 0.05; <xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>; <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>), and CA treatment increased inclusion of alternative exons more frequently than it increased their skipping in both lines (<italic>n</italic> = 239 vs. 193 in D21; <italic>n</italic> = 256 vs. 188 in T21). Similarly in IFNγ-treated D21 and T21 cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>; <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>), Mediator kinase inhibition favored exon inclusion (<italic>n</italic> = 178 in D21; 213 in T21) over exon skipping (<italic>n</italic> = 130 in D21; 148 in T21).</p><p>To assess whether the exon inclusion events sensitive to Mediator kinase function were selective for specific gene sets, we completed pathway analyses (IPA) across all conditions tested (<xref ref-type="fig" rid="fig5">Figure 5E–G</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1H, I</xref>; <xref ref-type="supplementary-material" rid="fig1sdata5">Figure 1—source data 5</xref>). To increase statistical power, we grouped exon skipping events together (i.e. alternative exon inclusion events +alternative exon skipping events). Thus, the T21 vs. D21 comparison included 741 events, D21 +CA vs. Ctrl included 432 events, and so on. The results revealed that splicing changes triggered by Mediator kinase inhibition were cell type-specific (T21 vs. D21) and selectively impacted inflammatory and metabolic pathway genes. As shown in <xref ref-type="fig" rid="fig5">Figure 5E</xref>, genes associated with inflammatory signaling (red highlighted pathways) showed evidence of differential splicing in CA-treated T21 cells (vs. D21) during IFNγ stimulation. In addition, pyrimidine salvage and biosynthesis genes were alternatively spliced in CA-treated T21 cells (vs. DMSO; <xref ref-type="fig" rid="fig5">Figure 5G</xref>). These pathway-specific effects in CA-treated cells were consistent with gene expression changes (e.g. GSEA Hallmark gene sets, <xref ref-type="supplementary-material" rid="fig1sdata4">Figure 1—source data 4</xref>) and metabolic changes observed in CA-treated cells. For instance, the pyrimidine biosynthesis intermediates <italic>N</italic>-carbamoylaspartate, dihydro-orotate, and orotate were markedly depleted (1.4- to 3-fold) in CA-treated T21 cells (vs. DMSO; <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). The data in <xref ref-type="fig" rid="fig5">Figure 5G</xref> implicate CA-dependent splicing changes as a contributing factor.</p><p>Finally, we completed parallel splicing analyses for (1) the different donor T21 cell line ±CA treatment for 4.5 hr, as well as for (2) the sibling-matched T21 line with 24 hr CA treatment (vs. DMSO controls). We identified 349 sites with altered exon skipping events in the 4.5 hr CA-treated non-sibling T21 cells, and 309 sites in the sibling-matched T21 line at 24 hr ±CA (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A, B</xref>; <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>). We next completed a pathway analysis (IPA) of genes with differential exon skipping (i.e. alternative exon inclusion events + alternative exon skipping events) ± CA (<xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>). For the sibling-matched line with 24 hr CA treatment, IPA identified various metabolic and signaling cascades, including JAK–STAT, whereas the IPA results from the different donor T21 line (<italic>t</italic> = 4.5 hr ±CA) yielded results more similar to the other T21 line after 4.5 hr CA treatment (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2C, D</xref>). In particular, IFN signaling pathways were represented, further implicating Mediator kinases as context-specific regulators of RNAPII transcription and splicing.</p></sec><sec id="s2-10"><title>Altered TF function underlies metabolic and anti-inflammatory effects in Mediator kinase-inhibited T21 cells</title><p>Sequence-specific, DNA-binding TFs are a major target of Mediator kinases, based upon quantitative phosphoproteomics data (<xref ref-type="bibr" rid="bib57">Poss et al., 2016</xref>). To broadly assess how TF activity changed in response to Mediator kinase inhibition, we completed PRO-seq experiments in control vs. CA-treated T21 cells. When sequenced at high depth (≥60 M reads/replicate), PRO-seq allows reliable detection of short, bidirectional transcripts that center around consensus TF-binding sites. Studies from numerous labs have shown that these bidirectional transcripts represent ‘signatures’ of active TFs bound to these sites (<xref ref-type="bibr" rid="bib11">Azofeifa et al., 2018</xref>; <xref ref-type="bibr" rid="bib82">Wang et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Kristjánsdóttir et al., 2020</xref>; <xref ref-type="bibr" rid="bib64">Rubin et al., 2021</xref>). Similarly, loss of bidirectional transcription indicates reduced TF activity.</p><p>Because our primary interest was CA-dependent suppression of hyperactive IFN signaling in DS, we completed PRO-seq experiments in T21 cells under basal conditions, ±CA treatment (<italic>t</italic> = 75 min). We then applied TFEA (Transcription Factor Enrichment Analysis), a well-tested method to globally assess TF activity from PRO-seq data (<xref ref-type="bibr" rid="bib64">Rubin et al., 2021</xref>). As shown in <xref ref-type="fig" rid="fig6">Figure 6A</xref>, CA treatment broadly shut down pro-inflammatory TFs in T21 cells (e.g. IRF4, IRF8, SPIB, BACH1, RELA; examples shown in <xref ref-type="fig" rid="fig6">Figure 6B</xref>), consistent with the ‘downstream’ RNA-seq (4.5 hr), cytokine (24 hr), and metabolomics data (24 hr). Furthermore, it was evident that CA treatment rapidly repressed the p53 family of TFs (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). As a tumor suppressor, p53 represses cholesterol and lipid biosynthesis pathways, in part by blocking activation of SREBP (<xref ref-type="bibr" rid="bib55">Moon et al., 2019</xref>). Rapid suppression of p53 by Mediator kinase inhibition is consistent with the metabolic changes observed in CA-treated T21 cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Moreover, the RNA-seq data implicated SREBP TF activation in CA-treated T21 cells vs. DMSO controls at later time points (4–24 hr), consistent with de-repression of SREBP following CA-dependent inhibition of p53 activity. From these results, we conclude that altered TF function is a major contributor to (1) CA-dependent metabolic changes and (2) suppression of pro-inflammatory IFN signaling in T21 cells.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Mediator kinase inhibition rapidly suppresses pro-inflammatory transcription factors (TFs) in T21 cells.</title><p>(<bold>A</bold>) MA plot of Transcription Factor Enrichment Analysis (TFEA) results comparing control (DMSO) vs. cortistatin A (CA)-treated T21 cells under basal conditions, from PRO-seq experiments completed after 75-min CA treatment. (<bold>B</bold>) Representative examples of bidirectional ‘eRNA’ transcription from PRO-seq data, showing reduced levels in CA-treated cells. Location of TF consensus binding motifs indicated with dashed line.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Transcription Factor Enrichment Analysis (TFEA) results from PRO-seq data, T21 ±CA.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100197-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig6-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Previous studies have shown that Mediator kinases regulate transcriptional responses to inflammatory stimuli (e.g. IFNγ or TNFα) in a variety of model systems (<xref ref-type="bibr" rid="bib16">Chen et al., 2017</xref>; <xref ref-type="bibr" rid="bib75">Steinparzer et al., 2019</xref>). Because individuals with DS have chronic, hyperactive IFN signaling (<xref ref-type="bibr" rid="bib77">Sullivan et al., 2016</xref>), we hypothesized that Mediator kinase inhibition would antagonize inflammatory signaling cascades in T21 cells. This hypothesis was supported by the experimental results described here. To maintain focus on Mediator kinase activity, we avoided knockdown or knockout experiments, in part because CDK8/CDK19 proteins serve additional functions that are not kinase-dependent (<xref ref-type="bibr" rid="bib57">Poss et al., 2016</xref>; <xref ref-type="bibr" rid="bib9">Audetat et al., 2017</xref>; <xref ref-type="bibr" rid="bib71">Sooraj et al., 2022</xref>; <xref ref-type="bibr" rid="bib17">Chen et al., 2023</xref>). Collectively, our results expand upon established concepts for CDK8 and CDK19 (e.g. regulation of IFNγ signaling) and reveal new insights about their impact on TF activation, metabolic and cytokine responses, as well as their effect on pre-mRNA splicing. Our results also establish Mediator kinases as potential therapeutic targets to suppress hyperactive IFN signaling in DS.</p><p>We acknowledge that individual-to-individual genetic variation could contribute to the differences we observe in our T21 vs. D21 comparisons (<xref ref-type="bibr" rid="bib77">Sullivan et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Hwang et al., 2021</xref>). We chose cell lines from sibling donors (both males of similar age) to minimize this possibility. Moreover, cross-referencing our results with data collected from large cohorts of individuals of varying age and sex (with/without T21) showed broadly similar trends in transcript (<xref ref-type="bibr" rid="bib84">Waugh et al., 2023</xref>), metabolite (<xref ref-type="bibr" rid="bib58">Powers et al., 2019</xref>), and cytokine levels (<xref ref-type="bibr" rid="bib53">Malle et al., 2023</xref>) in the T21/D21 comparisons. Although our multi-omics T21/D21 comparisons yielded new insights, Mediator kinases were a focus of this study, and the T21/D21 comparisons primarily served as benchmarks to assess CDK8/CDK19 function in the context of DS and IFNγ signaling. A limitation of this study was that only two donor-derived T21 cell lines were evaluated, with one sibling-matched D21 line. Furthermore, the transcriptomic, metabolomic, and cytokine data were collected at select time points, such that some temporal trends in IFNγ responses can only be inferred (see below).</p><sec id="s3-1"><title>CDK8 and CDK19 kinase activity impacts core metabolic pathways</title><p>Metabolomics has been described as the most direct readout of cell state, yielding a ‘front line’ assessment of the biochemicals that drive all cellular processes (<xref ref-type="bibr" rid="bib62">Rinschen et al., 2019</xref>). The role of Mediator kinases in human cell metabolism is poorly understood. As a whole, our metabolomics data revealed the most striking CDK8/CDK19 effects on nucleotide biosynthesis (especially in D21) and lipid homeostasis. Nucleotide levels (purines and pyrimidines) and their intermediates were broadly reduced in CA-treated cells whereas different classes of lipids were generally elevated (<xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>).</p><p>The gene expression changes (RNA-seq, 4.5 or 24 hr) triggered by Mediator kinase inhibition tracked with these ‘downstream’ (24 hr) metabolic changes (e.g. <xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). For example, nucleotide biosynthesis mRNAs were downregulated whereas lipid metabolism mRNAs were upregulated in CA-treated cells; this was reflected in the GSEA Hallmarks, with positive enrichment for pathways such as cholesterol homeostasis, bile acid metabolism, and FA metabolism and negative enrichment for DNA repair pathways, which contains many nucleotide biosynthesis genes. The differential timing of the transcriptomics and metabolomics experiments helps link CA-dependent metabolic changes to gene expression changes; however, we cannot exclude other factors and pathways. For example, reduced levels of nucleotides can trigger cellular compensation through upregulation of FA levels (<xref ref-type="bibr" rid="bib67">Schoors et al., 2015</xref>). Consequently, elevated levels of FA and other lipids may result, in part, from compensatory mechanisms triggered by CA-dependent reductions in nucleotide levels.</p></sec><sec id="s3-2"><title>Pathway-specific regulation of splicing by Mediator kinases</title><p>Despite widespread study of Mediator kinases as regulators of RNAPII transcription, their potential function in splicing has not been addressed. We hypothesized that CDK8 and/or CDK19 may impact splicing based upon prior results that identified NAB2, SRRM2, and KDM3A as high-confidence CDK8/CDK19 substrates in human cells (<xref ref-type="bibr" rid="bib57">Poss et al., 2016</xref>) each of these proteins has been linked to regulation of splicing (<xref ref-type="bibr" rid="bib30">Gautam et al., 2015</xref>; <xref ref-type="bibr" rid="bib72">Soucek et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Baker et al., 2021</xref>). Our analysis revealed that exon skipping was dependent upon the kinase function of CDK8 and/or CDK19; increased inclusion or skipping of hundreds of alternative exons was observed in CA-treated cells (D21 or T21), and this was observed under both basal and IFNγ-stimulated conditions (e.g. <xref ref-type="fig" rid="fig5">Figure 5C, D</xref>).</p><p>Pathway analysis of the CA-dependent alternative splicing events identified gene sets associated with signaling pathways known to be regulated by Mediator kinases, such as TGFβ and IFN signaling (<xref ref-type="fig" rid="fig5">Figure 5E</xref>; <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Interestingly, CA-dependent alternative splicing of IFN-related gene sets occurred specifically in T21 cells (not D21); moreover, other pathways were selectively affected by Mediator kinase inhibition in cell type and context-specific ways. For instance, mTOR pathway genes in CA-treated D21 cells and pyrimidine metabolism genes in T21 cells (<xref ref-type="fig" rid="fig5">Figure 5F, G</xref>).</p><p>Taken together, these results suggest that Mediator kinases regulate pre-mRNA splicing, which adds to the mechanisms by which CDK8 and CDK19 can influence gene expression. Our data further suggest that kinase-dependent splicing regulation occurs in cell type- and context-specific ways, similar to other known regulatory functions for CDK8 and CDK19 (<xref ref-type="bibr" rid="bib50">Luyties and Taatjes, 2022</xref>). We emphasize, however, that the effects of CDK8/CDK19 on splicing are modest, especially compared with CDK7, a different transcription-associated kinase (<xref ref-type="bibr" rid="bib61">Rimel et al., 2020</xref>).</p><p>The mechanisms by which CDK8 and/or CDK19 influence pre-mRNA splicing remain unclear, but are likely to involve both direct kinase-dependent regulation of splicing factors (e.g. through phosphorylation of NAB2 or SRRM2) and indirect regulation through phosphorylation of DNA-binding TFs, which can regulate splicing (<xref ref-type="bibr" rid="bib59">Rambout et al., 2018</xref>) and are common Mediator kinase substrates (<xref ref-type="bibr" rid="bib57">Poss et al., 2016</xref>). Differential expression of splicing regulatory proteins in CA-treated cells may also contribute, based upon the reduced expression of splicing regulators at longer timeframes (<italic>t</italic> = 24 hr CA treatment; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E</xref>).</p></sec><sec id="s3-3"><title>Mediator kinase inhibition activates nuclear receptors through lipid metabolites</title><p>The anti-inflammatory lipids elevated in CA-treated cells included oleamide, desmosterol, endocannabinoids such as OEA, and PUFAs such as EPA, DPA, DHA, and various other ω3 or ω6 PUFAs. These metabolites act as signaling molecules, at least in part, through binding nuclear receptors or GPCRs such as FFAR1, FFAR4, and GPR119, to initiate a cascade of anti-inflammatory responses (<xref ref-type="bibr" rid="bib27">Fu et al., 2003</xref>; <xref ref-type="bibr" rid="bib14">Basil and Levy, 2016</xref>; <xref ref-type="bibr" rid="bib35">Husted et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Kimura et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Jordan and Werz, 2022</xref>). Our RNA-seq results (4.5 and 24 hr) confirmed CA-dependent activation of nuclear receptors PPAR and LXR, but only under conditions with elevated IFN signaling (e.g. T21 cells or D21 +IFNγ). Furthermore, metabolomics data revealed elevated levels of PPAR and LXR ligands (e.g. oleamide, endocannabinoids, desmosterol) only in CA-treated cells in the context of hyperactive IFN signaling. These results reveal an unexpected mechanistic link between Mediator kinase activity and nuclear receptor function, and suggest potential regulation of GPCR function as well (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Metabolic changes are generally not considered when evaluating the biological function of transcription-associated kinases such as CDK8 and CDK19. Our results demonstrate that kinase inhibition can activate TFs through metabolic changes, and suggest that during IFNγ stimulation, Mediator kinases normally suppress metabolic pathways that would activate PPAR and LXR nuclear receptors.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Working model for Mediator kinase-dependent regulation of IFNγ signaling.</title><p>Under conditions of IFN stimulation, Mediator kinase inhibition suppresses pro-inflammatory transcriptional responses, including expression of cytokine genes and receptors. Mechanistically, this occurs through rapid inhibition of IRF and NFκB transcription factors (TFs), which persists 4–24 hr after Mediator kinase inhibition. Mediator kinase inhibition also activates SREBP, which likely results from rapid suppression of p53 (<xref ref-type="bibr" rid="bib55">Moon et al., 2019</xref>). Metabolic changes include increased levels of PPAR and LXR ligands, which tracks with activation of PPAR and LXR target genes 4–24 hr after Mediator kinase inhibition. See text for additional details.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-fig7-v1.tif"/></fig></sec><sec id="s3-4"><title>Mediator kinase inhibition antagonizes IFN signaling</title><p>Independently and collectively, our transcriptomics, metabolomics, and cytokine screen data revealed that Mediator kinase inhibition suppressed pro-inflammatory signaling. This was most evident during IFNγ stimulation but was also apparent under basal conditions, especially in T21 cells due to their high ‘baseline’ activation of IFN signaling pathways. We acknowledge that metabolites and cytokines can have variable, dynamic, and context-specific effects on inflammatory signaling. For example, sphingolipids (<xref ref-type="bibr" rid="bib51">Maceyka and Spiegel, 2014</xref>) and bile acids may serve pro- or anti-inflammatory roles depending upon cell type (<xref ref-type="bibr" rid="bib18">Chiang and Ferrell, 2019</xref>), and cytokine responses are complex, in part because cytokines regulate each other (e.g. MIP3α/CCL20 is downregulated by IL10). For this study, a more straightforward metric for an anti-inflammatory change was whether CA treatment countered the effect of IFNγ stimulation alone. This was observed in a large number of cases across all experiments.</p><p>CDK8 and CDK19 are established regulators of RNAPII transcription (<xref ref-type="bibr" rid="bib50">Luyties and Taatjes, 2022</xref>). Accordingly, the majority of CA-dependent effects that we have characterized here result from gene expression changes, consistent with our TFEA results (<xref ref-type="fig" rid="fig7">Figure 7</xref>) and prior phosphoproteomics data that identified TFs and other RNAPII regulatory factors as high-confidence targets of CDK8/CDK19 in human cells (<xref ref-type="bibr" rid="bib57">Poss et al., 2016</xref>). The staggered timing of our PRO-seq (75 min), RNA-seq (4.5 or 24 hr), metabolomics (24 hr), and cytokine screen experiments (24 hr) allowed inference of direct vs. indirect effects of Mediator kinase inhibition. As expected, we observed changes in anti-inflammatory transcriptional responses over time, which likely reflects compensatory responses to Mediator kinase inhibition.</p><p>Taken as a whole, our results suggest that under conditions of IFN pathway stimulation, CDK8/CDK19 inhibition initiates a cascade of events that mediate anti-inflammatory responses (<xref ref-type="fig" rid="fig7">Figure 7</xref>). At short timeframes (75 min), Mediator kinase inhibition suppressed activation of IFN-responsive, pro-inflammatory TFs in T21 cells (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Consistent with these results, mRNA levels of pro-inflammatory genes were subsequently reduced in CA-treated T21 cells (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5C, D</xref>), as were protein levels of pro-inflammatory cytokines (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Similar CA-dependent effects were observed with exogenous IFNγ stimulation in both T21 and D21 cells (<xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>). TFEA also identified p53 as rapidly suppressed in CA-treated T21 cells (<italic>t</italic> = 75 min); p53 blocks SREBP activation and this contributes partially or completely to p53-dependent suppression of cholesterol and lipid biosynthesis (e.g. to suppress growth) (<xref ref-type="bibr" rid="bib55">Moon et al., 2019</xref>). CA-dependent suppression of p53 function in T21 cells could therefore activate SREBP to elevate cholesterol and lipid biosynthesis. In agreement, RNA-seq data (<italic>t</italic> = 4.5 or 24 hr) identified SREBP (IPA upstream regulators), cholesterol homeostasis and fatty acid metabolism (GSEA Hallmarks) as activated upon Mediator kinase inhibition. SREBP TFs activate cholesterol and lipid biosynthesis pathways, and metabolomics data revealed elevated levels of anti-inflammatory lipids in CA-treated cells during IFNγ signaling (e.g. D21 cells +IFNγ; T21 cells at basal conditions). Among these elevated lipids, oleamide, desmosterol, and PUFAs are nuclear receptor agonists that activate PPAR and LXR (<xref ref-type="bibr" rid="bib86">Yang et al., 2006</xref>; <xref ref-type="bibr" rid="bib79">Sun and Bennett, 2007</xref>; <xref ref-type="bibr" rid="bib73">Spann et al., 2012</xref>; <xref ref-type="bibr" rid="bib63">Roy et al., 2016</xref>); PPAR and LXR, in turn, broadly control fatty acid biosynthesis (<xref ref-type="bibr" rid="bib68">Schultz et al., 2000</xref>), including PUFAs such as DPA, DHA, and EPA, whose levels were consistently elevated in CA-treated cells. In this way, Mediator kinase inhibition may robustly and durably elevate lipid metabolites, with potential downstream consequences for inflammatory signaling and nuclear receptor function (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p></sec><sec id="s3-5"><title>Concluding remarks</title><p>Although the factors that contribute to the DS condition are complex (<xref ref-type="bibr" rid="bib6">Antonarakis et al., 2020</xref>), it has been described as both an interferonopathy (<xref ref-type="bibr" rid="bib77">Sullivan et al., 2016</xref>) and a cytokinopathy (<xref ref-type="bibr" rid="bib53">Malle et al., 2023</xref>). An emerging theme in DS research is that individuals with DS could benefit from therapeutic strategies that diminish chronic, hyperactive IFN signaling (<xref ref-type="bibr" rid="bib78">Sullivan et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tuttle et al., 2020</xref>; <xref ref-type="bibr" rid="bib84">Waugh et al., 2023</xref>). Through multi-omics evaluation of CA-dependent effects in T21 cells, we have demonstrated that Mediator kinase inhibition antagonizes hyperactive IFN signaling, via diverse mechanisms that extend beyond transcription (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Consequently, selective inhibition of Mediator kinase function represents a potential therapeutic strategy to address chronic inflammation and its associated co-morbidities in DS.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture</title><p>Immortalized lymphoblastoid cell lines derived from age- and sex-matched sibling pairs (male; one D21, age 5.7 years: TIC0000259, one T21, age 3.1 years: TIC0000177) were obtained from the Nexus Biobank. The non-sibling T21 line was also obtained from the Nexus Biobank (male, age 10.7 years; TIC0001672). Cell lines were authenticated (STR profiling) by Nexus Biobank and tested negative for mycoplasma. Cells were cultured in RPMI medium (Gibco, 23400062) supplemented with 20% fetal bovine serum (Peak Serum Inc, PS-FB3), 1× GlutaminePlus (R&amp;D Systems, R90210), and 1× penicillin–streptomycin (Gibco, 15140-163), on low-attachment flasks at 37°C and 5% CO<sub>2</sub>. Due to the lower proliferation rate of T21 cells compared to D21 cells, T21 cells were seeded at twice the density of D21 cells for all experiments unless otherwise noted. For all CA treatments, the compound remained in the media during IFNγ stimulation.</p></sec><sec id="s4-2"><title>Western blotting</title><p>RIPA lysis buffer (Thermo Scientific, 89900) was used to generate cell lysates; all lysis was performed at 4°C in the presence of Halt Protease and Phosphatase Inhibitor Cocktail, EDTA-free (100×) (Thermo Scientific, 78441) and Benzonase endonuclease (Millipore Sigma, 101697). The BCA Protein Assay Kit (Pierce, 23227) was used to measure and normalize protein concentrations across samples. Protein samples were boiled for 5 min at 95°C in 4× Laemmli Sample Buffer (Bio-Rad, 1610747) and run on SDS-acrylamide gels, followed by transfer to nitrocellulose membranes. Blocking was performed using either 5% milk in TBS-T or in 5% bovine serum albumin for phospho-antibodies.</p><p>Antibodies used are as follows: anti-STAT1 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2198300">AB_2198300</ext-link>; Cell Signaling Technology, 9172), anti-phospho STAT1 S727 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2197983">AB_2197983</ext-link>; Cell Signaling Techology, 9177), and anti-GAPDH (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_1080976">AB_1080976</ext-link>; GeneTex, GTX100118). HRP-conjugated anti-rabbit secondary antibody was used for detection (Invitrogen, 31480) and protein was visualized using Immunobilon Western Chemilumiescent HRP Substrate (Millipore, WBKLS0500) on an ImageQuant LAS 4000 (GE Healthcare). Intensity values were quantified and normalized using ImageJ.</p></sec><sec id="s4-3"><title>RT-qPCR</title><p>Cells were seeded and allowed to recover for 24 hr prior to being treated with 10 ng/ml interferon gamma (Gibco PHC4031) or vehicle (40 mM Tris pH 7.4). Total RNA was isolated using TRizol (Invitrogen, 15596026) according to the manufacturer’s instructions, quantified with a Qubit 3.0 using the RNA High Sensitivity (HS) kit (Invitrogen, Q32855), and 100 ng of RNA from each sample was converted to cDNA using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 4368813) following the manufacturer’s instructions. cDNA was diluted to 0.25 ng/μl for all samples, and amplification was performed using Sybr Select Master Mix (Thermo Fisher Scientific, 4472908) on a Bio-Rad CFX384 Real Time PCR System. ΔΔCT values were calculated using GAPDH as a loading control. Treatments, RNA isolation, and RT-qPCR were performed in biological duplicate. The primers used for qPCR are as follows – GAPDH Forward: <named-content content-type="sequence">ACCACAGTCCATGCCATCAC</named-content>, GAPDH Reverse: <named-content content-type="sequence">TCCACCACCCTGTTGCTGTA</named-content>, GBP1 Forward: <named-content content-type="sequence">GTGCTAGAAGCCAGTGCTCGT</named-content>, GBP1 Reverse: <named-content content-type="sequence">TGGGCCTGTCATGTGGATCTC</named-content>, IRF1 Forward: <named-content content-type="sequence">GAGGAGGTGAAAGACCAGAGC</named-content>, IRF1 Reverse: <named-content content-type="sequence">TAGCATCTCGGCTGGACTTCGA</named-content>.</p><p>To probe the timing of the RNA-seq experiments, we completed RT-qPCR at various time points as shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>. The 4 hr time point (post-IFNγ) was chosen because robust induction of GBP1 and IRF1 mRNA was observed. Whereas mRNA levels remained high at 6 hr, we selected the 4 hr time point because it would better represent the primary transcriptional response; moreover, the 4 hr time point was consistent with prior transcriptomics studies of IFNγ response in mammalian cells (<xref ref-type="bibr" rid="bib75">Steinparzer et al., 2019</xref>).</p></sec><sec id="s4-4"><title>Metabolomics</title><p>For each treatment condition, six flasks of cells were seeded and allowed to recover for 24 hr prior to treatment. Cells were pre-treated with 0.1% DMSO or 100 nM CA for 1 hr, then treated with 40 mM Tris, pH 7.4 or 10 ng/ml interferon gamma (Gibco, PHC4031). After 24 hr of interferon gamma treatment, cells were harvested and snap-frozen in liquid nitrogen. Sample preparation was carried out by Metabolon (Durham, North Carolina, USA) using a previously published workflow (<xref ref-type="bibr" rid="bib25">Ford et al., 2020</xref>). Samples were prepared using the automated MicroLab STAR system from Hamilton Company, and several recovery standards were added prior to the first step in the extraction process for QC purposes. To remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. The resulting extract was divided into five fractions: two for analysis by two separate reverse phase (RP)/UPLC–MS/MS methods with positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC–MS/MS with negative ion mode ESI, one for analysis by HILIC/UPLC–MS/MS with negative ion mode ESI, and one sample was reserved for backup. Samples were placed briefly on a TurboVap (Zymark) to remove the organic solvent.</p><p>All methods utilized a Waters ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. The sample extract was dried then reconstituted in solvents compatible to each of the four methods. Each reconstitution solvent contained a series of standards at fixed concentrations to ensure injection and chromatographic consistency. One aliquot was analyzed using acidic positive ion conditions, chromatographically optimized for more hydrophilic compounds. In this method, the extract was gradient eluted from a C18 column (Waters UPLC BEH C18-2.1 × 100 mm, 1.7 µm) using water and methanol, containing 0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA). Another aliquot was also analyzed using acidic positive ion conditions, however it was chromatographically optimized for more hydrophobic compounds. In this method, the extract was gradient eluted from the same afore mentioned C18 column using methanol, acetonitrile, water, 0.05% PFPA, and 0.01% FA and was operated at an overall higher organic content. Another aliquot was analyzed using basic negative ion optimized conditions using a separate dedicated C18 column. The basic extracts were gradient eluted from the column using methanol and water, however with 6.5 mM Ammonium Bicarbonate at pH 8. The fourth aliquot was analyzed via negative ionization following elution from a HILIC column (Waters UPLC BEH Amide 2.1 × 150 mm, 1.7 µm) using a gradient consisting of water and acetonitrile with 10 mM Ammonium Formate, pH 10.8. The MS analysis alternated between MS and data-dependent MSn scans using dynamic exclusion. The scan range varied slighted between methods but covered 70–1000 <italic>m</italic>/<italic>z</italic>.</p><p>Identification of metabolites was performed through automated comparison of the ion features in experimental samples to a reference library of chemical standard entries (<xref ref-type="bibr" rid="bib22">Dehaven et al., 2010</xref>), and are based on three criteria: retention index within a narrow RI window of the proposed identification, accurate mass match to the library ±10 ppm, and the MS/MS forward and reverse scores between the experimental data and authentic standards. The MS/MS scores are based on a comparison of the ions present in the experimental spectrum to the ions present in the library spectrum. While there may be similarities between these molecules based on one of these factors, the use of all three data points can be utilized to distinguish and differentiate biochemicals.</p></sec><sec id="s4-5"><title>Statistical and pathway analysis of metabolomics data</title><p>Two types of statistical analyses were performed: (1) significance tests and (2) classification analysis. Standard statistical analyses were performed in Array Studio on log-transformed data. For analyses not standard in Array Studio, the R program (<ext-link ext-link-type="uri" xlink:href="http://cran.r-project.org/">http://cran.r-project.org/</ext-link>) was used. Following log transformation and imputation of missing values, if any, with the minimum observed value for each compound, Welch two-sample <italic>t</italic> test was used as a significance test to identify biochemicals that differed significantly (p &lt; 0.05) between experimental groups. An estimate of the false discovery rate (<italic>q</italic>-value) was calculated to take into account the multiple comparisons that normally occur in metabolomic-based studies. Classification analyses included principal component analysis, hierarchical clustering, and random forest.</p><p>Pathway analysis of metabolomic data was performed using the Ingenuity Pathway Analysis software (QIAGEN) (<xref ref-type="bibr" rid="bib42">Krämer et al., 2014</xref>). For metabolomic analysis, a total of 566 out of 675 metabolites could be mapped using one of the following identifiers: CAS registry number, Human Metabolome Database (HMDB) identification, KEGG, PubChem CID, or RefSeq number; metabolites not used in IPA analysis can be found in <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>. Metabolomic pathway analysis used only mapped metabolites with a p-value of &lt;0.1 when making pathway predictions.</p></sec><sec id="s4-6"><title>Seahorse metabolic assays</title><p>Cells for metabolic assays were seeded 24 hr prior to treatments and allowed to recover, then were treated with either vehicle or CA at a final concentration of 100 nM. After 24 hr of treatment, cells were collected, washed, and resuspended in Seahorse XF RPMI Assay Media (Agilent, 103576) supplemented with 10 mM glucose (Agilent, 103577-100), 1 mM pyruvate (Agilent, 103578-100), and 2 mM glutamine (Agilent, 103579-100). Cells were counted and for each cell line 100,000 cells were seeded per well on XF24 cell culture plates that had been pre-coated with poly-<sc>D</sc>-lysine (Gibco, A3890401). The plates were spun down at 300 × <italic>g</italic> for 3 min using the minimum brake setting, and cells were then allowed to recover for 30–60 min in a humidified, non-CO<sub>2</sub> incubator set to 37°C. Compounds from the Mito Stress Test Kit (Agilent, 103015-100) were used at the following final concentrations: 1.5 µM Oligomycin, 1 µM FCCP, and 5 µM Rotenone/Antimycin A. All assays were performed on an Agilent Seahorse XFe24 Analyzer (XFe version 2.6.3.5), and data were processed using the Agilent Wave software (version 2.6.3). Two to three technical replicates of each treatment condition were plated per assay, and three biological replicates of each assay were completed on different days. Across all three biological replicates, measurements from 2 wells that did not exhibit a drop in OCR of at least 30% following Oligomycin injection were considered outliers and were removed from analysis. Technical replicates from each assay were averaged, and the average OCR or ECAR values for each treatment condition or genotype at each time point were normalized relative to the first baseline measurement taken of vehicle-treated cells (for treatment comparisons) or D21 cells (for the cross-genotype comparisons). Relative values for OCR or ECAR at each time point, for each treatment condition, were averaged between all three biological replicates.</p></sec><sec id="s4-7"><title>RNA-seq</title><p>Cells were pre-treated with 0.1% DMSO or 100 nM CA for 30 min, then treated with 40 mM Tris, pH 7.4 or 10 ng/ml interferon gamma (Gibco, PHC4031). After 4 hr, total RNA was isolated from D21 or T21 cells using TRizol (Invitrogen, 15596026) as specified by the manufacturer and quantified with a Qubit 3.0 using the RNA High Sensitivity (HS) kit (Invitrogen, Q32855). 1 μg of total RNA with an RIN number of ≥8 was used for RNA-seq library prep. Libraries were constructed using Universal Plus mRNA-Seq library preparation kit with NuQuant (Tecan, 0520). Library construction and sequencing were performed at the Genomics Shared Resource (CU Anschutz). Paired-end libraries (151 bp × 151 bp) were sequenced on the Illumina NextSeq 6000 platform (Firmware version 1.26.1, RTA version: v3.4.4, Instrument ID: A00405).</p><p>For the non-sibling T21 and sibling T21 <italic>t</italic> = 24 hr RNA-seq experiments, cells were treated with 0.1% DMSO or 100 nM CA for 4.5 hr (non-sibling T21) or 24 hr (sibling T21). After treatment, total RNA was isolated using TRizol (Invitrogen, 15596026) as specified by the manufacturer and quantified with a Qubit 3.0 using the RNA High Sensitivity (HS) kit (Invitrogen, Q32855). 200 ng of total RNA with an RIN number of ≥8 was used for RNA-seq library prep. Libraries were constructed using the Zymo-Seq RiboFree Total RNA Library Kit (Zymo Research). Paired-end sequencing reads of 150 nucleotides were generated on a NovaSeq X (RTA v4.6.7, Serial Number LH00407, Firmware v1.2.0.28691) and de-multiplexed using bcl2fastq.</p></sec><sec id="s4-8"><title>RNA-seq computational analysis</title><p>For differential gene expression analysis, the workflow was as follows: adaptor sequences were trimmed from the RNA-seq raw fastq files using BBDuk (<ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/projects/bbmap/">https://sourceforge.net/projects/bbmap/</ext-link>) and mapped using HISAT2 (<xref ref-type="bibr" rid="bib40">Kim et al., 2019</xref>). Gene counts were generated using featureCounts (<xref ref-type="bibr" rid="bib47">Liao et al., 2014</xref>), and differential expression analysis was performed using DESeq2 (<xref ref-type="bibr" rid="bib3">Anders and Huber, 2010</xref>). When there were multiple transcripts per gene, those with the highest FPKM were kept for analysis. For inter-genotype (T21 vs. D21) comparisons, expression of genes on chromosome 21 was normalized to ploidy. While ERCC RNA Spike-In Mix (Invitrogen, 4456740) was added to isolated RNA samples prior to sequencing, ERCC gene counts were variable across vehicle-treated samples even after accounting for read depth, and when using multiple normalization methods and a linear regression. As such, the median of ratios method native to DESeq2 was used to generate size factors and normalize samples. QIAGEN Ingenuity Pathway Analysis (IPA) version 90348151 (<xref ref-type="bibr" rid="bib42">Krämer et al., 2014</xref>), GSEA 4.2.3 (<xref ref-type="bibr" rid="bib76">Subramanian et al., 2005</xref>), and Gene Ontology analysis (<xref ref-type="bibr" rid="bib8">Ashburner et al., 2000</xref>) were used for identification of activated and inhibited pathways. For IPA analysis, a total of 27,647 out of 28,265 genes could be mapped using Entrez Gene Symbols. For cross-genotype (i.e. T21 vs. D21) pathway analysis, only genes with a fold-change &gt; |1.25| and adjusted p-value &lt;0.1 were used. For within-genotype (i.e. treatment effects) pathway analysis, only genes with an adjusted p-value &lt;0.1 were used.</p><p>For analysis of RNA-seq data collected from sibling T21 cell line at 24 hr ±CA, and non-sibling T21 at 4.5 hr ±CA, batch correction was applied to gene counts using Surrogate Variable Analysis (<xref ref-type="bibr" rid="bib46">Leek et al., 2019</xref>) as initial principal component analysis revealed inter-replicate variability as a stronger source of variation than kinase inhibition. However, differential expression analysis demonstrated that the same pathways were predicted to be up- or downregulated regardless of whether batch correction was performed. GSEA was performed by generating a list of genes with differential expression across treatments/genotypes, ranked by the negative log10 adjusted p-value and the sign (positive or negative) of log2(fold-change). Ranked gene lists were loaded onto GSEA (v4.2.3) and GSEAPreranked was run with the following settings – Number of permutations: 1000, Collapse/Remap: No_collapse, Enrichment statistic: weighted, Max size: 500, Min size: 15.</p><p>For splicing analysis, the workflow was as follows: duplicates were removed and adaptors trimmed using the bbTools function (v39.01), trimmed reads were mapped uniquely against the hg38 genome using HISAT2 (v2.1.0) (<xref ref-type="bibr" rid="bib40">Kim et al., 2019</xref>), mapped reads were processed with rMATS (v4.0.1) (<xref ref-type="bibr" rid="bib70">Shen et al., 2014</xref>), and results were filtered based on FDR &lt;0.05, absolute(IncLevelDifference) &lt;0.2, and ≥2 reads/replicate. Sashimi plots were generated from rMATS results using a modified script based on ggsashimi.py.</p><p>The IFN score was calculated as described (<xref ref-type="bibr" rid="bib29">Galbraith et al., 2023</xref>) using normalized gene counts from DESeq2. The score is calculated with 18 genes: BPGM, CCL5, IFI27, GMPR, IRF7, CMKLR1, IFITM3, GZMA, FCGR1A, USP18, PLSCR1, CXCL9, IFI44, CD274, CXCL10, ISG15, IFI44L, and RSAD2. For each gene, the mean and standard deviation of the D21 replicates was calculated. Then the measured level of each sample was subtracted by the mean of the D21 replicates and divided by the standard deviation of the D21 replicates to create a standardized gene value. For each sample, the sum of the standardized values was taken to get the IFN score.</p><p>The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number GSE220652 or GSE263239. Code used to process and visualize data can be found at <ext-link ext-link-type="uri" xlink:href="https://github.com/kira-alia/Cozzolino2023">https://github.com/kira-alia/Cozzolino2023</ext-link> (copy archived at <xref ref-type="bibr" rid="bib20">Cozzolino, 2024</xref>).</p></sec><sec id="s4-9"><title>Cytokine screen</title><p>Cells were pre-treated with 0.1% DMSO or 100 nM CA for 30 min, then treated with 40 mM Tris, pH 7.4 or 10 ng/ml interferon gamma (Gibco, PHC4031). After 24 hr, cells were lysed in RIPA buffer (Thermo Scientific, 89900) supplemented with Halt Protease and Phosphatase Inhibitor Cocktail, EDTA-free (100×) (Thermo Scientific, 78441) and Benzonase endonuclease (Millipore Sigma, 101697). Lysate concentrations were determined using the Pierce BCA Protein Assay Kit (Thermo Scientific, 23225), and 250 μg of protein from each condition was incubated with a membrane array from the Proteome Profiler Human XL Cytokine Array Kit (R&amp;D Systems, ARY022B). Membranes were processed according to the manufacturer’s instructions and imaged using an ImageQuant LAS 4000 (GE Healthcare). Background-subtracted technical replicate values for each cytokine in each condition were quantified using ImageJ and averaged giving a normalized intensity value. The relative intensity was compared on a per cytokine basis and was statistically assessed using a one-way ANOVA test between the eight total conditions across two biological replicates.</p></sec><sec id="s4-10"><title>PRO-seq</title><p>Cells were treated with 0.1% DMSO or 100 nM CA for 75 min before being transferred into a lysis buffer consisting of final concentrations of 10 mM Tris pH 7.4, 2 mM MgCl<sub>2</sub>, 3 mM CaCl<sub>2</sub>, 0.5% NP-40, 10% glycerol, 1 mM DTT, 1× Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, 78441), and 2 U/μl SUPERase•In RNase Inhibitor (Invitrogen, AM2696). Nuclei were isolated and cleaned through repeated centrifugation and washes, and were counted, aliquoted, and snap-frozen in using liquid nitrogen in a freezing buffer consisting of 50 mM Tris pH 8.3, 5 mM MgCl<sub>2</sub>, 40% glycerol. 0.1 mM EDTA, and 4 U/μl SUPERase•In RNase Inhibitor (Invitrogen, AM2696). Nuclear run-ons were performed for 3 min at 37°C on a Groovin’ Tubes thermoshaker (Boekel Scientific, 270500), on a mixture of 10 million human and 100,000 <italic>Drosophila melanogaster</italic> nuclei per replicate. PRO-seq library preparation was performed as described (<xref ref-type="bibr" rid="bib24">Fant et al., 2020</xref>). Library sequencing was performed at the Cornell Genomics Facility (Cornell Institute of Biotechnology) on the Illumina NextSeq 2000 platform (Instrument ID VH00231).</p></sec><sec id="s4-11"><title>PRO-seq data analysis</title><p>Raw fastq files from the sequencing pipeline described above were trimmed and mapped using the NascentFlow pipeline (DOI 10.17605/OSF.IO/NDHJ2). Bidirectional sites of transcription in the human genome (assembly hg38) were identified using the BidirectionalFlow pipeline (<ext-link ext-link-type="uri" xlink:href="https://github.com/Dowell-Lab/Bidirectional-Flow">https://github.com/Dowell-Lab/Bidirectional-Flow</ext-link>; <xref ref-type="bibr" rid="bib65">Sanford, 2023</xref>), which runs TFIT (<xref ref-type="bibr" rid="bib10">Azofeifa and Dowell, 2017</xref>). Bidirectional calls across all replicates and conditions relevant to this study were merged using muMerge (<ext-link ext-link-type="uri" xlink:href="https://github.com/Dowell-Lab/mumerge">https://github.com/Dowell-Lab/mumerge</ext-link>; <xref ref-type="bibr" rid="bib74">Stanley, 2022</xref>) and used as an annotation file for running TFEA (<xref ref-type="bibr" rid="bib64">Rubin et al., 2021</xref>). Example traces of differentially active sites of bidirectional transcription were plotted using pyGenomeTracks (<xref ref-type="bibr" rid="bib48">Lopez-Delisle et al., 2021</xref>).</p><p>The data in this publication have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number GSE249549. Code used to process and visualize data can be found at <ext-link ext-link-type="uri" xlink:href="https://github.com/kira-alia/Cozzolino2023">https://github.com/kira-alia/Cozzolino2023</ext-link> (copy archived at <xref ref-type="bibr" rid="bib20">Cozzolino, 2024</xref>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Affilated to Metabolon Inc, no other competing interest to declare</p></fn><fn fn-type="COI-statement" id="conf3"><p>JME has provided consulting services for Eli Lily and Gilead, and serves on the advisory board of Perha Pharmaceuticals</p></fn><fn fn-type="COI-statement" id="conf4"><p>RDD is a founder of Arpeggio Biosciences</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con3"><p>Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Project administration</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con10"><p>Supervision, Funding acquisition, Project administration</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Methodology</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-100197-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The data in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE249549, GSE220652, or GSE263239.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Cozzolino</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome II</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE249549">GSE249549</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Cozzolino</surname><given-names>KA</given-names></name><name><surname>Erickson</surname><given-names>B</given-names></name><name><surname>Bentley</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE220652">GSE220652</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Cozzolino</surname><given-names>KA</given-names></name><name><surname>Courvan</surname><given-names>MCS</given-names></name></person-group><source>NCBI Gene Expression Omnibus</source><year iso-8601-date="2025">2025</year><data-title>Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome III</data-title><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263239">GSE263239</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Galbraith</surname><given-names>MD</given-names></name><name><surname>Rachubinski</surname><given-names>AL</given-names></name><name><surname>Smith</surname><given-names>KP</given-names></name><name><surname>Sullivan</surname><given-names>KD</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Crnic Institute Human Trisome Project: PolyA RNA-sequence from whole blood</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE190125">GSE190125</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank A York (Yale University; University of Washington) and P Kovarik (University of Vienna) for helpful comments on the manuscript; we thank Matt Shair (Harvard) for providing Cortistatin A. We acknowledge the Linda Crnic Institute for Down Syndrome Research, particularly the Human Trisome Project Biobank and the Nexus Biobank, for providing the cells used in this work. We thank Theresa Nahreini for cell culture assistance. We acknowledge the Flow Cytometry Shared Core (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:S10ODO21601">S10ODO21601</ext-link>) and other funding support for instrumentation (S10OD025267) at UC-Boulder and the Genomics Shared Resource (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_021984">SCR_021984</ext-link>) at UC-Anschutz. This work was supported by the NIH (R01 AI156739 to DJT; R35 GM139550 to DJT; R01 HD100935 to DLB; R01 AI50305 to JME), and the Global Down Syndrome Foundation (JME) and the Anna &amp; John J Sie Foundation (JME, KC, MCSC). KC was supported in part by the NIH (T32 GM065103); KM was supported by the Arnold and Mabel Beckman Foundation and the NSF (MCB-1818147).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akamatsu</surname><given-names>M</given-names></name><name><surname>Mikami</surname><given-names>N</given-names></name><name><surname>Ohkura</surname><given-names>N</given-names></name><name><surname>Kawakami</surname><given-names>R</given-names></name><name><surname>Kitagawa</surname><given-names>Y</given-names></name><name><surname>Sugimoto</surname><given-names>A</given-names></name><name><surname>Hirota</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Ujihara</surname><given-names>S</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name><name><surname>Hamaguchi</surname><given-names>H</given-names></name><name><surname>Harada</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>G</given-names></name><name><surname>Morita</surname><given-names>Y</given-names></name><name><surname>Aramori</surname><given-names>I</given-names></name><name><surname>Narumiya</surname><given-names>S</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Conversion of antigen-specific effector/memory T cells into Foxp3-expressing T<sub>reg</sub> cells by inhibition of CDK8/19</article-title><source>Science Immunology</source><volume>4</volume><elocation-id>eaaw2707</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aaw2707</pub-id><pub-id pub-id-type="pmid">31653719</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhouayek</surname><given-names>M</given-names></name><name><surname>Muccioli</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>COX-2-derived endocannabinoid metabolites as novel inflammatory mediators</article-title><source>Trends in Pharmacological Sciences</source><volume>35</volume><fpage>284</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.03.001</pub-id><pub-id pub-id-type="pmid">24684963</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Differential expression analysis for sequence count data</article-title><source>Genome Biology</source><volume>11</volume><elocation-id>R106</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2010-11-10-r106</pub-id><pub-id pub-id-type="pmid">20979621</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrysik</surname><given-names>Z</given-names></name><name><surname>Bender</surname><given-names>H</given-names></name><name><surname>Galbraith</surname><given-names>MD</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Multi-omics analysis reveals contextual tumor suppressive and oncogenic gene modules within the acute hypoxic response</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1375</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21687-2</pub-id><pub-id pub-id-type="pmid">33654095</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonarakis</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Down syndrome and the complexity of genome dosage imbalance</article-title><source>Nature Reviews. Genetics</source><volume>18</volume><fpage>147</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1038/nrg.2016.154</pub-id><pub-id pub-id-type="pmid">28029161</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonarakis</surname><given-names>SE</given-names></name><name><surname>Skotko</surname><given-names>BG</given-names></name><name><surname>Rafii</surname><given-names>MS</given-names></name><name><surname>Strydom</surname><given-names>A</given-names></name><name><surname>Pape</surname><given-names>SE</given-names></name><name><surname>Bianchi</surname><given-names>DW</given-names></name><name><surname>Sherman</surname><given-names>SL</given-names></name><name><surname>Reeves</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Down syndrome</article-title><source>Nature Reviews. Disease Primers</source><volume>6</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1038/s41572-019-0143-7</pub-id><pub-id pub-id-type="pmid">32029743</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araya</surname><given-names>P</given-names></name><name><surname>Waugh</surname><given-names>KA</given-names></name><name><surname>Sullivan</surname><given-names>KD</given-names></name><name><surname>Núñez</surname><given-names>NG</given-names></name><name><surname>Roselli</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>KP</given-names></name><name><surname>Granrath</surname><given-names>RE</given-names></name><name><surname>Rachubinski</surname><given-names>AL</given-names></name><name><surname>Enriquez Estrada</surname><given-names>B</given-names></name><name><surname>Butcher</surname><given-names>ET</given-names></name><name><surname>Minter</surname><given-names>R</given-names></name><name><surname>Tuttle</surname><given-names>KD</given-names></name><name><surname>Bruno</surname><given-names>TC</given-names></name><name><surname>Maccioni</surname><given-names>M</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity</article-title><source>PNAS</source><volume>116</volume><fpage>24231</fpage><lpage>24241</lpage><pub-id pub-id-type="doi">10.1073/pnas.1908129116</pub-id><pub-id pub-id-type="pmid">31699819</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburner</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>CA</given-names></name><name><surname>Blake</surname><given-names>JA</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Butler</surname><given-names>H</given-names></name><name><surname>Cherry</surname><given-names>JM</given-names></name><name><surname>Davis</surname><given-names>AP</given-names></name><name><surname>Dolinski</surname><given-names>K</given-names></name><name><surname>Dwight</surname><given-names>SS</given-names></name><name><surname>Eppig</surname><given-names>JT</given-names></name><name><surname>Harris</surname><given-names>MA</given-names></name><name><surname>Hill</surname><given-names>DP</given-names></name><name><surname>Issel-Tarver</surname><given-names>L</given-names></name><name><surname>Kasarskis</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Matese</surname><given-names>JC</given-names></name><name><surname>Richardson</surname><given-names>JE</given-names></name><name><surname>Ringwald</surname><given-names>M</given-names></name><name><surname>Rubin</surname><given-names>GM</given-names></name><name><surname>Sherlock</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Gene Ontology: tool for the unification of biology</article-title><source>Nature Genetics</source><volume>25</volume><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1038/75556</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Audetat</surname><given-names>KA</given-names></name><name><surname>Galbraith</surname><given-names>MD</given-names></name><name><surname>Odell</surname><given-names>AT</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name><name><surname>Dowell</surname><given-names>RD</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A kinase-independent role for cyclin-dependent kinase 19 in p53 response</article-title><source>Molecular and Cellular Biology</source><volume>37</volume><lpage>e00626</lpage><fpage>e00616</fpage><pub-id pub-id-type="doi">10.1128/MCB.00626-16</pub-id><pub-id pub-id-type="pmid">28416637</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azofeifa</surname><given-names>JG</given-names></name><name><surname>Dowell</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A generative model for the behavior of RNA polymerase</article-title><source>Bioinformatics</source><volume>33</volume><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw599</pub-id><pub-id pub-id-type="pmid">27663494</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azofeifa</surname><given-names>JG</given-names></name><name><surname>Allen</surname><given-names>MA</given-names></name><name><surname>Hendrix</surname><given-names>JR</given-names></name><name><surname>Read</surname><given-names>T</given-names></name><name><surname>Rubin</surname><given-names>JD</given-names></name><name><surname>Dowell</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Enhancer RNA profiling predicts transcription factor activity</article-title><source>Genome Research</source><volume>28</volume><fpage>334</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1101/gr.225755.117</pub-id><pub-id pub-id-type="pmid">29449408</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Petasny</surname><given-names>M</given-names></name><name><surname>Taqatqa</surname><given-names>N</given-names></name><name><surname>Bentata</surname><given-names>M</given-names></name><name><surname>Kay</surname><given-names>G</given-names></name><name><surname>Engal</surname><given-names>E</given-names></name><name><surname>Nevo</surname><given-names>Y</given-names></name><name><surname>Siam</surname><given-names>A</given-names></name><name><surname>Dahan</surname><given-names>S</given-names></name><name><surname>Salton</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>KDM3A regulates alternative splicing of cell-cycle genes following DNA damage</article-title><source>RNA</source><volume>27</volume><fpage>1353</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1261/rna.078796.121</pub-id><pub-id pub-id-type="pmid">34321328</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bancerek</surname><given-names>J</given-names></name><name><surname>Poss</surname><given-names>ZC</given-names></name><name><surname>Steinparzer</surname><given-names>I</given-names></name><name><surname>Sedlyarov</surname><given-names>V</given-names></name><name><surname>Pfaffenwimmer</surname><given-names>T</given-names></name><name><surname>Mikulic</surname><given-names>I</given-names></name><name><surname>Dölken</surname><given-names>L</given-names></name><name><surname>Strobl</surname><given-names>B</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name><name><surname>Kovarik</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response</article-title><source>Immunity</source><volume>38</volume><fpage>250</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.10.017</pub-id><pub-id pub-id-type="pmid">23352233</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basil</surname><given-names>MC</given-names></name><name><surname>Levy</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Specialized pro-resolving mediators: endogenous regulators of infection and inflammation</article-title><source>Nature Reviews. Immunology</source><volume>16</volume><fpage>51</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1038/nri.2015.4</pub-id><pub-id pub-id-type="pmid">26688348</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>D</given-names></name><name><surname>Galambos</surname><given-names>C</given-names></name><name><surname>Dunbar Ivy</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pulmonary hypertension in children with Down syndrome</article-title><source>Pediatric Pulmonology</source><volume>56</volume><fpage>621</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1002/ppul.24687</pub-id><pub-id pub-id-type="pmid">32049444</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Altilia</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Schronce</surname><given-names>A</given-names></name><name><surname>McDermott</surname><given-names>MSJ</given-names></name><name><surname>Schools</surname><given-names>GP</given-names></name><name><surname>Lim</surname><given-names>C-U</given-names></name><name><surname>Oliver</surname><given-names>D</given-names></name><name><surname>Shtutman</surname><given-names>MS</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Stark</surname><given-names>GR</given-names></name><name><surname>Porter</surname><given-names>DC</given-names></name><name><surname>Broude</surname><given-names>EV</given-names></name><name><surname>Roninson</surname><given-names>IB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CDK8/19 Mediator kinases potentiate induction of transcription by NFκB</article-title><source>PNAS</source><volume>114</volume><fpage>10208</fpage><lpage>10213</lpage><pub-id pub-id-type="doi">10.1073/pnas.1710467114</pub-id><pub-id pub-id-type="pmid">28855340</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Altilia</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>G</given-names></name><name><surname>Altomare</surname><given-names>D</given-names></name><name><surname>Shtutman</surname><given-names>M</given-names></name><name><surname>Byrum</surname><given-names>SD</given-names></name><name><surname>Mackintosh</surname><given-names>SG</given-names></name><name><surname>Feoktistov</surname><given-names>A</given-names></name><name><surname>Soshnikova</surname><given-names>N</given-names></name><name><surname>Mogila</surname><given-names>VA</given-names></name><name><surname>Tatarskiy</surname><given-names>V</given-names></name><name><surname>Erokhin</surname><given-names>M</given-names></name><name><surname>Chetverina</surname><given-names>D</given-names></name><name><surname>Prawira</surname><given-names>A</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Urban</surname><given-names>S</given-names></name><name><surname>McInnes</surname><given-names>C</given-names></name><name><surname>Broude</surname><given-names>EV</given-names></name><name><surname>Roninson</surname><given-names>IB</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>CDK8 and CDK19: positive regulators of signal-induced transcription and negative regulators of Mediator complex proteins</article-title><source>Nucleic Acids Research</source><volume>51</volume><fpage>7288</fpage><lpage>7313</lpage><pub-id pub-id-type="doi">10.1093/nar/gkad538</pub-id><pub-id pub-id-type="pmid">37378433</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>JYL</given-names></name><name><surname>Ferrell</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bile acids as metabolic regulators and nutrient sensors</article-title><source>Annual Review of Nutrition</source><volume>39</volume><fpage>175</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1146/annurev-nutr-082018-124344</pub-id><pub-id pub-id-type="pmid">31018107</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clopper</surname><given-names>KC</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Chemical inhibitors of transcription-associated kinases</article-title><source>Current Opinion in Chemical Biology</source><volume>70</volume><elocation-id>102186</elocation-id><pub-id pub-id-type="doi">10.1016/j.cbpa.2022.102186</pub-id><pub-id pub-id-type="pmid">35926294</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Cozzolino</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Cozzolino2023</data-title><version designator="swh:1:rev:556fc0c1c7ebb0fff9c7cd7c6e4ee8ed3d9542ed">swh:1:rev:556fc0c1c7ebb0fff9c7cd7c6e4ee8ed3d9542ed</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:6632652c5dc806f6887c223354e6e0a2a38efc58;origin=https://github.com/kira-alia/Cozzolino2023;visit=swh:1:snp:95c64c0436e78ed7834a5cddc5af5ad099d1389f;anchor=swh:1:rev:556fc0c1c7ebb0fff9c7cd7c6e4ee8ed3d9542ed">https://archive.softwareheritage.org/swh:1:dir:6632652c5dc806f6887c223354e6e0a2a38efc58;origin=https://github.com/kira-alia/Cozzolino2023;visit=swh:1:snp:95c64c0436e78ed7834a5cddc5af5ad099d1389f;anchor=swh:1:rev:556fc0c1c7ebb0fff9c7cd7c6e4ee8ed3d9542ed</ext-link></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Graaf</surname><given-names>G</given-names></name><name><surname>Buckley</surname><given-names>F</given-names></name><name><surname>Skotko</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Estimation of the number of people with Down syndrome in the United States</article-title><source>Genetics in Medicine</source><volume>19</volume><fpage>439</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/gim.2016.127</pub-id><pub-id pub-id-type="pmid">27608174</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehaven</surname><given-names>CD</given-names></name><name><surname>Evans</surname><given-names>AM</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Lawton</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Organization of GC/MS and LC/MS metabolomics data into chemical libraries</article-title><source>Journal of Cheminformatics</source><volume>2</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1186/1758-2946-2-9</pub-id><pub-id pub-id-type="pmid">20955607</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Historical insights into cytokines</article-title><source>European Journal of Immunology</source><volume>37</volume><fpage>S34</fpage><lpage>S45</lpage><pub-id pub-id-type="doi">10.1002/eji.200737772</pub-id><pub-id pub-id-type="pmid">17972343</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fant</surname><given-names>CB</given-names></name><name><surname>Levandowski</surname><given-names>CB</given-names></name><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Maas</surname><given-names>ZL</given-names></name><name><surname>Moir</surname><given-names>J</given-names></name><name><surname>Rubin</surname><given-names>JD</given-names></name><name><surname>Sawyer</surname><given-names>A</given-names></name><name><surname>Esbin</surname><given-names>MN</given-names></name><name><surname>Rimel</surname><given-names>JK</given-names></name><name><surname>Luyties</surname><given-names>O</given-names></name><name><surname>Marr</surname><given-names>MT</given-names></name><name><surname>Berger</surname><given-names>I</given-names></name><name><surname>Dowell</surname><given-names>RD</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TFIID enables RNA polymerase II promoter-proximal pausing</article-title><source>Molecular Cell</source><volume>78</volume><fpage>785</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.03.008</pub-id><pub-id pub-id-type="pmid">32229306</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>L</given-names></name><name><surname>Kennedy</surname><given-names>AD</given-names></name><name><surname>Goodman</surname><given-names>KD</given-names></name><name><surname>Pappan</surname><given-names>KL</given-names></name><name><surname>Evans</surname><given-names>AM</given-names></name><name><surname>Miller</surname><given-names>LAD</given-names></name><name><surname>Wulff</surname><given-names>JE</given-names></name><name><surname>Wiggs</surname><given-names>BR</given-names></name><name><surname>Lennon</surname><given-names>JJ</given-names></name><name><surname>Elsea</surname><given-names>S</given-names></name><name><surname>Toal</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Precision of a clinical metabolomics profiling platform for use in the identification of inborn errors of metabolism</article-title><source>The Journal of Applied Laboratory Medicine</source><volume>5</volume><fpage>342</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1093/jalm/jfz026</pub-id><pub-id pub-id-type="pmid">32445384</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freitas</surname><given-names>KA</given-names></name><name><surname>Belk</surname><given-names>JA</given-names></name><name><surname>Sotillo</surname><given-names>E</given-names></name><name><surname>Quinn</surname><given-names>PJ</given-names></name><name><surname>Ramello</surname><given-names>MC</given-names></name><name><surname>Malipatlolla</surname><given-names>M</given-names></name><name><surname>Daniel</surname><given-names>B</given-names></name><name><surname>Sandor</surname><given-names>K</given-names></name><name><surname>Klysz</surname><given-names>D</given-names></name><name><surname>Bjelajac</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Burdsall</surname><given-names>KA</given-names></name><name><surname>Tieu</surname><given-names>V</given-names></name><name><surname>Duong</surname><given-names>VT</given-names></name><name><surname>Donovan</surname><given-names>MG</given-names></name><name><surname>Weber</surname><given-names>EW</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Majzner</surname><given-names>RG</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name><name><surname>Satpathy</surname><given-names>AT</given-names></name><name><surname>Mackall</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Enhanced T cell effector activity by targeting the Mediator kinase module</article-title><source>Science</source><volume>378</volume><elocation-id>eabn5647</elocation-id><pub-id pub-id-type="doi">10.1126/science.abn5647</pub-id><pub-id pub-id-type="pmid">36356142</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Gaetani</surname><given-names>S</given-names></name><name><surname>Oveisi</surname><given-names>F</given-names></name><name><surname>Lo Verme</surname><given-names>J</given-names></name><name><surname>Serrano</surname><given-names>A</given-names></name><name><surname>Rodríguez De Fonseca</surname><given-names>F</given-names></name><name><surname>Rosengarth</surname><given-names>A</given-names></name><name><surname>Luecke</surname><given-names>H</given-names></name><name><surname>Di Giacomo</surname><given-names>B</given-names></name><name><surname>Tarzia</surname><given-names>G</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha</article-title><source>Nature</source><volume>425</volume><fpage>90</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/nature01921</pub-id><pub-id pub-id-type="pmid">12955147</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galbraith</surname><given-names>MD</given-names></name><name><surname>Andrysik</surname><given-names>Z</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Hoh</surname><given-names>M</given-names></name><name><surname>Bonner</surname><given-names>EA</given-names></name><name><surname>Hill</surname><given-names>AA</given-names></name><name><surname>Sullivan</surname><given-names>KD</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CDK8 kinase activity promotes glycolysis</article-title><source>Cell Reports</source><volume>21</volume><fpage>1495</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.10.058</pub-id><pub-id pub-id-type="pmid">29117556</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galbraith</surname><given-names>MD</given-names></name><name><surname>Rachubinski</surname><given-names>AL</given-names></name><name><surname>Smith</surname><given-names>KP</given-names></name><name><surname>Araya</surname><given-names>P</given-names></name><name><surname>Waugh</surname><given-names>KA</given-names></name><name><surname>Enriquez-Estrada</surname><given-names>B</given-names></name><name><surname>Worek</surname><given-names>K</given-names></name><name><surname>Granrath</surname><given-names>RE</given-names></name><name><surname>Kinning</surname><given-names>KT</given-names></name><name><surname>Paul Eduthan</surname><given-names>N</given-names></name><name><surname>Ludwig</surname><given-names>MP</given-names></name><name><surname>Hsieh</surname><given-names>EWY</given-names></name><name><surname>Sullivan</surname><given-names>KD</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition</article-title><source>Science Advances</source><volume>9</volume><elocation-id>eadg6218</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.adg6218</pub-id><pub-id pub-id-type="pmid">37379383</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautam</surname><given-names>A</given-names></name><name><surname>Grainger</surname><given-names>RJ</given-names></name><name><surname>Vilardell</surname><given-names>J</given-names></name><name><surname>Barrass</surname><given-names>JD</given-names></name><name><surname>Beggs</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cwc21p promotes the second step conformation of the spliceosome and modulates 3’ splice site selection</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>3309</fpage><lpage>3317</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv159</pub-id><pub-id pub-id-type="pmid">25740649</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Wan</surname><given-names>YY</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inhibition of Cdk8/Cdk19 activity promotes treg cell differentiation and suppresses autoimmune diseases</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>1988</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01988</pub-id><pub-id pub-id-type="pmid">31552016</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasle</surname><given-names>H</given-names></name><name><surname>Clemmensen</surname><given-names>IH</given-names></name><name><surname>Mikkelsen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Risks of leukaemia and solid tumours in individuals with Down’s syndrome</article-title><source>Lancet</source><volume>355</volume><fpage>165</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(99)05264-2</pub-id><pub-id pub-id-type="pmid">10675114</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>MH</given-names></name><name><surname>Mani</surname><given-names>R</given-names></name><name><surname>Engelhardt</surname><given-names>H</given-names></name><name><surname>Impagnatiello</surname><given-names>MA</given-names></name><name><surname>Carotta</surname><given-names>S</given-names></name><name><surname>Kerenyi</surname><given-names>M</given-names></name><name><surname>Lorenzo-Herrero</surname><given-names>S</given-names></name><name><surname>Böttcher</surname><given-names>J</given-names></name><name><surname>Scharn</surname><given-names>D</given-names></name><name><surname>Arnhof</surname><given-names>H</given-names></name><name><surname>Zoephel</surname><given-names>A</given-names></name><name><surname>Schnitzer</surname><given-names>R</given-names></name><name><surname>Gerstberger</surname><given-names>T</given-names></name><name><surname>Sanderson</surname><given-names>MP</given-names></name><name><surname>Rajgolikar</surname><given-names>G</given-names></name><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Vasu</surname><given-names>S</given-names></name><name><surname>Ettmayer</surname><given-names>P</given-names></name><name><surname>Gonzalez</surname><given-names>S</given-names></name><name><surname>Pearson</surname><given-names>M</given-names></name><name><surname>McConnell</surname><given-names>DB</given-names></name><name><surname>Kraut</surname><given-names>N</given-names></name><name><surname>Muthusamy</surname><given-names>N</given-names></name><name><surname>Moll</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selective and potent CDK8/19 inhibitors enhance nk-cell activity and promote tumor surveillance</article-title><source>Molecular Cancer Therapeutics</source><volume>19</volume><fpage>1018</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-19-0789</pub-id><pub-id pub-id-type="pmid">32024684</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>S</given-names></name><name><surname>Hendrix</surname><given-names>J</given-names></name><name><surname>Freeman</surname><given-names>J</given-names></name><name><surname>Dowell</surname><given-names>RD</given-names></name><name><surname>Allen</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Transcription dosage compensation does not occur in Down syndrome</article-title><source>BMC Biology</source><volume>21</volume><elocation-id>228</elocation-id><pub-id pub-id-type="doi">10.1186/s12915-023-01700-4</pub-id><pub-id pub-id-type="pmid">37946204</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husted</surname><given-names>AS</given-names></name><name><surname>Trauelsen</surname><given-names>M</given-names></name><name><surname>Rudenko</surname><given-names>O</given-names></name><name><surname>Hjorth</surname><given-names>SA</given-names></name><name><surname>Schwartz</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GPCR-mediated signaling of metabolites</article-title><source>Cell Metabolism</source><volume>25</volume><fpage>777</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.03.008</pub-id><pub-id pub-id-type="pmid">28380372</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>S</given-names></name><name><surname>Cavaliere</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>LJ</given-names></name><name><surname>Dephoure</surname><given-names>N</given-names></name><name><surname>Torres</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Consequences of aneuploidy in human fibroblasts with trisomy 21</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2014723118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2014723118</pub-id><pub-id pub-id-type="pmid">33526671</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannessen</surname><given-names>L</given-names></name><name><surname>Sundberg</surname><given-names>TB</given-names></name><name><surname>O’Connell</surname><given-names>DJ</given-names></name><name><surname>Kolde</surname><given-names>R</given-names></name><name><surname>Berstler</surname><given-names>J</given-names></name><name><surname>Billings</surname><given-names>KJ</given-names></name><name><surname>Khor</surname><given-names>B</given-names></name><name><surname>Seashore-Ludlow</surname><given-names>B</given-names></name><name><surname>Fassl</surname><given-names>A</given-names></name><name><surname>Russell</surname><given-names>CN</given-names></name><name><surname>Latorre</surname><given-names>IJ</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Graham</surname><given-names>DB</given-names></name><name><surname>Perez</surname><given-names>JR</given-names></name><name><surname>Sicinski</surname><given-names>P</given-names></name><name><surname>Phillips</surname><given-names>AJ</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name><name><surname>Shamji</surname><given-names>AF</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells</article-title><source>Nature Chemical Biology</source><volume>13</volume><fpage>1102</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2458</pub-id><pub-id pub-id-type="pmid">28805801</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RG</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MenTORing Immunity: mtor signaling in the development and function of tissue-resident immune cells</article-title><source>Immunity</source><volume>46</volume><fpage>730</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.04.028</pub-id><pub-id pub-id-type="pmid">28514674</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>PM</given-names></name><name><surname>Werz</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Specialized pro-resolving mediators: biosynthesis and biological role in bacterial infections</article-title><source>The FEBS Journal</source><volume>289</volume><fpage>4212</fpage><lpage>4227</lpage><pub-id pub-id-type="doi">10.1111/febs.16266</pub-id><pub-id pub-id-type="pmid">34741578</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Paggi</surname><given-names>JM</given-names></name><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Bennett</surname><given-names>C</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype</article-title><source>Nature Biotechnology</source><volume>37</volume><fpage>907</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0201-4</pub-id><pub-id pub-id-type="pmid">31375807</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>I</given-names></name><name><surname>Ichimura</surname><given-names>A</given-names></name><name><surname>Ohue-Kitano</surname><given-names>R</given-names></name><name><surname>Igarashi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Free fatty acid receptors in health and disease</article-title><source>Physiological Reviews</source><volume>100</volume><fpage>171</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1152/physrev.00041.2018</pub-id><pub-id pub-id-type="pmid">31487233</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krämer</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Pollard</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Tugendreich</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Causal analysis approaches in ingenuity pathway analysis</article-title><source>Bioinformatics</source><volume>30</volume><fpage>523</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt703</pub-id><pub-id pub-id-type="pmid">24336805</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kristjánsdóttir</surname><given-names>K</given-names></name><name><surname>Dziubek</surname><given-names>A</given-names></name><name><surname>Kang</surname><given-names>HM</given-names></name><name><surname>Kwak</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Population-scale study of eRNA transcription reveals bipartite functional enhancer architecture</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5963</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19829-z</pub-id><pub-id pub-id-type="pmid">33235186</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CF</given-names></name><name><surname>Carley</surname><given-names>RE</given-names></name><name><surname>Butler</surname><given-names>CA</given-names></name><name><surname>Morrison</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Rac GTPase signaling in immune-mediated mechanisms of atherosclerosis</article-title><source>Cells</source><volume>10</volume><elocation-id>2808</elocation-id><pub-id pub-id-type="doi">10.3390/cells10112808</pub-id><pub-id pub-id-type="pmid">34831028</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>LY-H</given-names></name><name><surname>Oldham</surname><given-names>WM</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Mulhern</surname><given-names>R</given-names></name><name><surname>Handy</surname><given-names>DE</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Interferon-γ impairs human coronary artery endothelial glucose metabolism by tryptophan catabolism and activates fatty acid oxidation</article-title><source>Circulation</source><volume>144</volume><fpage>1612</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.053960</pub-id><pub-id pub-id-type="pmid">34636650</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Leek</surname><given-names>JT</given-names></name><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Parker</surname><given-names>HS</given-names></name><name><surname>Fertig</surname><given-names>EJ</given-names></name><name><surname>Jaffe</surname><given-names>AE</given-names></name><name><surname>Storey</surname><given-names>JD</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Torres</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>SVA: surrogate variable analysis</data-title><version designator="3321">3321</version><source>R Package</source><ext-link ext-link-type="uri" xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3307112/">https://pmc.ncbi.nlm.nih.gov/articles/PMC3307112/</ext-link></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Delisle</surname><given-names>L</given-names></name><name><surname>Rabbani</surname><given-names>L</given-names></name><name><surname>Wolff</surname><given-names>J</given-names></name><name><surname>Bhardwaj</surname><given-names>V</given-names></name><name><surname>Backofen</surname><given-names>R</given-names></name><name><surname>Grüning</surname><given-names>B</given-names></name><name><surname>Ramírez</surname><given-names>F</given-names></name><name><surname>Manke</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>pyGenomeTracks: reproducible plots for multivariate genomic datasets</article-title><source>Bioinformatics</source><volume>37</volume><fpage>422</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa692</pub-id><pub-id pub-id-type="pmid">32745185</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lunt</surname><given-names>SY</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Aerobic glycolysis: meeting the metabolic requirements of cell proliferation</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>27</volume><fpage>441</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-092910-154237</pub-id><pub-id pub-id-type="pmid">21985671</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luyties</surname><given-names>O</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The Mediator kinase module: an interface between cell signaling and transcription</article-title><source>Trends in Biochemical Sciences</source><volume>47</volume><fpage>314</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2022.01.002</pub-id><pub-id pub-id-type="pmid">35193797</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maceyka</surname><given-names>M</given-names></name><name><surname>Spiegel</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Sphingolipid metabolites in inflammatory disease</article-title><source>Nature</source><volume>510</volume><fpage>58</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1038/nature13475</pub-id><pub-id pub-id-type="pmid">24899305</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madan</surname><given-names>V</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Lear</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Dermatological manifestations of Down’s syndrome</article-title><source>Clinical and Experimental Dermatology</source><volume>31</volume><fpage>623</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2230.2006.02164.x</pub-id><pub-id pub-id-type="pmid">16901300</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malle</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>RS</given-names></name><name><surname>Martin-Fernandez</surname><given-names>M</given-names></name><name><surname>Stewart</surname><given-names>OJ</given-names></name><name><surname>Philippot</surname><given-names>Q</given-names></name><name><surname>Buta</surname><given-names>S</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Barcessat</surname><given-names>V</given-names></name><name><surname>Taft</surname><given-names>J</given-names></name><name><surname>Bastard</surname><given-names>P</given-names></name><name><surname>Samuels</surname><given-names>J</given-names></name><name><surname>Mircher</surname><given-names>C</given-names></name><name><surname>Rebillat</surname><given-names>AS</given-names></name><name><surname>Maillebouis</surname><given-names>L</given-names></name><name><surname>Vilaire-Meunier</surname><given-names>M</given-names></name><name><surname>Tuballes</surname><given-names>K</given-names></name><name><surname>Rosenberg</surname><given-names>BR</given-names></name><name><surname>Trachtman</surname><given-names>R</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Notarangelo</surname><given-names>LD</given-names></name><name><surname>Gnjatic</surname><given-names>S</given-names></name><name><surname>Bush</surname><given-names>D</given-names></name><name><surname>Bogunovic</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c+ B cells</article-title><source>Nature</source><volume>615</volume><fpage>305</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05736-y</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mårild</surname><given-names>K</given-names></name><name><surname>Stephansson</surname><given-names>O</given-names></name><name><surname>Grahnquist</surname><given-names>L</given-names></name><name><surname>Cnattingius</surname><given-names>S</given-names></name><name><surname>Söderman</surname><given-names>G</given-names></name><name><surname>Ludvigsson</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Down syndrome is associated with elevated risk of celiac disease: a nationwide case-control study</article-title><source>The Journal of Pediatrics</source><volume>163</volume><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2012.12.087</pub-id><pub-id pub-id-type="pmid">23399451</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>SH</given-names></name><name><surname>Huang</surname><given-names>CH</given-names></name><name><surname>Houlihan</surname><given-names>SL</given-names></name><name><surname>Regunath</surname><given-names>K</given-names></name><name><surname>Freed-Pastor</surname><given-names>WA</given-names></name><name><surname>Morris</surname><given-names>JP</given-names></name><name><surname>Tschaharganeh</surname><given-names>DF</given-names></name><name><surname>Kastenhuber</surname><given-names>ER</given-names></name><name><surname>Barsotti</surname><given-names>AM</given-names></name><name><surname>Culp-Hill</surname><given-names>R</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Ho</surname><given-names>YJ</given-names></name><name><surname>Baslan</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Mayle</surname><given-names>A</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Zender</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>DR</given-names></name><name><surname>D’Alessandro</surname><given-names>A</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>p53 represses the mevalonate pathway to mediate tumor suppression</article-title><source>Cell</source><volume>176</volume><fpage>564</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.11.011</pub-id><pub-id pub-id-type="pmid">30580964</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelish</surname><given-names>HE</given-names></name><name><surname>Liau</surname><given-names>BB</given-names></name><name><surname>Nitulescu</surname><given-names>II</given-names></name><name><surname>Tangpeerachaikul</surname><given-names>A</given-names></name><name><surname>Poss</surname><given-names>ZC</given-names></name><name><surname>Da Silva</surname><given-names>DH</given-names></name><name><surname>Caruso</surname><given-names>BT</given-names></name><name><surname>Arefolov</surname><given-names>A</given-names></name><name><surname>Fadeyi</surname><given-names>O</given-names></name><name><surname>Christie</surname><given-names>AL</given-names></name><name><surname>Du</surname><given-names>K</given-names></name><name><surname>Banka</surname><given-names>D</given-names></name><name><surname>Schneider</surname><given-names>EV</given-names></name><name><surname>Jestel</surname><given-names>A</given-names></name><name><surname>Zou</surname><given-names>G</given-names></name><name><surname>Si</surname><given-names>C</given-names></name><name><surname>Ebmeier</surname><given-names>CC</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Krivtsov</surname><given-names>AV</given-names></name><name><surname>Myers</surname><given-names>AG</given-names></name><name><surname>Kohl</surname><given-names>NE</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Lemieux</surname><given-names>ME</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name><name><surname>Shair</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mediator kinase inhibition further activates super-enhancer-associated genes in AML</article-title><source>Nature</source><volume>526</volume><fpage>273</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1038/nature14904</pub-id><pub-id pub-id-type="pmid">26416749</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poss</surname><given-names>ZC</given-names></name><name><surname>Ebmeier</surname><given-names>CC</given-names></name><name><surname>Odell</surname><given-names>AT</given-names></name><name><surname>Tangpeerachaikul</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Pelish</surname><given-names>HE</given-names></name><name><surname>Shair</surname><given-names>MD</given-names></name><name><surname>Dowell</surname><given-names>RD</given-names></name><name><surname>Old</surname><given-names>WM</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of mediator kinase substrates in human cells using cortistatin a and quantitative phosphoproteomics</article-title><source>Cell Reports</source><volume>15</volume><fpage>436</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.03.030</pub-id><pub-id pub-id-type="pmid">27050516</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>RK</given-names></name><name><surname>Culp-Hill</surname><given-names>R</given-names></name><name><surname>Ludwig</surname><given-names>MP</given-names></name><name><surname>Smith</surname><given-names>KP</given-names></name><name><surname>Waugh</surname><given-names>KA</given-names></name><name><surname>Minter</surname><given-names>R</given-names></name><name><surname>Tuttle</surname><given-names>KD</given-names></name><name><surname>Lewis</surname><given-names>HC</given-names></name><name><surname>Rachubinski</surname><given-names>AL</given-names></name><name><surname>Granrath</surname><given-names>RE</given-names></name><name><surname>Carmona-Iragui</surname><given-names>M</given-names></name><name><surname>Wilkerson</surname><given-names>RB</given-names></name><name><surname>Kahn</surname><given-names>DE</given-names></name><name><surname>Joshi</surname><given-names>M</given-names></name><name><surname>Lleó</surname><given-names>A</given-names></name><name><surname>Blesa</surname><given-names>R</given-names></name><name><surname>Fortea</surname><given-names>J</given-names></name><name><surname>D’Alessandro</surname><given-names>A</given-names></name><name><surname>Costello</surname><given-names>JC</given-names></name><name><surname>Sullivan</surname><given-names>KD</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>4766</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-12739-9</pub-id><pub-id pub-id-type="pmid">31628327</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rambout</surname><given-names>X</given-names></name><name><surname>Dequiedt</surname><given-names>F</given-names></name><name><surname>Maquat</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Beyond transcription: roles of transcription factors in pre-mrna splicing</article-title><source>Chemical Reviews</source><volume>118</volume><fpage>4339</fpage><lpage>4364</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.7b00470</pub-id><pub-id pub-id-type="pmid">29251915</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>WF</given-names></name><name><surname>Nayak</surname><given-names>S</given-names></name><name><surname>Iwasa</surname><given-names>J</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The Mediator complex as a master regulator of transcription by RNA polymerase II</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>23</volume><fpage>732</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1038/s41580-022-00498-3</pub-id><pub-id pub-id-type="pmid">35725906</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimel</surname><given-names>JK</given-names></name><name><surname>Poss</surname><given-names>ZC</given-names></name><name><surname>Erickson</surname><given-names>B</given-names></name><name><surname>Maas</surname><given-names>ZL</given-names></name><name><surname>Ebmeier</surname><given-names>CC</given-names></name><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Decker</surname><given-names>T-M</given-names></name><name><surname>Yaron</surname><given-names>TM</given-names></name><name><surname>Bradley</surname><given-names>MJ</given-names></name><name><surname>Hamman</surname><given-names>KB</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Malojcic</surname><given-names>G</given-names></name><name><surname>Marineau</surname><given-names>JJ</given-names></name><name><surname>White</surname><given-names>PW</given-names></name><name><surname>Brault</surname><given-names>M</given-names></name><name><surname>Tao</surname><given-names>L</given-names></name><name><surname>DeRoy</surname><given-names>P</given-names></name><name><surname>Clavette</surname><given-names>C</given-names></name><name><surname>Nayak</surname><given-names>S</given-names></name><name><surname>Damon</surname><given-names>LJ</given-names></name><name><surname>Kaltheuner</surname><given-names>IH</given-names></name><name><surname>Bunch</surname><given-names>H</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Geyer</surname><given-names>M</given-names></name><name><surname>Iwasa</surname><given-names>J</given-names></name><name><surname>Dowell</surname><given-names>RD</given-names></name><name><surname>Bentley</surname><given-names>DL</given-names></name><name><surname>Old</surname><given-names>WM</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription</article-title><source>Genes &amp; Development</source><volume>34</volume><fpage>1452</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1101/gad.341545.120</pub-id><pub-id pub-id-type="pmid">33060135</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinschen</surname><given-names>MM</given-names></name><name><surname>Ivanisevic</surname><given-names>J</given-names></name><name><surname>Giera</surname><given-names>M</given-names></name><name><surname>Siuzdak</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of bioactive metabolites using activity metabolomics</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>20</volume><fpage>353</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1038/s41580-019-0108-4</pub-id><pub-id pub-id-type="pmid">30814649</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Kundu</surname><given-names>M</given-names></name><name><surname>Jana</surname><given-names>M</given-names></name><name><surname>Mishra</surname><given-names>RK</given-names></name><name><surname>Yung</surname><given-names>Y</given-names></name><name><surname>Luan</surname><given-names>CH</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Pahan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification and characterization of PPARα ligands in the hippocampus</article-title><source>Nature Chemical Biology</source><volume>12</volume><fpage>1075</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2204</pub-id><pub-id pub-id-type="pmid">27748752</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>JD</given-names></name><name><surname>Stanley</surname><given-names>JT</given-names></name><name><surname>Sigauke</surname><given-names>RF</given-names></name><name><surname>Levandowski</surname><given-names>CB</given-names></name><name><surname>Maas</surname><given-names>ZL</given-names></name><name><surname>Westfall</surname><given-names>J</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name><name><surname>Dowell</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transcription factor enrichment analysis (TFEA) quantifies the activity of multiple transcription factors from a single experiment</article-title><source>Communications Biology</source><volume>4</volume><elocation-id>661</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-021-02153-7</pub-id><pub-id pub-id-type="pmid">34079046</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Sanford</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Bidirectional-flow</data-title><version designator="0e83e67">0e83e67</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/Dowell-Lab/Bidirectional-Flow">https://github.com/Dowell-Lab/Bidirectional-Flow</ext-link></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarver</surname><given-names>DC</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Rodriguez</surname><given-names>S</given-names></name><name><surname>Aja</surname><given-names>S</given-names></name><name><surname>Jaffe</surname><given-names>AE</given-names></name><name><surname>Gao</surname><given-names>FJ</given-names></name><name><surname>Delannoy</surname><given-names>M</given-names></name><name><surname>Periasamy</surname><given-names>M</given-names></name><name><surname>Kazuki</surname><given-names>Y</given-names></name><name><surname>Oshimura</surname><given-names>M</given-names></name><name><surname>Reeves</surname><given-names>RH</given-names></name><name><surname>Wong</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Hypermetabolism in mice carrying a near-complete human chromosome 21</article-title><source>eLife</source><volume>12</volume><elocation-id>e86023</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.86023</pub-id><pub-id pub-id-type="pmid">37249575</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoors</surname><given-names>S</given-names></name><name><surname>Bruning</surname><given-names>U</given-names></name><name><surname>Missiaen</surname><given-names>R</given-names></name><name><surname>Queiroz</surname><given-names>KC</given-names></name><name><surname>Borgers</surname><given-names>G</given-names></name><name><surname>Elia</surname><given-names>I</given-names></name><name><surname>Zecchin</surname><given-names>A</given-names></name><name><surname>Cantelmo</surname><given-names>AR</given-names></name><name><surname>Christen</surname><given-names>S</given-names></name><name><surname>Goveia</surname><given-names>J</given-names></name><name><surname>Heggermont</surname><given-names>W</given-names></name><name><surname>Goddé</surname><given-names>L</given-names></name><name><surname>Vinckier</surname><given-names>S</given-names></name><name><surname>Van Veldhoven</surname><given-names>PP</given-names></name><name><surname>Eelen</surname><given-names>G</given-names></name><name><surname>Schoonjans</surname><given-names>L</given-names></name><name><surname>Gerhardt</surname><given-names>H</given-names></name><name><surname>Dewerchin</surname><given-names>M</given-names></name><name><surname>Baes</surname><given-names>M</given-names></name><name><surname>De Bock</surname><given-names>K</given-names></name><name><surname>Ghesquière</surname><given-names>B</given-names></name><name><surname>Lunt</surname><given-names>SY</given-names></name><name><surname>Fendt</surname><given-names>S-M</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fatty acid carbon is essential for dNTP synthesis in endothelial cells</article-title><source>Nature</source><volume>520</volume><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/nature14362</pub-id><pub-id pub-id-type="pmid">25830893</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>JR</given-names></name><name><surname>Tu</surname><given-names>H</given-names></name><name><surname>Luk</surname><given-names>A</given-names></name><name><surname>Repa</surname><given-names>JJ</given-names></name><name><surname>Medina</surname><given-names>JC</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Schwendner</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Thoolen</surname><given-names>M</given-names></name><name><surname>Mangelsdorf</surname><given-names>DJ</given-names></name><name><surname>Lustig</surname><given-names>KD</given-names></name><name><surname>Shan</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Role of LXRs in control of lipogenesis</article-title><source>Genes &amp; Development</source><volume>14</volume><fpage>2831</fpage><lpage>2838</lpage><pub-id pub-id-type="doi">10.1101/gad.850400</pub-id><pub-id pub-id-type="pmid">11090131</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scotti</surname><given-names>MM</given-names></name><name><surname>Swanson</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RNA mis-splicing in disease</article-title><source>Nature Reviews. Genetics</source><volume>17</volume><fpage>19</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/nrg.2015.3</pub-id><pub-id pub-id-type="pmid">26593421</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Henry</surname><given-names>MD</given-names></name><name><surname>Wu</surname><given-names>YN</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data</article-title><source>PNAS</source><volume>111</volume><fpage>E5593</fpage><lpage>E5601</lpage><pub-id pub-id-type="doi">10.1073/pnas.1419161111</pub-id><pub-id pub-id-type="pmid">25480548</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sooraj</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Doan</surname><given-names>A</given-names></name><name><surname>Garama</surname><given-names>DJ</given-names></name><name><surname>Dannappel</surname><given-names>MV</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Chua</surname><given-names>HK</given-names></name><name><surname>Mahara</surname><given-names>S</given-names></name><name><surname>Wan Hassan</surname><given-names>WA</given-names></name><name><surname>Tay</surname><given-names>YK</given-names></name><name><surname>Guanizo</surname><given-names>A</given-names></name><name><surname>Croagh</surname><given-names>D</given-names></name><name><surname>Prodanovic</surname><given-names>Z</given-names></name><name><surname>Gough</surname><given-names>DJ</given-names></name><name><surname>Wan</surname><given-names>C</given-names></name><name><surname>Firestein</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase</article-title><source>Molecular Cell</source><volume>82</volume><fpage>123</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2021.11.015</pub-id><pub-id pub-id-type="pmid">34910943</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soucek</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Bellur</surname><given-names>DL</given-names></name><name><surname>Bergkessel</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>KJ</given-names></name><name><surname>Deng</surname><given-names>Q</given-names></name><name><surname>Duong</surname><given-names>D</given-names></name><name><surname>Seyfried</surname><given-names>NT</given-names></name><name><surname>Guthrie</surname><given-names>C</given-names></name><name><surname>Staley</surname><given-names>JP</given-names></name><name><surname>Fasken</surname><given-names>MB</given-names></name><name><surname>Corbett</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The evolutionarily-conserved polyadenosine RNA binding protein, Nab2, cooperates with splicing machinery to regulate the fate of pre-mRNA</article-title><source>Molecular and Cellular Biology</source><volume>36</volume><fpage>2697</fpage><lpage>2714</lpage><pub-id pub-id-type="doi">10.1128/MCB.00402-16</pub-id><pub-id pub-id-type="pmid">27528618</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spann</surname><given-names>NJ</given-names></name><name><surname>Garmire</surname><given-names>LX</given-names></name><name><surname>McDonald</surname><given-names>JG</given-names></name><name><surname>Myers</surname><given-names>DS</given-names></name><name><surname>Milne</surname><given-names>SB</given-names></name><name><surname>Shibata</surname><given-names>N</given-names></name><name><surname>Reichart</surname><given-names>D</given-names></name><name><surname>Fox</surname><given-names>JN</given-names></name><name><surname>Shaked</surname><given-names>I</given-names></name><name><surname>Heudobler</surname><given-names>D</given-names></name><name><surname>Raetz</surname><given-names>CRH</given-names></name><name><surname>Wang</surname><given-names>EW</given-names></name><name><surname>Kelly</surname><given-names>SL</given-names></name><name><surname>Sullards</surname><given-names>MC</given-names></name><name><surname>Murphy</surname><given-names>RC</given-names></name><name><surname>Merrill</surname><given-names>AH</given-names><suffix>Jr</suffix></name><name><surname>Brown</surname><given-names>HA</given-names></name><name><surname>Dennis</surname><given-names>EA</given-names></name><name><surname>Li</surname><given-names>AC</given-names></name><name><surname>Ley</surname><given-names>K</given-names></name><name><surname>Tsimikas</surname><given-names>S</given-names></name><name><surname>Fahy</surname><given-names>E</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Quehenberger</surname><given-names>O</given-names></name><name><surname>Russell</surname><given-names>DW</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses</article-title><source>Cell</source><volume>151</volume><fpage>138</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.06.054</pub-id><pub-id pub-id-type="pmid">23021221</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Mumerge</data-title><version designator="95fec10">95fec10</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/Dowell-Lab/mumerge">https://github.com/Dowell-Lab/mumerge</ext-link></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinparzer</surname><given-names>I</given-names></name><name><surname>Sedlyarov</surname><given-names>V</given-names></name><name><surname>Rubin</surname><given-names>JD</given-names></name><name><surname>Eislmayr</surname><given-names>K</given-names></name><name><surname>Galbraith</surname><given-names>MD</given-names></name><name><surname>Levandowski</surname><given-names>CB</given-names></name><name><surname>Vcelkova</surname><given-names>T</given-names></name><name><surname>Sneezum</surname><given-names>L</given-names></name><name><surname>Wascher</surname><given-names>F</given-names></name><name><surname>Amman</surname><given-names>F</given-names></name><name><surname>Kleinova</surname><given-names>R</given-names></name><name><surname>Bender</surname><given-names>H</given-names></name><name><surname>Andrysik</surname><given-names>Z</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name><name><surname>Dowell</surname><given-names>RD</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name><name><surname>Kovarik</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transcriptional responses to ifn-γ require mediator kinase-dependent pause release and mechanistically distinct CDK8 and CDK19 functions</article-title><source>Molecular Cell</source><volume>76</volume><fpage>485</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.07.034</pub-id><pub-id pub-id-type="pmid">31495563</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>KD</given-names></name><name><surname>Lewis</surname><given-names>HC</given-names></name><name><surname>Hill</surname><given-names>AA</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Jackson</surname><given-names>LP</given-names></name><name><surname>Cabral</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>KP</given-names></name><name><surname>Liggett</surname><given-names>LA</given-names></name><name><surname>Gomez</surname><given-names>EB</given-names></name><name><surname>Galbraith</surname><given-names>MD</given-names></name><name><surname>DeGregori</surname><given-names>J</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Trisomy 21 consistently activates the interferon response</article-title><source>eLife</source><volume>5</volume><elocation-id>e16220</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.16220</pub-id><pub-id pub-id-type="pmid">27472900</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>KD</given-names></name><name><surname>Evans</surname><given-names>D</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Hraha</surname><given-names>TH</given-names></name><name><surname>Smith</surname><given-names>KP</given-names></name><name><surname>Markham</surname><given-names>N</given-names></name><name><surname>Rachubinski</surname><given-names>AL</given-names></name><name><surname>Wolter-Warmerdam</surname><given-names>K</given-names></name><name><surname>Hickey</surname><given-names>F</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name><name><surname>Blumenthal</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>14818</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-13858-3</pub-id><pub-id pub-id-type="pmid">29093484</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Bennett</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cannabinoids: a new group of agonists of PPARs</article-title><source>PPAR Research</source><volume>2007</volume><elocation-id>23513</elocation-id><pub-id pub-id-type="doi">10.1155/2007/23513</pub-id><pub-id pub-id-type="pmid">18288264</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuttle</surname><given-names>KD</given-names></name><name><surname>Waugh</surname><given-names>KA</given-names></name><name><surname>Araya</surname><given-names>P</given-names></name><name><surname>Minter</surname><given-names>R</given-names></name><name><surname>Orlicky</surname><given-names>DJ</given-names></name><name><surname>Ludwig</surname><given-names>M</given-names></name><name><surname>Andrysik</surname><given-names>Z</given-names></name><name><surname>Burchill</surname><given-names>MA</given-names></name><name><surname>Tamburini</surname><given-names>BAJ</given-names></name><name><surname>Sempeck</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Granrath</surname><given-names>R</given-names></name><name><surname>Tracy</surname><given-names>D</given-names></name><name><surname>Baxter</surname><given-names>J</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name><name><surname>Sullivan</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>JAK1 inhibition blocks lethal immune hypersensitivity in a mouse model of Down Syndrome</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108407</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108407</pub-id><pub-id pub-id-type="pmid">33207208</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Jeon</surname><given-names>R</given-names></name><name><surname>Vuckovic</surname><given-names>I</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name><name><surname>Folmes</surname><given-names>CD</given-names></name><name><surname>Dzeja</surname><given-names>PD</given-names></name><name><surname>Herrmann</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Interferon gamma induces reversible metabolic reprogramming of m1 macrophages to sustain cell viability and pro-inflammatory activity</article-title><source>EBioMedicine</source><volume>30</volume><fpage>303</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.02.009</pub-id><pub-id pub-id-type="pmid">29463472</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chu</surname><given-names>T</given-names></name><name><surname>Choate</surname><given-names>LA</given-names></name><name><surname>Danko</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of regulatory elements from nascent transcription using dREG</article-title><source>Genome Research</source><volume>29</volume><fpage>293</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1101/gr.238279.118</pub-id><pub-id pub-id-type="pmid">30573452</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waugh</surname><given-names>KA</given-names></name><name><surname>Araya</surname><given-names>P</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Jordan</surname><given-names>KR</given-names></name><name><surname>Smith</surname><given-names>KP</given-names></name><name><surname>Granrath</surname><given-names>RE</given-names></name><name><surname>Khanal</surname><given-names>S</given-names></name><name><surname>Butcher</surname><given-names>ET</given-names></name><name><surname>Estrada</surname><given-names>BE</given-names></name><name><surname>Rachubinski</surname><given-names>AL</given-names></name><name><surname>McWilliams</surname><given-names>JA</given-names></name><name><surname>Minter</surname><given-names>R</given-names></name><name><surname>Dimasi</surname><given-names>T</given-names></name><name><surname>Colvin</surname><given-names>KL</given-names></name><name><surname>Baturin</surname><given-names>D</given-names></name><name><surname>Pham</surname><given-names>AT</given-names></name><name><surname>Galbraith</surname><given-names>MD</given-names></name><name><surname>Bartsch</surname><given-names>KW</given-names></name><name><surname>Yeager</surname><given-names>ME</given-names></name><name><surname>Porter</surname><given-names>CC</given-names></name><name><surname>Sullivan</surname><given-names>KD</given-names></name><name><surname>Hsieh</surname><given-names>EW</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in down syndrome</article-title><source>Cell Reports</source><volume>29</volume><fpage>1893</fpage><lpage>1908</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.10.038</pub-id><pub-id pub-id-type="pmid">31722205</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waugh</surname><given-names>KA</given-names></name><name><surname>Minter</surname><given-names>R</given-names></name><name><surname>Baxter</surname><given-names>J</given-names></name><name><surname>Chi</surname><given-names>C</given-names></name><name><surname>Galbraith</surname><given-names>MD</given-names></name><name><surname>Tuttle</surname><given-names>KD</given-names></name><name><surname>Eduthan</surname><given-names>NP</given-names></name><name><surname>Kinning</surname><given-names>KT</given-names></name><name><surname>Andrysik</surname><given-names>Z</given-names></name><name><surname>Araya</surname><given-names>P</given-names></name><name><surname>Dougherty</surname><given-names>H</given-names></name><name><surname>Dunn</surname><given-names>LN</given-names></name><name><surname>Ludwig</surname><given-names>M</given-names></name><name><surname>Schade</surname><given-names>KA</given-names></name><name><surname>Tracy</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>KP</given-names></name><name><surname>Granrath</surname><given-names>RE</given-names></name><name><surname>Busquet</surname><given-names>N</given-names></name><name><surname>Khanal</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>RD</given-names></name><name><surname>Cox</surname><given-names>LL</given-names></name><name><surname>Estrada</surname><given-names>BE</given-names></name><name><surname>Rachubinski</surname><given-names>AL</given-names></name><name><surname>Lyford</surname><given-names>HR</given-names></name><name><surname>Britton</surname><given-names>EC</given-names></name><name><surname>Fantauzzo</surname><given-names>KA</given-names></name><name><surname>Orlicky</surname><given-names>DJ</given-names></name><name><surname>Matsuda</surname><given-names>JL</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Cox</surname><given-names>TC</given-names></name><name><surname>Sullivan</surname><given-names>KD</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model</article-title><source>Nature Genetics</source><volume>55</volume><fpage>1034</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1038/s41588-023-01399-7</pub-id><pub-id pub-id-type="pmid">37277650</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Hagihara</surname><given-names>T</given-names></name><name><surname>Horiuchi</surname><given-names>Y</given-names></name><name><surname>Okui</surname><given-names>A</given-names></name><name><surname>Wani</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>A</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Hirose</surname><given-names>Y</given-names></name><name><surname>Ohkuma</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mediator cyclin-dependent kinases upregulate transcription of inflammatory genes in cooperation with NF-κB and C/EBPβ on stimulation of Toll-like receptor 9</article-title><source>Genes to Cells</source><volume>22</volume><fpage>265</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1111/gtc.12475</pub-id><pub-id pub-id-type="pmid">28151579</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>McDonald</surname><given-names>JG</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Umetani</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Westover</surname><given-names>EJ</given-names></name><name><surname>Covey</surname><given-names>DF</given-names></name><name><surname>Mangelsdorf</surname><given-names>DJ</given-names></name><name><surname>Cohen</surname><given-names>JC</given-names></name><name><surname>Hobbs</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>27816</fpage><lpage>27826</lpage><pub-id pub-id-type="doi">10.1074/jbc.M603781200</pub-id><pub-id pub-id-type="pmid">16857673</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Dan Zhang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oleoylethanolamide exerts anti-inflammatory effects on LPS-induced THP-1 cells by enhancing PPARα signaling and inhibiting the NF-κB and ERK1/2/AP-1/STAT3 pathways</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>34611</elocation-id><pub-id pub-id-type="doi">10.1038/srep34611</pub-id><pub-id pub-id-type="pmid">27721381</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Abdulla</surname><given-names>A</given-names></name><name><surname>Xie</surname><given-names>X-J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>ES</given-names></name><name><surname>Liu</surname><given-names>L-P</given-names></name><name><surname>Vaitheesvaran</surname><given-names>B</given-names></name><name><surname>Bridges</surname><given-names>L</given-names></name><name><surname>Kurland</surname><given-names>IJ</given-names></name><name><surname>Strich</surname><given-names>R</given-names></name><name><surname>Ni</surname><given-names>J-Q</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Ericsson</surname><given-names>J</given-names></name><name><surname>Pessin</surname><given-names>JE</given-names></name><name><surname>Ji</surname><given-names>J-Y</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulation of lipogenesis by cyclin-dependent kinase 8–mediated control of SREBP-1</article-title><source>Journal of Clinical Investigation</source><volume>122</volume><fpage>2417</fpage><lpage>2427</lpage><pub-id pub-id-type="doi">10.1172/JCI61462</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metabolic regulation of cell growth and proliferation</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>20</volume><fpage>436</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1038/s41580-019-0123-5</pub-id><pub-id pub-id-type="pmid">30976106</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100197.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hinnebusch</surname><given-names>Alan G</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Eunice Kennedy Shriver National Institute of Child Health and Human Development</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This is an <bold>important</bold> study providing <bold>compelling</bold> evidence that the Mediator kinase module mediates an elevated inflammatory response, manifested by heightened cytokine levels, associated with Downs syndrome (DS) via transcriptional changes impacting cell signaling and metabolism that involve mobilization of nuclear receptors by altered lipid metabolites, which has significance for the treatment of DS and other chronic inflammatory conditions. Particular strengths of the study include the combined experimental approaches of transcriptomics, untargeted metabolomics and cytokine screens and the use of sibling matched cell lines (trisomy 21 vs disomy 21) from various donors. Evidence is also provided implicating the Mediator kinase module in controlling mRNA splicing and mitochondrial function that should stimulate new research to elucidate the mechanistic bases for these novel functions.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100197.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The main conclusion of this manuscript, that the mediator kinases supporting the IFN response in Downs syndrome cell lines, represents an important addition to understanding the pathology of this affliction.</p><p>Strengths:</p><p>Mediator kinase stimulates cytokine production. Both RNAseq and metabolomics clearly demonstrate a stimulatory role for CDK8/CDK19 in the IFN response. The nature of this role, direct vs. indirect, is inferred by previous studies demonstrating that inflammatory transcription factors are Cdk8/19 substrates. The cytokine and metabolic changes are clear cut and provide a potential avenue to mitigate these associated pathologies.</p><p>Weaknesses:</p><p>Seahorse analysis is normally calculated with specific units for oxygen consumption, ATP production, etc. It would be of interest to see the actual values of OCR (e.g., pmol/O2 consumption/number of cells) between the D21 and T21 cell lines rather than standardizing the results. Previous studies reported reduced mitochondrial function with DS cell lines and model systems e.g., see [10.1016/j.bbadis.2022.166388] and aberrant mitochondrial morphology/oxidative stress [10.1016/j.cmet.2012.12.005] [10.1016/j.neuroscience.2022.12.003]. This report observes elevated mitochondrial function in the T21 cells vs. the D21 control. There are several potential reasons for these differences but it is not up to the authors to rectify their results with others. However, it would be of interest to the general reader that they be mentioned in the discussion.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100197.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this manuscript, Cozzolino et al. demonstrate that inhibition of the Mediator kinase CDK8 and its paralog CDK19 suppresses hyperactive interferon (IFN) signaling in Down syndrome (DS), which results from trisomy of chromosome 21 (T21). Numerous pathologies associated with DS are considered direct consequences of chronic IFN pathway activation, and thus hyperactive IFN signaling lies at the heart of pathophysiology. The collective interrogation of transcriptomics, metabolomics, and cytokine screens in sibling-matched cell lines (T21 vs D21) allows the authors to conclude that Mediator kinase inhibition could mitigate chronic, hyperactive IFN signaling in T21. To probe the functional outcomes of Mediator kinase inhibition, the authors performed cytokine screens, transcriptomic, and untargeted metabolomics. This collective approach revealed that Mediator kinases establish IFN-dependent cytokine responses at least in part through transcriptional regulation of cytokine genes and receptors. Mediator kinase inhibition suppresses cell responses during hyperactive IFN signaling through inhibition of pro-inflammatory transcription factor activity (anti-inflammatory effect) and alteration of core metabolic pathways, including upregulation of anti-inflammatory lipid mediators, which served as ligands for specific nuclear receptors and downstream phenotypic outcomes (e.g., oxygen consumption). These data provided a mechanistic link between Mediator kinase activity and nuclear receptor function. Finally, the authors also disclosed that Mediator kinase inhibition alters splicing outcomes.</p><p>Overall, this study reveals a mechanism by which Mediator kinases regulate gene expression and establish that its inhibition antagonizes chronic IFN signaling through collective transcriptional, metabolic, and cytokine responses. The data have implications for DS and other chronic inflammatory conditions, as Mediator kinase inhibition could potentially mitigate pathological immune system hyperactivation.</p><p>Comments on revisions:</p><p>In the record of version, the authors have improved readability and also incorporated experiments that provide compelling support to the main discovery of the story. Below I summarize the previous strengths and how they improved noted weaknesses.</p><p>(1) One major strength of this study is the mechanistic evidence linking Mediator kinases to hyperactive IFN signaling through transcriptional changes impacting cell signaling and metabolism.</p><p>(2) Another major strength of this study is the use of sibling matched cell lines (T21 vs D21) from various donors (not just one sibling pair), and further cross-referencing with data from large cohorts, suggesting that part of the data and conclusions are generalizable.</p><p>(3) Another major strength of this study is the combined experimental approach including transcriptomics, untargeted metabolomics and cytokine screens to define the mechanisms underlying suppression of hyperactive interferon signaling in DS upon Mediator kinase inhibition.</p><p>(4) Another major strength of this study is the significance of the work to DS and its potential impact to other chronic inflammatory conditions.</p><p>(5) The previously noted weakness regarding the roles of nuclear receptors to activation of an anti-inflammatory program upon Mediator kinase inhibition was not directly experimentally addressed because existing data from other studies (referenced in this version) have linked specific nuclear receptors to lipid biosynthesis and anti-inflammatory cascades. This is considered acceptable.</p><p>(6) The presentation of the splicing data analysis is not better integrated in the overall story.</p><p>(7) The authors improved the readability of the manuscript by providing specific details throughout.</p><p>(8) Figures were improved and simplified when possible to facilitate readability.</p><p>(9) The authors now clarified the PRO-Seq (TFEA analysis) explaining that their data is consistent with the general observation that stimulus-responsive genes is controlled by enhancer-bound TFs.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100197.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cozzolino</surname><given-names>Kira A</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Boulder</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Sanford</surname><given-names>Lynn</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Boulder</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Hunter</surname><given-names>Samuel</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Boulder</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Molison</surname><given-names>Kayla</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Boulder</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Erickson</surname><given-names>Benjamin</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Anschutz Medical Campus</institution><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Courvan</surname><given-names>Meaghan CS</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Boulder</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Taylor</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Boulder</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ajit</surname><given-names>Deepa</given-names></name><role specific-use="author">Author</role><aff><institution>Metabolon</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Galbraith</surname><given-names>Matthew D</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Anschutz Medical Campus</institution><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Espinosa</surname><given-names>Joaquín M</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Anschutz Medical Campus</institution><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Bentley</surname><given-names>David</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Anschutz Medical Campus</institution><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Allen</surname><given-names>Mary Ann</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Boulder</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Dowell</surname><given-names>Robin D</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Taatjes</surname><given-names>Dylan J</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Boulder</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>The main conclusion of this manuscript is that the mediator kinases supporting the IFN response in Downs syndrome cell lines represent an important addition to understanding the pathology of this affliction.</p><p>Strengths:</p><p>Mediator kinase stimulates cytokine production. Both RNAseq and metabolomics clearly demonstrate a stimulatory role for CDK8/CDK19 in the IFN response. The nature of this role, direct vs. indirect, is inferred by previous studies demonstrating that inflammatory transcription factors are Cdk8/19 substrates. The cytokine and metabolic changes are clear-cut and provide a potential avenue to mitigate these associated pathologies.</p><p>Weaknesses:</p><p>This study revealed a previously undescribed role for the CKM in splicing. The previous identification of splicing factors as substrates of CDK8/CDK19 is also intriguing. However, additional studies seem to be necessary in order to attach this new function to the CKM. As the authors point out, the changes in splicing patterns are relatively modest compared to other regulators. In addition, some indication that the proteins encoded by these genes exhibit reduced levels or activities would support their RNAseq findings.</p></disp-quote><p>We have added new splicing data for the version of record. Specifically, we have added splicing data analysis for the &quot;non-sibling&quot; T21 cell line (±cortistatin A, t=4.5h) and for the sibling T21 line (±cortistatin A) at t=24h. The results are summarized in new Figure 5 – figure supplement 2. The data are in agreement with our prior data from the sibling T21 line ±CA at t=4.5h. In particular, (i) similar numbers of genes were impacted by splicing changes (alternative exon inclusion or alternative exon skipping) in CA-treated cells in the &quot;non-sibling&quot; T21 line compared with the sibling T21 line; (ii) upon completion of a pathway analysis of these alternatively spliced genes, similar pathways were affected by CA in each case (non-sibling T21 vs. sibling T21), in particular those related to IFN signaling; (iii) regarding the new t=24h timepoint for the sibling T21 line, similar numbers of genes were alternatively spliced (alternative exon inclusion or alternative exon skipping) in CA-treated cells compared with the 4.5h timepoint, and (iv) the IPA results with the alternately spliced genes identified inflammatory signaling, mRNA processing, and lipid metabolism among other pathways, which broadly reflect the cytokine screen and metabolomics data in CA-treated cells (t=24h).</p><p>Additional evidence for CDK8/CDK19 regulation of splicing comes from our t=24h RNA-seq data in T21 cells ±CA. GSEA results revealed down-regulation of many pathways related to RNA processing and splicing, suggesting that the splicing changes caused by Mediator kinase inhibition result from reduced expression of splicing regulators, at least at this longer timeframe. These results are summarized in new Figure 2 – figure supplement 2E. Collectively, the data shown in this article reveal a previously unidentified role for Mediator kinases as splicing regulators. We emphasize in the article, however, that the splicing effects of Mediator kinase inhibition appear modest, at least within the cell lines and timeframes of our experiments, especially when compared with CDK7 inhibition [Rimel et al. Genes Dev 2020 1452].</p><disp-quote content-type="editor-comment"><p>Seahorse analysis is normally calculated with specific units for oxygen consumption, ATP production, etc. It would be of interest to see the actual values of OCR between the D21 and T21 cell lines rather than standardizing the results. This will address the specific question about relative mitochondrial function between these cells. Reduced mitochondrial function has been associated with DS patients. Therefore, it would be important to know whether mitochondrial function is reduced in the T21 cells vs. the D21 control. Importantly for the authors' goal of investigating the use of CDK8/19 inhibitors in DS patients, does CA treatment reduce mitochondrial function to pathological levels?</p></disp-quote><p>These are good points. We have addressed as follows.</p><p>(1) We have added a comparative analysis of Seahorse data for the sibling-matched T21 and D21 lines. As shown in new Figure 2 – figure supplement 4A-C, the T21 line shows higher basal levels of OCR and ECAR compared with D21. Although reviewer 1 states that &quot;reduced mitochondrial function has been associated with DS patients&quot; we are unaware of the study from which this conclusion was made. Our results are consistent with a Down syndrome mouse model study published last year [Sarver et al. eLife 2023 e86023]. We acknowledge that in this study, T21/D21 OCR levels varied in different tissues, but the majority of tissue types showed elevated OCR in T21, similar to our results in the human B-cells used here.</p><p>(2) Interestingly, CA treatment reduced OCR and ECAR in T21 cells (and D21), suggesting that Mediator kinase inhibition might normalize mitochondrial function (and ECAR) toward D21 levels. We show this comparison in new Figure 2 – figure supplement 4D-F. Indeed, CA treatment appears to normalize T21 mitochondrial function and ECAR toward D21 levels. Although this may suggest a therapeutic benefit, we emphasize that more experiments would be needed to make such claims with confidence.</p><p>(3) We include a breakdown of mitochondrial parameters from Seahorse data in the bar plots shown in Figure 2–figure supplement 3. This includes ATP production, which shows reduced ATP levels in CA-treated T21 cells specifically.</p><p>(4) We have added Seahorse data for ECAR (extracellular acidification rate) in the siblingmatched D21 and T21 cells, ±CA. These results are shown in new Figure 2 – figure supplement 3D, and indicate that CA treatment reduces ECAR in both D21 and T21 cells. This result is consistent with a prior report that analyzed ECAR in CDK8 analog-sensitive HCT116 cells [Galbraith et al. Cell Rep 2017 1495].</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>In this manuscript, Cozzolino et al. demonstrate that inhibition of the Mediator kinase CDK8 and its paralog CDK19 suppresses hyperactive interferon (IFN) signaling in Down syndrome (DS), which results from trisomy of chromosome 21 (T21). Numerous pathologies associated with DS are considered direct consequences of chronic IFN pathway activation, and thus hyperactive IFN signaling lies at the heart of pathophysiology. The collective interrogation of transcriptomics, metabolomics, and cytokine screens in sibling-matched cell lines (T21 vs D21) allows the authors to conclude that Mediator kinase inhibition could mitigate chronic, hyperactive IFN signaling in T21. To probe the functional outcomes of Mediator kinase inhibition, the authors performed cytokine screens, transcriptomic, and untargeted metabolomics. This collective approach revealed that Mediator kinases establish IFN-dependent cytokine responses at least in part through transcriptional regulation of cytokine genes and receptors. Mediator kinase inhibition suppresses cell responses during hyperactive IFN signaling through inhibition of pro- inflammatory transcription factor activity (anti-inflammatory effect) and alteration of core metabolic pathways, including upregulation of anti-inflammatory lipid mediators, which served as ligands for specific nuclear receptors and downstream phenotypic outcomes (e.g., oxygen consumption). These data provided a mechanistic link between Mediator kinase activity and nuclear receptor function. Finally, the authors also disclosed that Mediator kinase inhibition alters splicing outcomes.</p><p>Overall, this study reveals a mechanism by which Mediator kinases regulate gene expression and establish that its inhibition antagonizes chronic IFN signaling through collective transcriptional, metabolic, and cytokine responses. The data have implications for DS and other chronic inflammatory conditions, as Mediator kinase inhibition could potentially mitigate pathological immune system hyperactivation.</p><p>Strengths:</p><p>(1) One major strength of this study is the mechanistic evidence linking Mediator kinases to hyperactive IFN signaling through transcriptional changes impacting cell signaling and metabolism. (2) Another major strength of this study is the use of sibling-matched cell lines (T21 vs D21) from various donors (not just one sibling pair), and further cross-referencing with data from large cohorts, suggesting that part of the data and conclusions are generalizable.</p><p>(3) Another major strength of this study is the combined experimental approach including transcriptomics, untargeted metabolomics, and cytokine screens to define the mechanisms underlying suppression of hyperactive interferon signaling in DS upon Mediator kinase inhibition. (4) Another major strength of this study is the significance of the work to DS and its potential impact on other chronic inflammatory conditions.</p><p>Weakness:</p><p>(1) Genetic evidence linking the mentioned nuclear receptors to activation of an anti-inflammatory program upon Mediator kinase inhibition could improve the definition of the mechanism and overall impact of the work.</p></disp-quote><p>Existing data from other studies, some of which are cited in the article, have linked PPAR and LXR to lipid biosynthesis and anti-inflammatory signaling cascades. We assume that reviewer 2 is suggesting knockdown and/or degron depletion of specific nuclear receptors, to compare/contrast the effect of CA on IFN responses in T21 and D21 cells. Such experiments would help de-couple the NR-specific contributions from other CA-dependent effects. We consider these experiments important next steps for this project, but beyond the scope of this study. That said, we anticipate that data from such experiments might be challenging to interpret, given the complex and inter-connected cascade of transcriptional and metabolic changes that would result from PPAR or LXR depletion.</p><disp-quote content-type="editor-comment"><p>(2) Page 5 states that &quot;Mediator kinases broadly regulate cholesterol and fatty acid biosynthesis and this was further confirmed by the metabolomics data&quot;, but a clear mechanistic explanation was lacking. Likewise, the data suggest but do not prove, that altered lipid metabolites influence the function of nuclear receptors to regulate an anti-inflammatory program in response to Mediator kinase inhibition (p. 6), despite the fact the gene expression changes elicited by Mediator kinase inhibition tracked with downstream metabolic changes.</p></disp-quote><p>We have clarified the text on page 5 to address this comment. Specifically, we note that CA treatment increases expression of FA metabolism and cholesterol metabolism genes in T21 cells under basal conditions, and the genes affected are shown in Figure 2–figure supplement 1E. Thus, the mechanistic explanation is that Mediator kinases cause elevated levels of FA and cholesterol metabolites via changes in expression of FA and cholesterol biosynthesis genes (at least in part). We further address the mechanism with the PRO-seq data and TFEA results in Figure 6; in particular, p53 activity is rapidly suppressed in CA-treated T21 cells (t=75min), and this alone is sufficient to activate SREBP [Moon et al. Cell 2019 564]. CA-dependent activation of SREBP target genes is a dominant feature in the T21 RNA-seq data (t=4.5h).</p><p>We agree with the second point raised by reviewer 2, that our data suggest but do not prove nuclear receptor function is altered by CA treatment. We do cite papers that have provided good evidence that the metabolites elevated in CA-treated cells are NR ligands and activate their target genes. Additional experiments to address this question might involve targeted depletion of select metabolites via inhibition of key biosynthetic enzymes. We consider these experiments beyond the scope of this already expansive article. That said, it will be challenging to conclusively demonstrate clear cause-effect relationships (e.g. to demonstrate whether select metabolites altered by CA treatment directly alter PPARA function), given (i) the myriad transcriptional and metabolic changes caused by CA treatment, coupled with the fact that (ii) the CA-dependent lipid metabolite changes are spread out across chemically distinct NR agonists (e.g. endocannabinoids, oleamide, or cholesterol metabolites such as desmosterol), and (iii) NR activation can occur via multiple different metabolites.</p><disp-quote content-type="editor-comment"><p>(3) The figures are outstanding but dense.</p></disp-quote><p>Thank you. We have done our best to represent the results clearly and within the publication guidelines. There was an enormous amount of data to summarize for this article.</p><disp-quote content-type="editor-comment"><p>(4) Figure 6 (PRO-Seq). The authors refer to pro-inflammatory TFs (e.g. NF-kB/RelA). It is not clear whether the authors have specifically examined TF binding at enhancers or more broadly at every region occupied by the interrogated TFs?</p></disp-quote><p>This is a good point. Our analysis (TFEA) only identified the TFs whose activity was changing in CA-treated cells. It did not distinguish where these TFs were bound (enhancers vs. promoters). We completed a modified TFEA by separating enhancer TFs vs. promoter TFs. The results showed a preference for CA-dependent suppression of enhancer-bound TFs. This result is consistent with the general observation that stimulus-response transcription is controlled by enhancer-bound TFs (e.g. Kim et al. Nature 2010 182; Azofeifa et al. Genome Res 2018 334; Jones et al. bioRxiv 2024 585303). However, our TFEA enhancer/promoter analysis is preliminary and more work would be needed to address this comment in a rigorous way. Therefore, we did not include this analysis in the revision.</p><disp-quote content-type="editor-comment"><p><bold>Reviewing Editor Comments:</bold></p><p>Main suggestions for improvement:</p><p>(1) Provide additional information about the mechanistic basis for the changes in lipid levels observed on kinase inhibition.</p></disp-quote><p>We have changed the text to better emphasize that the mechanistic basis involves (i) gene expression changes resulting from Mediator kinase inhibition (e.g. Fig 2 – figure supplement 1D, E, Fig 2 – figure supplement 2B, Fig 2 – figure supplement 4B-D); (ii) activation of SREBP and PPAR and LXR, based upon IPA results with RNA-seq data (e.g. Fig 2B, Fig 2 – figure supplement 1F, Fig 2 – figure supplement 2D, Fig 2 – figure supplement 4E; Fig 3E), and (iii) rapid CAdependent suppression of p53 function (Fig 6A), which will activate SREBP (Moon et al. Cell 2019 564).</p><disp-quote content-type="editor-comment"><p>(2) Provide direct genetic evidence that the nuclear receptors are activated by the lipid changes to mediate an anti-inflammatory program in response to Mediator kinase inhibition.</p></disp-quote><p>This is an excellent question but we consider it beyond the scope of this already expansive study. That said, we cite several papers in the article that demonstrate that the lipids we observe elevated in CA-treated cells (i) directly bind PPAR or LXR and (ii) activate their TF function. We also note that the anti-inflammatory impacts of Mediator kinase inhibition are broad, affecting distinct gene sets through transcriptional changes, metabolites, and cytokines. Any NR-specific contributions could be challenging to de-couple from CA-dependent effects using knockdown or depletion methods, given the compensatory responses that would result.</p><disp-quote content-type="editor-comment"><p>(3) Improve/expand the evidence that Mediator kinase inhibition confers reduced mitochondrial function.</p></disp-quote><p>We have added new Seahorse data for sibling-matched D21 and T21 cells (±CA) for the version of record. Our prior results showed reduced mitochondrial function and OCR in CA-treated T21 cells. We have added data that compares D21 and T21 mitochondrial function. As shown in new Figure 2 – figure supplement 4A-C, the T21 line shows higher basal levels of OCR and ECAR compared with D21. These results are consistent with a Down syndrome mouse model study published last year [Sarver et al. eLife 2023 e86023]. When we compare CA-treated T21 with D21 cells, mitochondrial respiration and OCR are similar, suggesting that Mediator kinase inhibition might normalize mitochondrial function (and ECAR) toward D21 levels. We show this comparison in new Figure 2 – figure supplement 4D-F. Although this may suggest a therapeutic benefit, we emphasize that more experiments would be needed to make such claims with confidence.</p><disp-quote content-type="editor-comment"><p>(4) Determine whether mitochondrial function is reduced in the T21 cells vs. the D21 controls and whether kinase inhibition with the inhibitor reduces mitochondrial function to pathological levels.</p></disp-quote><p>For the version of record, we have added a direct comparison of mitochondrial parameters and OCR in the sibling-matched D21/T21 lines. The data show that T21 cells have higher OCR compared with D21. These results are consistent with a Down syndrome mouse model study published last year [Sarver et al. eLife 2023 e86023]. Our results also indicate that CA treatment brings OCR and other &quot;mitochondrial parameters&quot; in T21 cells toward D21 levels, as noted above.</p><disp-quote content-type="editor-comment"><p>(5) Consider whether the CDK8/19 inhibitor has off-target effects that would lessen its therapeutic value.</p></disp-quote><p>We chose cortistatin A (CA) for this project because it is the most potent and selective inhibitor available for targeting CDK8/CDK19. Initial published reports suggested off-target effects (Cee et al. Angew Chem IEE 2009), but these experiments used binding assays against the kinase protein alone, and did not measure binding or inhibition with biologically relevant, active kinase complexes. Kinome-wide screens involving native, active kinase complexes showed no evidence of off-target effects for cortistatin A, even at concentrations 5000-times the measured KD (Pelish et al. Nature 2015). See Author response image 1.</p><p>Related to CA therapeutic value, that is an important issue but beyond the scope of this study. We consider CA a valuable chemical probe, to use as a means to define CDK8/CDK19-dependent functions in cell line models. As a chemical probe, we consider CA the &quot;best-in-class&quot; Mediator kinase inhibitor, based upon all available data (Clopper &amp; Taatjes Curr Opin Chem Biol 2022 102186).</p><p>That said, we understand the concern about off-target effects, which can never be ruled out with a chemical inhibitor. We include quantitative western data (Fig 1 – figure supplement 1A) that compares CA with a structurally distinct CDK8/CDK19 inhibitor, CCT251545. The data show that, as expected, CA (100nM) and CCT251545 (250nM) similarly inhibit STAT1 S727 phosphorylation in IFN-stimulated cells. The samples were pre-treated with inhibitor for 30 minutes prior to IFNg and collected 45 minutes after IFNg treatment.</p><p>We did not complete any experiments with knockouts or kinasedead alleles primarily because knockouts or kinase-dead alleles are not reliable comparisons for chemical inhibition because of the different time frames involved. For example, there will be genetic compensation in edited cell lines (Rossi/Stanier Nature 2015 230) and we and others have shown that there are major differences between kinase protein loss through knockdown or knockout methods vs. rapid inhibition with small molecules (e.g. Poss et al. Cell Rep 2016 436; Sooraj et al. Mol Cell 2022 123).</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><caption><title>Information about cortistatin A.</title><p>(A) KiNativ kinome screen from HEK293 lysates. CA blocked capture of only CDK8/CDK19 in this MSbased assay, among over 200 kinases detected. (B) Equilibrium binding constants and kinetics for CA. (C) CA structure; note the dimethylamine is protonated at physiological pH, and forms a pi-cation interaction with W105 (crystal structure, panel D). Only CDK8 and CDK19 have an aromatic residue (W) at this position, providing a structural basis for high selectivity.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100197-sa3-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(6) Improve the presentation of the splicing data and better discuss how the splicing alterations may be contributing to the disease phenotype.</p></disp-quote><p>We have added new splicing data for the version of record. Specifically, we have added splicing data analysis for the &quot;non-sibling&quot; T21 cell line (±cortistatin A, t=4.5h) and for the sibling T21 line (±cortistatin A) at t=24h. The results are summarized in new Figure 5 – figure supplement 2. The data are in agreement with our prior results from the sibling T21 line ±CA at t=4.5h. In particular, (i) similar numbers of genes were impacted by splicing changes (alternative exon inclusion or alternative exon skipping) in CA-treated cells in the &quot;non-sibling&quot; T21 line compared with the sibling T21 line; (ii) upon completion of a pathway analysis of these alternatively spliced genes, similar pathways, including IFN signaling pathways, were affected by CA in each case (non-sibling T21 vs. sibling T21); (iii) regarding the new t=24h timepoint for the sibling T21 line, similar numbers of genes were alternatively spliced (alternative exon inclusion or alternative exon skipping) in CA-treated cells compared with the 4.5h timepoint, and (iv) the IPA results with the alternately spliced genes identified inflammatory signaling, mRNA processing, nucleotide and lipid metabolism among other pathways, which broadly reflect the cytokine screen and metabolomics data in CA-treated cells (t=24h).</p><p>Additional evidence for CDK8/CDK19 regulation of splicing comes from our t=24h RNA-seq data in T21 cells ±CA. GSEA results from sibling T21 cells ±CA revealed down-regulation of many pathways related to RNA processing and splicing (RNA-seq data, t=24h), suggesting that the splicing changes caused by Mediator kinase inhibition result from reduced expression of splicing regulators, at least at longer timeframes. These results are summarized in new Figure 2 – figure supplement 2E.</p><p>Related to how splicing alterations may be contributing to the CA-dependent effects and their potential therapeutic implications, this is an interesting question but open-ended. It will not be straightforward to link specific splicing changes to possible therapeutic outcomes, especially given that there are hundreds of genes affected and because the effects are modest (i.e. not all-ornothing).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>The findings that CA treatment leads to upregulation of as many genes are downregulated is consistent with previous studies of a 50:50 role for the CKM. However, most previous studies utilized knockout alleles or knockdown approaches. As the authors demonstrated in a previous study, CA inhibits kinase activity without changing CDK8 levels. Does this indicate that the kinase activity of Cdk8/19 is required for transcriptional repression? Previous in vitro studies suggested that Cdk8/19-dependent repression was independent of their kinase activity. The authors should comment on this.</p></disp-quote><p>This is a challenging question to address, because the answer will depend on the timing of the experiment and the experimental context. The short answer is that the kinase activity of CDK8/19 will activate some genes and reduce expression of others, at least in part because CDK8/19 phosphorylate TFs, which drive global gene expression programs. TF phosphorylation by CDK8/19 appears to activate some genes and repress others (e.g. STAT1 S727A example from Steinparzer et al. Mol Cell 2019 485), at least based upon RNA-seq data, but this doesn't measure the immediate effects on the transcriptome. It is true that kinase activity isn't required to block pol II incorporation into the PIC (Knuesel et al. Genes Dev 2009 439). This is a kinase-independent function of the module; MKM-Mediator binding will block Mediator-pol II interaction and therefore block PIC assembly and pol II initiation (Knuesel 2009; Ebmeier &amp; Taatjes PNAS 2010 11283). The kinase-independent functions of CDK8/19 were not a focus of the work described here. We only focus on Mediator kinase activity. We also do not focus on potential effects on RNAPII initiation or PIC assembly, although these are important peripheral topics.</p><disp-quote content-type="editor-comment"><p>Descriptors are less useful as the reader must go back to reconstruct the experiment: &quot;Although metabolites were measured 24h after CA treatment, these data suggest that altered lipid metabolites influence LXR and PPAR function&quot;. Does &quot;altered&quot; mean the lipid concentrations were up or down? Similarly, lipids that &quot;influenced&quot; LXR function - were they stimulatory or inhibitory?</p></disp-quote><p>Good point. Where possible, we used more accurate language when describing CAdependent changes.</p><disp-quote content-type="editor-comment"><p>I found many sections in the text confusing. For example: Figure 3. Mediator kinase inhibition antagonizes IFNγ transcriptional responses in T21 and D21. It takes a while to unpack this figure title. Instead of the double negative, the authors could simply state that &quot;Mediator kinase is required for IFN-dependent transcriptional activation&quot;. Describing the protein activity, versus the drug-induced phenotype, can often clarify complicated scenarios.</p></disp-quote><p>Good idea. We have edited the text to eliminate some but not all of these double negatives. In some cases we prefer to describe the consequence of kinase inhibition.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>(1) The splicing data analysis is compelling, but not well integrated into the overall story and it cuts the storytelling logic in the Abstract. The authors could consider better integrating the large amount of data generated and better explaining how it relates to the various aspects of the proposed model (transcriptional, metabolism) to help improve potential cause-and-effect outcomes. -</p></disp-quote><p>We agree. The large amount of data, combined with the different experimental approaches, makes it a challenge to summarize the data in a concise way. We have done our best to organize the results in a logical and clear manner. To address this comment, we have gone through the text and re-organized where possible, and we have edited the abstract. We have added new splicing data and the splicing results are now better integrated (in our opinion) in part because of the pathway results from the t=24h ±CA RNA-seq data, which show major reductions in gene sets related to splicing and RNA processing.</p><disp-quote content-type="editor-comment"><p>(2) The manuscript could improve its readability by providing specific details throughout. Examples include (i) explaining why and what 29 cytokines were chosen for the screen (p. 3, p. 4) (ii) providing major data analysis conclusions to the cytokine screen part (p. 3) (iii) expanding the conclusions to the metabolic pathway analysis (p. 4) (iv) being more precise when referring to T21-specific changes (up or down?) (p 4), and &quot;significantly altered&quot; by CA treatment in T21 cells (up or down?) (p. 5).</p></disp-quote><p>Good points. We have edited the text to address these comments. Please note that the 29 cytokines refers to a different study (Malle et al. Nature 2023) and we had no role in selecting the cytokines. Our screen involved 105 cytokines that were arrayed as part of a commercially available panel.</p><disp-quote content-type="editor-comment"><p>(3) The figures are outstanding but dense (e.g., Figure 1b, can any simplification and/or highlighting be done to underscore important features?). Some panels are illegible (e.g. Figure 1- supplement Figure 2a and b). The authors could improve data presentation. For example, the Venn diagrams (e.g., Figure 2f) are hard to quickly digest. Can the authors find a better way to highlight important data (e.g., hard to distinguish the meaning of font bolding from italics)?</p></disp-quote><p>Thank you for these suggestions. Regarding Figure 1B, we simplified the metabolic pathways to emphasize the biochemicals that specifically relate to this study. We decided against highlighting specific metabolites beyond this simplification, because in our opinion it causes as many problems as it solves. Where possible, we have enlarged the panels with hard-to-read text; thank you for the suggestion. For the Venn diagrams, they convey a large amount of information in a single panel: increased or decreased gene expression in T21 or D21, cytokine genes or cytokine receptors, and gene expression convergence or divergence compared with protein levels from cytokine screens. There is a different way to display the results, but it would involve generating more data panels to parse out the results. This could be considered better, but we opted for something that is more information-rich that requires only a single data panel. Given the large amount of data already shown, we hope the reviewer can understand this choice.</p></body></sub-article></article>